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J.H Garvin 
THE INFLUENCE OF THE HORMONAL MILIEU ON EICOSANOID AND 
CYTOKINE PRODUCTION IN TISSUES FROM THE FEMALE 
REPRODUCTIVE TRACT 
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In the human uterus prostaglandins (PG) PGE2, PGD2, PGI2, PGF2α and 
Thromboxane A2 (TXA2), also termed prostanoids, are synthesised and deactivated 
to 15-keto PGE2, J2 metabolites, 6-keto-PGF1α, 15-keto PGF2α and TXB2 
respectively.  However, not all metabolites have been analysed simultaneously 
within the same tissue.  The primary objective of this thesis was to determine full 
uterine prostanoid profiles in human non-pregnancy, pregnancy and parturition, to 
better understand these processes and find suitable tocolytic targets.  In addition, ten 
cytokines in human cervico-vaginal fluid (CVF) were measured according to interval 
to labour to test their suitability as labour onset predictors, with a view to developing 
a test to determine women at risk of preterm labour. 
Prostanoid analysis was carried out in endometrium (n=9) and myometrium (n=15-
16) donated by non-pregnant women and lower segment myometrium obtained from 
pregnant women (before (n=14) and after labour onset (n=7)) by liquid 
chromatography coupled with electrospray ionisation mass spectrometry (LC/ESI-
MS/MS).  Cytokines produced by CVF collected from pregnant donors (20-41 
weeks gestation, n=2-10) were investigated using Enzyme-Linked Immunosorbent 
Assay (ELISA) or Luminex®. 
Human endometrium produced greater concentrations of TXB2, PGE2 and PGF2α 
than myometrium in vitro (p<0.05).  Fifteen prostanoids were detected in human 
myometrium.  Production of 6-keto-PGF1α, PGE1 and PGF1α increased whilst 15-
keto PGE2 and PGJ2 decreased at term pregnancy (37-41 weeks gestation) versus 
non-pregnancy (p<0.05).  Myometrium from parturient donors synthesised TXB2 
and PGE2 more abundantly than the non-labouring equivalent.  Cytokine 
concentration was greatest in CVF sampled the week before labour, in particular 
Interleukin-6 (IL-6), Macrophage Inflammatory Protein-1α (MIP-1α) and Monocyte 
Chemotactic Protein-1 (MCP-1) (p<0.05). 
Endometrial TXB2, PGE2 and PGF2α could aid in proliferation of glandular 
epithelium prior to ovulation.  Prostacyclin may facilitate prolongation of pregnancy 
to term and thromboxane could contribute to uterine stimulation during labour.  
Cervical dilation may be influenced by PGE2 in lower segment myometrium.  MCP-
1, MIP-1α and IL-6 could mark a short interval to labour onset. 
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Chapter 1: Introduction 
1.1 The uterus 
The female uterus is a hollow, thick walled, muscular, simplex organ, which is 
shaped like an inverted pear and located between the bladder and rectum.  The 
murine uterus in contrast, comprises a duplex structure, whereby each uterine horn 
adjoins at the cervix.  The dimensions of the uterus are highly variable in women of 
reproductive age.  In nulliparae (women who have never given birth), the uterus is 
approximately 6-8 cm long, 5 cm in diameter and 1.5 cm to 2.5 cm thick, enlarging 
to four or five times this size in pregnancy (Martini, 2004).  The uterus has multiple 
important roles within the reproductive tract, namely nidation (or implantation of the 
fertilised ovum), protection and evacuation. 
During pregnancy, the uterus provides the perfect environment for the blastocyst to 
develop into the embryo (weeks 1-8 of gestation) and later the foetus (9+ weeks 
gestation), which gestates until term (between the 37th and 41st week of pregnancy).  
The sheer thickness and bulk of the uterus, the fundus in particular, protects the 
foetus from outside harm.  At term, when childbirth takes place, the uterus is the 
major facilitator of foetal evacuation down through the birth canal (the uterus 
through to the vaginal entrance) by contracting strongly.  This multifunctional, 
hormone responsive organ has two distinct parts, the body or corpus, which is 
rounded in shape, and the elongated cervix.  The lumen of the corpus is known as the 
uterine cavity, whilst that of the cervix is termed the cervical canal.  The uterus 
becomes narrower and decreases in smooth muscle content towards the cervix 
(Hofmann et al., 1983). 
  Chapter One: Introduction 
3 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Schematic representing the human non-pregnant uterine a) broad ligament 
and b) myometrium, endometrium and cervix based on adaptations from (Hill, 2010) 
and (MedicaLook, 2007-2012). 
 
During parturition, the cervix effaces and dilates to enable opening of the cervical 
canal.  Meanwhile, the foetus is pushed from the uterine cavity down into the vagina 
for delivery by a series of strong, intense myometrial contractions, emanating from 
the fundus towards the cervix.  The peritoneum, also known as the broad ligament 
surrounding the uterus provides support and limits the range of uterine movement 
(Martini, 2004), which is essential for the heavier gravid uterus. 
b) 
a) 
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The uterine wall has three main layers differing in their structural characteristics 
(refer to Figure 1.1).  A serosa or serous membrane (perimetrium) encapsulates the 
main component, the middle fibro-muscular layer called the myometrium 
surrounding the inner, glandular endometrium or mucosa (Chard and Grudzinskas, 
2003).  
1.1.1 Myometrium in non-pregnancy 
The myometrium comprises the thickest portion of the uterine wall and is made up of 
involuntary smooth muscle fibres, which can tense and relax.  Myometrial muscle 
fibres run longitudinally closest to the serosa and circularly adjacent to the 
endometrium with oblique fibres interspersed within bundles (Weiss et al., 2006).  
New imaging techniques have enabled the isolation of the myometrium into more 
complex functional units, with distinctions being made between a myometrial zone 
(comprising an outer subserosal stratum supravasculare and an inner stratum 
vasculare) and an inner subendometrial layer (junctional zone or stratum 
subvasculare) (Noe et al., 1999).  The myometrium predominantly comprises smooth 
muscle cells (myocytes) (Fusi et al., 2006), which are long (approximately 200µm) 
and narrow (5-10µm), with a spindle or fusiform shape and contain thick and thin 
filaments of myosin and actin respectively (Somlyo et al., 1981, Somlyo et al., 
1983).  Filaments form cross-bridges to generate force for a contraction, which 
requires intracellular calcium to be available.  The particular arrangement of these 
proteins and their interaction with the cell cytoskeleton enables shortening of the 
myocyte.  Smooth muscle cells are bound together at dense bodies so that contractile 
forces spread from cell to cell, which is facilitated further by gap junctions joining 
adjacent myocytes (Sherwood, 2007). 
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Consequently, myocytes turn from their relaxed state to units contracting in a co-
ordinated fashion as a syncytium.  Spontaneous depolarisations in pacemaker cells 
(Marshall, 1962) spread via gap junctions to neighbouring myocytes stimulating 
their plasma membrane voltage operated calcium channels (VOCs) to open (Chard 
and Grudzinskas, 2003).  Therefore, the myometrium is able to self-generate 
synchronous, phasic contractions.  Various hormonal and physical factors, such as 
prostanoids act at their receptors on the plasma membranes to alter the intensity and 
frequency of the contractile state.  One receptor type elicits contraction by 
stimulating intracellular calcium release and the second type inhibits myogenicity by 
disrupting excitation-contraction coupling.  During pregnancy, myometrial 
contraction is suppressed (Figure 1.2b, page 6) and increases (Figure 1.2a) at 
parturition to enable delivery of the foetus. 
The mechanism of contraction is referred to as excitation-contraction coupling, 
whereby a complex forms between four calcium ions (Ca++) and calmodulin.  This 
complex binds to and dephosphorylates myosin light chain kinase (MLCK), which 
phosphorylates myosin (Grover and Daniel, 1985).  Adenosine triphosphate (ATP) is 
hydrolysed to Adenosine diphosphate (ADP) by myosin so that cross-bridges form 
between the myosin head and actin filament, generating force (Horowitz et al., 
1996).  The phosphorylation process of myosin is very rapid and calcium elevation 
in the cell is transient, therefore, another mechanism indirectly promotes a 
contractile state by sensitising the cell to calcium.  As shown in Figure 1.2a, RhoA 
activation increases Rho kinase (ROK) activity, which prevents myosin light chain 
phosphatase (MLCP) inhibition of MLCK (Webb, 2003) and possibly promotes 
phosphorylation of myosin on the same site as MLCK (Lopez Bernal, 2003). 
  
  
Fig 1.2a shows stimulation of contraction depends on Ca++ 
Action potentials open VOC on the plasma membrane, allowing 
from the extracellular environment. Alternatively, hormones bind to specific receptors to 
generate specific second messengers and Ca++ depending upon the G protein species they 
are coupled with.  E.g. phospholipase C (PLC) activation occurs when the spasmog
prostaglandin PGF2α binds to the FP-Gq coupled receptor (Narumiya et al., 1999
potent second messengers are formed: 1, 4, 5 inositol triphosphate (IP
the Sarcoplasmic Reticulum (SR) and stimulates Ca++ release and diacylglyercol (DG) 
activating protein kinase C (PKC).  PKC promotes opening of L type calcium channels
whilst calcium release activated currents (iCRAC) or store operated channels (SOCs) 
the plasma membrane replenish intracellular Ca++ stores, when those inside the SR are 
depleted (Webb, 2003). 
Figure 1.2:  The mechanism behind a) stimulation and b) inhibition of smooth muscle contraction
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The second messenger, 3’, 5’ cyclic adenosine monophosphate (cAMP) contributes 
to myometrial relaxation via inhibition and activation of RhoA and MLCP 
respectively (Aslam et al., 2010). 
1.1.2 Junctional zone 
High resolution ultrasound visualises the junctional zone (JZ) as a “subendometrial 
halo”, whose 5 mm or less thickness changes in line with the endometrium during 
the uterine cycle (Fusi et al., 2006).  Unique to non-pregnancy, contraction waves 
originate from the JZ (Birnholz, 1984), corresponding with strong staining of the 
spasmogenic oxytocin receptor (OTR) (Einspanier et al., 1998).  Unsurprisingly, 
smooth muscle density and vascularity in the JZ is higher than in outer myometrium 
(Tetlow et al., 1999, Fusi et al., 2006).  Contractility of the JZ is abnormal in a small 
proportion of women manifesting as menstrual problems, for example, 
hyperperistalsis of the inner myometrium correlates with excessive menstrual blood 
loss (menorrhagia) (Chalubinski et al., 1993), endometriosis (Bulletti et al., 2002) 
and reduced fecundability (Ijland et al., 1997).  Disruption to the JZ structure may 
detrimentally affect uterine function, since uterine fibroid presence correlates with 
subfertility (Hart et al., 2001) and expansion of the inner myometrium occurs in 
endometriosis sufferers (Kunz et al., 2000). 
1.1.3 Endometrium 
The endometrium, which is the lining present within the lumen of the uterus, makes 
up approximately 10% of the total uterine mass and comprises two layers, the outer 
basilar zone (adjacent to the myometrium) and the functional zone (in close 
proximity to the uterine cavity). 
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Both layers contain the luminal epithelium, underlying stromal tissue and a rich 
blood supply that enters from the adjacent myometrium.  It is the functional layer, 
which contains most of the uterine glands and contributes to endometrial thickness.  
In nulliparae, the endometrium maintains patency of the uterine cavity by preventing 
adhesion of the opposed myometrial walls and is shed and reformed with each 
menstrual cycle.  During pregnancy, decidualised endometrium provides an optimal, 
nutrient rich medium for the blastocyst to bury into and supports physiological 
demands of the developing foetus via the extensive glandular, lymphatic and 
vascular components (Martini, 2004). 
1.2 The menstrual cycle in relation to ovarian function 
The onset of the menstrual cycle begins at puberty in girls most commonly between 
the ages of 11-12 years (Martini, 2004) and remains undisrupted until midlife unless 
illness, stress, starvation or pregnancy ensue.  The menstrual cycle takes place every 
28 ± 3 days (Berkow, 1987) in healthy, non-pregnant women of reproductive age.  
Each month a repeated series of changes to the endometrial structure, in response to 
ovarian steroids, takes place priming the uterus for possible pregnancy.  There are 
three menstrual phases: menses or menstruation, the proliferative (or follicular) 
phase and the secretory (also referred to as luteal) phase.  During the proliferative 
phase the endometrium is restored after menses.  Oestrogen produced by developing 
ovarian follicles acts at specific uterine receptors to promote endometrial growth 
(Ferenczy et al., 1979) and vascularisation of uterine tissues (Critchley et al., 2002).  
Mid-cycle the tertiary ovarian follicular wall ruptures and releases the oocyte, 
awaiting fertilisation by sperm. 
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Myometrial contractions modulate uterine peristalsis, particularly at ovulation, by 
conducting a series of rhythmic contractions which ease the transit of sperm up 
through the uterine cavity to the Fallopian tubes (Kunz et al., 1996).  Meanwhile, 
oestrogen induces the transcription of specific uterine receptors for progesterone 
(Gronemeyer et al., 1991), which are required for the decidualisation process post-
ovulation.  The empty tertiary follicle collapses to form the corpus luteum in 
response to LH (also known as lutropin, a hormone produced by the pituitary gland, 
refer to Figure 1.3 on the next page), signalling the start of the secretory phase and 
synthesises progesterone and smaller quantities of oestrogen (Neill et al., 1967, 
Johansson, 1969). 
Preparing the uterus for pregnancy is progesterone, stimulating endometrial 
differentiation, which accompanies enhancement of glandular secretions and 
thickening and maturation of the endometrium, ready for implantation of the 
blastocyst (Brosens et al., 2002).  Myometrial activity is also inhibited (Fischer, 
2010), coinciding with down-regulation of gap junctions in response to progesterone 
(Chwalisz et al., 1991, Jahn et al., 1995).  The second smaller post-ovulatory peak in 
oestrogen could facilitate blastocyst attachment (Lim et al., 2002) and 
decidualisation (Lecce et al., 2001, Critchley et al., 2002).  Alongside changes to the 
endometrium, particular immune cells (uterine natural killer cells, uNKs) are 
recruited into the uterus during the secretory phase, possibly to help support 
placental development (King, 2000) .  In the late secretory phase, a sharp decline in 
oestrogen and progesterone production follows the demise of the corpus luteum, if 
fertilisation and implantation has been unsuccessful. 
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Figure 1.3: Luteinising hormone (LH) stimulates ovarian thecal cells to produce 
androgens which are converted to oestrogens by ovarian granulosa cells. Follicular 
development begins under follicle-stimulating hormone (FSH) stimulation, which in 
turn stimulates follicle growth and maturation and promotes oestrogen-dependent 
endometrial growth.  Oestrogens interact with the oestrogen receptor (ER) to mediate 
proliferation.  At around day 14, when oestrogen has peaked, an LH surge from the 
anterior pituitary gland permits ovulation to occur.  LH drops along with FSH and 
the corpus luteum develops from the ruptured follicle, which secretes abundant 
progesterone.  This steroid hormone binds and activates the progesterone receptor 
(PR) to support endometrial decidualisation, whilst a second smaller peak in 
oestrogen production occurs.  If fertilisation is unsuccessful, the corpus luteum 
regresses and consequently progesterone and oestrogen levels fall markedly 
stimulating endometrial sloughing (diagram adapted from (DuoFertility: Cambridge 
Temperature Concepts Ltd, 2007-2012). 
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The withdrawal of progesterone causes spiral arteries in the functionalis to constrict, 
become hypoxic (deprived of adequate oxygen supply) and consequently deteriorate 
(Critchley et al., 2006).  Stromal degradation occurs when cytokines are produced 
(Tabibzadeh and Sun, 1992, Wolff et al., 2000), which chemoattract macrophages 
(Jeziorska et al., 1996, Zhang et al., 2000) and mast cells (Jeziorska et al., 1995, 
Milne et al., 2001b) in turn producing metalloproteinase (MMP) and other tissue 
degrading enzymes (Irani and Schwartz, 1989).  Myometrial contractions help to rid 
blood from degenerating uterine blood vessels and the entire endometrial 
functionalis from the uterine cavity lasting for 5 ± 2 days (Berkow, 1987) with a 
blood loss averaging 35 ml (Martini, 2004).  When women reach 45-55 years of age, 
there is a major reduction in ovarian sex steroid hormone production and primary 
ovarian function, whereby cycles become less regular (peri-menopause), which can 
occur over a period of years.  The menopause, a natural part of the ageing process; is 
defined as the last uterine cycle when amenorrhoea (absence of menstruation) is 
experienced from then on and thus signalling the end of the reproductive phase. 
1.3 Non-cancerous pathophysiology in non-pregnant women: menorrhagia 
Repeated episodes of menstrual bleeding indicate normal functioning of the ovaries 
(Critchley et al., 2001), however, menstrual blood loss (MBL) can be abnormal in 
some women, with a major impact on quality of life.  For example, in one study it 
was reported that one out of twenty women (aged between 30-49 years) consulted 
their General Practitioner each year for heavy MBL (Vessey et al., 1992).  
Menorrhagia (MBL greater than 80ml (Hallberg et al., 1966)) is a common clinical 
problem associated with the development of iron deficiency anaemia (Rees, 1987). 
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Menorrhagia can be caused by other disorders such as abnormal blood coagulation, 
endometrial hyperplasia, pelvic inflammatory disease and benign polyps such as 
fibroids (also known as leiomyomas).  However, half of sufferers appear to be 
otherwise healthy with no pathology apparent upon gynaecological investigation.  In 
these women, abnormal production of mediators of endometrial vascular 
homeostasis, namely plasminogen activator (a blood thinning agent) (Gleeson, 1994) 
and an imbalance of prostanoids, such as TXA2 and PGI2, which stimulate 
vasoconstriction and vasodilatation respectively are implicated (Makarainen and 
Ylikorkala, 1986b). 
1.4 Pregnancy 
The gestational length of mammalian pregnancy is typically 40 weeks calculated 
from the last menstrual period and tightly regulated to assure the delivery of a 
newborn mature enough to survive the extra-uterine environment.  The nulliparous 
uterus weighs 50-70g, increasing by 1110g during pregnancy (Chard and 
Grudzinskas, 2003).  This demonstrates the ability of the uterus to accommodate the 
growing foetus assisted by uterine hyperplasia and hypertrophy, whereby cells 
increase in number and size respectively.  Hyperplasia occurs during the first 
trimester followed by hypertrophy at the beginning of the second trimester of 
pregnancy.  Mid-gestation, hypertrophy is halted and instead the uterus converts or 
stretches (Reynolds, 1947).  Various uterine tissues (refer to Figure 1.4 on the next 
page) support the growing foetus during gestation, such as the placenta, an organ 
connected to both the uterine wall and the umbilical cord so that the foetus can be 
sustained by the maternal blood supply.  The amniotic membranes (amnion and 
chorion) surround the amniotic fluid and foetus, whilst the choriodecidua makes 
contact with the myometrium. 
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Figure 1.4: The various tissues comprising the pregnant reproductive tract in the first 
trimester of gestation.  Gestational tissues include: the foetal membranes (amnion, 
and chorion), placenta, umbilical cord, amniotic fluid, the foetus, decidua, 
myometrium and cervix.  As pregnancy progresses, the chorion fuses with the 
decidua to form the choriodecidua.  Schematic adapted from (Martini, 2004). 
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Ninety-five percent of pregnancy involves the myometrial smooth muscle 
overcoming an inherent tendency to contract with stretch, requiring not only the near 
absence of myometrial contractions (relative quiescence), but also refractoriness to 
contractile agents (Carvajal and Weiner, 2003).  Spasmolytic proteins are abundantly 
synthesised by the uterus throughout gestation.  Relaxin (Bell et al., 1987), nitric 
oxide (Choi et al., 2002), prostacyclin (Korita et al., 2002) and Corticotrophin-
Release Hormone (CRH) (Grammatopoulos and Hillhouse, 1999) act at specific 
receptors to maintain an inhibitory uterine state.  Correspondingly, the excitatory JZ 
undergoes focal disruption in early gestation, whereby on ultrasound the signal 
intensity is substantially reduced (Turnbull et al., 1995). 
1.4.1 Ovarian steroids and pregnancy 
Oestrogen and progesterone play pivotal roles in pregnancy and parturition.  They 
are produced predominantly by the ovaries and act in an endocrine manner at their 
specific cognate receptors in the endometrium, myometrium and the uterine 
vasculature.  The non-gravid uterus expresses both ER and PR (Snijders et al., 1992).  
Oestrogen receptor-α (ER-α) and oestrogen receptor-β (ER-β) are structurally related 
nuclear receptors transcribed by different genes.  Progesterone binds to the 
progesterone receptor, of which there are two isoforms named progesterone receptor 
A (PRA) and progesterone receptor (PRB), deriving from a single gene (Clarke and 
Sutherland, 1990, Kastner et al., 1990).  In addition to an activator role, PRA is 
known to repress PRB mediated transcription through ligand but not 
Deoxyribonucleic acid (DNA) interaction (Savouret et al., 1994).  Ovarian steroids 
use genomic cell signalling to regulate initiation of and adaption to the pregnant state 
through maternal uterine changes. 
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For example, for pregnancy to be established, the endometrium must differentiate to 
a receptive state through a complex interplay of prostaglandins, adhesion molecules, 
cytokines and embryonic factors, all of which are dependent on ovarian steroid 
synthesis (Lim et al., 2002).  This lasts between days 21-24 (the window of 
implantation) of an idealised 28 day cycle in the human (Wilcox et al., 1999) and 
ensures successful blastocyst implantation.  Progesterone suppression of ER-α could 
prevent defective endometrial receptivity (Lecce et al., 2001, Critchley et al., 2001, 
Lessey et al., 2006).  Progesterone activation of PRB offers another implantation-
protective mechanism by suppressing progesterone-PRA induced immune cell 
migration (Lydon et al., 1995), possibly by negatively regulating chemotactic factors 
implicated in menstruation and corpus luteal regression (Critchley et al., 2003). 
Corpus luteal function is maintained by conceptus hormone secretion enabling the 
foeto-placental unit to develop (Spencer and Bazer, 2004).  The placenta largely 
contributes to progesterone and oestrogen synthesis which increase during gestation 
(Soldin et al., 2005) and alter uterine gene expression to support foetal growth and 
development.  Progesterone dominates over oestrogen and sustains myometrial 
quiescence by suppressing oestrogen-induced myometrial activators such as gap 
junctions (MacKenzie et al., 1983, Saito et al., 1987).  Consequently, electrical 
activity cannot spread from cell to cell, which perturbs synchronous contraction.   
ER is detectable in pregnant myometrium yet, it is the β subtype, which dominates 
over ER-α and inversely with Connexin-43 (CX-43) (Wu et al., 2000), so that 
despite rising oestrogen with gestation progression, early activation of the 
myometrium is repressed. 
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In the weeks leading up to term, secretion of foetal cortisol stimulates increases in 
maternal oestradiol (Liggins et al., 1977), altering the ratio of oestrogen: 
progesterone to favour oestrogen (Darne et al., 1987, Fischer-Rasmussen et al., 
1981).  Although ER fails to increase at term (Padayachi et al., 1990, Kawaguchi et 
al., 1991), most notably ER-α (Wu et al., 2000),  hormone changes may be enough to 
up-regulate contractile associated proteins (CAPs) including oxytocin, prostanoid 
receptors and gap junctions to prime the myometrium for labour (Cook et al., 2000).  
Preceding human labour, progesterone does not decline (Rezapour et al., 1997) and 
so the classic luteolytic mechanism, which is crucial for labour initiation in other 
species may instead involve changes in myometrial PR receptor densities or their 
downstream effects.  PR increases with labour (Rezapour et al., 1997), yet it is the 
high ratio of PRA: PRB (Pieber et al., 2001, Winkler et al., 2002) that prevents the 
suppression of oestrogen-mediated gene expression required for parturition.  
Oestradiol levels are unchanged with labour onset (Kofinas et al., 1990), 
corresponding with constant ER (Rezapour et al., 1997) and hence oestrogen appears 
to be unessential for labour initiation.  Interestingly ER-α is detected after parturition 
has begun (Winkler et al., 2002) and possibly the result of altered PRA expression 
(Mesiano et al., 2002) to help sensitise myometrial contractility when parturition 
begins. 
1.4.2 Parturition 
Human parturition, or labour as it is otherwise known, is a complex physiological 
process, which involves the synchronization of uterine contraction, cervical dilation 
and foetal membrane rupture.  The already activated myometrium becomes 
stimulated to produce powerful downward contractions, which allow the successful 
passage of the foetus through the birth canal. 
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At the same time the cervix must be effaced and then dilated to a sufficient diameter 
(10 cm) and the foetal membranes ruptured (Sohan et al., 1999).  Labour is divided 
into three main stages, the first stage commences with the onset of forceful uterine 
contractions and terminates when the cervix has reached full dilation and is no 
longer palpable.  The second stage begins at full cervical dilation and the third stage 
or placental stage begins with foetal delivery and ends with the separation and 
expulsion of the placenta.  It is speculated that because the neurohypophysial 
hormone oxytocin and the uterine hormone PGF2α are potent smooth muscle 
stimulants of gravid myometrium in vitro, they may also stimulate uterine contractile 
activity in vivo during labour (Wikland et al., 1982). 
1.4.3 Preterm labour syndrome 
Preterm labour syndrome (delivery of the foetus at less than 37 weeks gestation), 
where there is asynchrony between the labour process and foetal maturation, has 
changed little in incidence in the past 40 years (Creasy, 1991).  The cause of preterm 
labour is multifactorial, may vary at different times during pregnancy and will not 
necessarily reflect acceleration of the processes at term gestation (Meis et al., 1998), 
hence why it is often referred to as a syndrome.  Causes of preterm labour, in 
general, fall into three categories: iatrogenic, (demonstrable complication of 
pregnancy), premature rupture of the foetal membranes with or without infection and 
idiopathic preterm labour (unknown cause).  It was quoted that one in ten of all 
births occur before term gestation is reached, with such births accounting for 75% of 
all major neonatal problems (Terzidou, 2007). 
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Preventing preterm labour would reduce the cost for healthcare providers running 
specialist units to care for premature newborns but more importantly reduce the 
neonatal morbidity and mortality concentrated among very low-birth weight 
(<1500g) and extremely premature infants, particularly those delivered prior to 32 
weeks (Goldenberg et al., 2000).  There are existing tocolytic therapies (for more 
detail refer to Appendix 2), such as calcium channel blockers (e.g. nifedipine), β2 
adrenoceptor agonists (e.g. ritodrine), OTR antagonists (e.g. atosiban) and Non-
Steroidal Anti-Inflammatory Drugs (NSAIDs, e.g. indometacin), which are 
administered to women showing signs of labour before 37 weeks gestation, with the 
aim to arrest uterine activity for 48 hours.  Thereby clinicians have sufficient time 
for maternal, parenteral steroid administration, to help the neonate to survive preterm 
birth.  Unfortunately, tocolytics cannot be used for more than 48 hours since the risk 
to the mother is increased (refer to Appendix 2). 
The OTR-antagonist atosiban and the β2 agonists: salbutamol or terbutaline are 
administered to labouring women who are between 24 and 33 weeks of gestation but 
cause maternal nausea, vomiting, tachycardia, hypotension and headache.  
Indometacin can be used off-label when other tocolytics have failed but carries the 
risk of harmful side effects to the foetus such as premature closure of the ductus 
arteriosis and transient impairment of renal function (Joint Formulary Committee, 
2012).  Nifedipine, although not licensed for use as a tocolytic agent, is administered 
in the clinic but requires further safety testing based on concerns owing to nifedipine 
resulting in severe hypotension in some pregnant women (Chan et al., 2008).  The 
choice of the first-line tocolytic agent in terms of safety, effectiveness and cost is a 
topic of continual debate (de Heus et al., 2010) and the search for alternative types of 
treatments, which are more specific and thereby safer in their actions continues. 
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1.5 Prostanoids 
1.5.1 Prostanoid biosynthesis 
Prostaglandins (PGs): D, E, F and I and thromboxane are collectively termed 
prostanoids.  They are a sub-class of the lipid mediator group known as eicosanoids 
and are implicated in a wide range of reproductive processes, both physiological and 
pathophysiological.  Research carried out by Kurzrok and Lieb (Kurzrok and Lieb, 
1930) demonstrated uterine stimulant activity of semen in vivo and hence brought to 
attention the existence of an undiscovered contractile substance.  The active 
substance was named prostaglandin (Von Euler, 1934) two of which, Prostaglandin 
E and Prostaglandin F, were later isolated from semen (Bergstrom and Sjovall, 
1957).  Prostanoids can be biosynthesized as the body requires from three related 
polyunsaturated fatty acid (PUFA) precursors present in cell membranes: dihomo-
gamma-linolenic acid (DGLA), arachidonic acid (AA) and eicosapentaenoic acid 
(EPA) giving rise to 1-, 2- and 3-series prostanoids, respectively (Narumiya et al., 
1999) and differing only in the number of carbon double bonds in their structures.  
As shown in Figure 1.5 on the next page, the first step of series-2 prostanoid 
formation is the release of AA (an n-6 PUFA) from membrane phospholipids, by 
Phospholipase A2 (PLA2) in response to a stimulus for example, trauma.  Similarly, 
the formation of series-1 and -3 prostanoids begins with DGLA and EPA liberation 
respectively from membranes by the action of PLA2. 
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Figure 1.5:  The biosynthesis of biologically active PGs (in purple) from precursor lipids 
(black).  Inactive metabolites are shown in brown.  Both DGLA and EPA are essential fatty 
acids obtained through dietary intake, whilst AA is a non-essential fatty acid.  TXA2 is pro-
thrombotic and vasoconstrictory and these effects are antagonised by PGI2.  The non-
enzymatic hydrolysis product of PGI2 is 6-keto-PGF1α.  PGF2α and PGE2 are essential for 
parturition and ovulation/fertilisation respectively.  PGD2 is anti-aggregatory, pro-
vasodilatatory (via DP1) and could promote allergic response (via CRTH2).  More recently 
it has been shown that PGD2 metabolites (shown in blue) can elicit physiological response.  
Series-3 PGs and their precursor, PGH3 are less potent than series-2 PGs and therefore are 
anti-thrombotic/inflammatory.  Series-1 PGs, namely PGE1 are also anti-inflammatory.  
Steroids and NSAIDs are anti-inflammatory and block PG production by inhibiting PLA2 
and COX respectively (Narumiya and FitzGerald, 2001, Hata et al., 2003, Catalano et al., 
2011). 
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Cyclo-oxygenases (COX-1 and COX-2, the latter being inducible) catalyse the 
formation of Prostaglandin G2 (PGG2) from AA, which then yields Prostaglandin H2 
(PGH2) (Chandrasekharan and Simmons, 2004).  The same enzymes catalyse the 
formation of PGG1 and PGH1 from DGLA and PGG3 and PGH3 from EPA.  Specific 
enzymes called prostanoid synthases: PGD synthase (PGDS), PGE synthase (PGES), 
PGF synthase (PGFS), PGI synthase (PGIS) and TXA synthase (TXAS) render the 
prostanoids: Prostaglandin D2 (PGD2), Prostaglandin E2 (PGE2), Prostaglandin F2α 
(PGF2α), Prostaglandin I2 (PGI2, also known as prostacyclin) and Thromboxane A2 
(TXA2) correspondingly from PGH2, all of which possess potent biological activity 
at specific receptors (refer to Table 1 on page 25). 
There are two enzymes which catalyse the formation of PGD2 from PGH2, 
haematopoietic PGDS (H-PGDS) (Kanaoka et al., 2000) and β-trace/lipocalin PGDS 
(L-PGDS) (Urade and Hayaishi, 2000).  PGE2 formation results from cytosolic 
(cPGES or PGES-3) (Tanioka et al., 2000) or membrane bound PGES (mPGES or 
PGES-1/PGES-2) (Jakobsson et al., 1999).  PGF2α biosynthesis can occur via three 
pathways, namely: action of PGH 9-, 11-endoperoxide reductase (Aldo-keto 
reductase family, member B1: AKR1B1 and Aldo-keto reductase family, member 
C3: AKR1C3), PGE 9-ketoreductase (Aldo-keto reductase family, member C1: 
AKR1C1, Aldo-keto reductase family, member C2: AKR1C2 or Carbonyl reductase 
1: CBR1) or PGD 11-ketoreductase (AKR1C3) on PGH2, PGE2 and PGD2 
respectively (Watanabe, 2002, Catalano et al., 2011). 
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Prostanoids can act in an autocrine manner and are capable also of paracrine action 
in other cells because they can enter and exit cells via membrane transporters, for 
example, the solute carrier organic anion transporter member 2A1 (SLCO2A1, also 
known as PG transporter) and human ATP-binding cassette transporter member 4 
(ABCC4) respectively (Chan et al., 2002, Rius et al., 2005).  Actions of prostanoids 
are short-lived in vivo (with half-lives of seconds to minutes provided they are 
deactivated).  Prostacyclin and thromboxane have very short half lives and form the 
stable but inactive metabolites 6-keto-Prostaglandin F1α (6-keto-PGF1α) and 
Thromboxane B2 (TXB2) correspondingly (Konturek and Pawlik, 1986).  Indeed, 6-
keto-PGF1α is a useful marker of PGI2 biosynthesis in vivo (Brash et al., 1983) and 
other groups have analysed these metabolites to reflect their precursor concentrations 
(Liggins et al., 1980, Rees et al., 1984). 
The effects of PGs are terminated upon transportation across cell membranes via the 
prostaglandin transporter (PGT), where they are delivered to cytoplasmic 15-
hydroxyprostaglandin dehydrogenase (15-PGDH) and prostaglandin ∆-13-reductase 
for metabolism (Nomura et al., 2004, Chi et al., 2005).  Prostaglandins are 
catabolised to their 15-keto metabolites by 15-PGDH whereas TXB2 inactivation is 
catalysed via 11-hydroxythromboxane B2 dehydrogenase (11-TXB2DH) (Tai et al., 
2002).  PGD2 also spontaneously forms active metabolites 9α, 11β-Prostaglandin F2 
(9α, 11β-PGF2), Prostaglandin J2 (PGJ2), ∆
12-Prostaglandin J2 (∆
12-PGJ2) and 15-
deoxy-∆12, 14 Prostaglandin J2 (15-deoxy-∆
12, 14 PGJ2) (Fitzpatrick and Wynalda, 
1983, Bullo et al., 2005).  Further oxidation of metabolites occurs before they are 
excreted in the urine (Moore, 1982). 
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Unlike series-2 prostanoids, series-1 and series-3 PGs occur at very low picomolar 
amounts in urine or plasma (Schweer et al., 1994, Hammes et al., 1999) although at 
higher concentrations if diets have been supplemented with n-six or n-three PUFAs 
respectively, as demonstrated in wound exudates (McDaniel et al., 2011).  The 
balance of series-1, -2 and -3 PG synthesis therefore depends on the abundance of 
each PUFA precursor.  Meats and evening primrose oil contain high amounts of 
Gamma Linolenic Acid (GLA) and contribute to enhanced DGLA levels in 
membrane phospholipids (Johnson et al., 1997), which is likely to increase the 
synthesis of series-1 (via COX) and to a lesser extent series-2 PGs (via Delta-5-
desaturase) in humans.  Predominantly, Prostaglandin E1 (PGE1) has been studied 
and has potent anti-inflammatory properties (Whittle et al., 1978, Ishikawa et al., 
1998), whilst the anti-inflammatory effects of the other series-1 PGs: Prostaglandin 
D1 (PGD1) and Prostaglandin 1α (PGF1α) are still questionable.  A diet rich in fish oils 
containing EPA can enhance serum EPA levels and series-3 PG production in a 
dose-dependent manner (von Schacky et al., 1985, Mantzioris et al., 1994).  Triene 
prostanoids appear to work together to promote anti-inflammation, for example, 
urinary Prostaglandin I3 (PGI3) predominates after EPA dietary supplementation, 
coinciding with anti-aggregatory effects and lowered blood pressure (von Schacky et 
al., 1985).  Correspondingly, long term consumption of EPA may offer 
cardiovascular protection (Kris-Etherton et al., 2003).  The series-3 prostanoid 
inflammatory effects are less potent than series-2 prostanoids, for example, PGE2 
attenuates PGD2 inhibitory effects, whilst Prostaglandin E3 (PGE3) does not prevent 
the Prostaglandin D3 (PGD3)-mediated inhibition of platelet aggregation (Gryglewski 
et al., 1979).  Series-3 prostanoids were detected in the human uvea (Kulkarni and 
Srinivasan, 1986) but have not been measured in uterine tissues from women as yet. 
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1.5.2 Prostanoid receptors 
In contrast to the detection and measurement of prostanoids, it was not until the early 
1990s that prostanoid receptor subtypes were classified (Coleman et al., 1994) and 
characterised as functional units in human myometrium using specific prostanoid 
agonists and antagonists (Senior et al., 1991, 1992, 1993).  Naturally occurring 
prostanoids elicit their effects by activating distinct receptors, for example, PGD2, 
PGI2, PGE2, TXA2 and PGF2α bind to DP1, IP, EP, TP and FP receptors 
correspondingly (Coleman et al., 1994).  A further four subtypes of EP receptors 
exist, (EP1-4) whose structure, G protein coupling and downstream signalling 
cascades differ to produce heterogenic effects. 
Also potentiating the diversity of prostanoid action is the alternative splicing of RNA 
so that the same gene can encode different proteins, in effect, isoforms.  One FP 
(Vielhauer et al., 2004), two TP and nine EP3 splice variants (Negishi et al., 1993, 
Pierce and Regan, 1998) have been cloned in the human whilst in other species, the 
cloning of two ovine FP (Pierce et al., 1997) and rodent EP1 receptors have been 
demonstrated (Pierce and Regan, 1998).  More recent studies have identified a 
second DP receptor (DP2) present on immune cells named Chemoattractant Receptor 
Homologous to the T helper 2 cell (CRTH2), coupled with Gαi at which PGD2 and 
its metabolites act with high affinity (Hirai et al., 2001).  PGD2 metabolites, 
specifically, 15-deoxy-∆12, 14 PGJ2 also bind to nuclear receptor, Peroxisome 
Proliferator-Activated Receptor-γ (PPAR-γ) but with lesser affinity than for CRTH2 
(Forman et al., 1995).  According to Table 1, prostanoids and their receptors can be 
divided into two main groups based on how they influence myometrial contractility. 
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Table 1: Prostanoid receptors and their respective signal transduction pathways.  
Gαq and Gαi proteins enhance uterine contraction by stimulating IP3 and inhibiting 
cAMP production respectively.  Gαs proteins elicit a relaxatory effect on 
myometrium via increases in cAMP production (Narumiya et al., 1999, Tsuboi et al., 
2002, Hata and Breyer, 2004, Yang et al., 2008).  Abbreviations are as follows: 
RXR: Retinoid X Receptor; PPAR: Peroxisome Proliferator-Activated Receptor; » 
Receptor dimer which binds to specific DNA response elements to promote target 
gene transcription; +ovine; R rat; (?) possible action. 
Type Subtype Isoforms G protein Second messenger 
IP 
IP Gαs/Gαi/Gαq ↑↓cAMP, ↑IP3 
PPAR-β/δ (?) - Genomic» 
DP  
DP1 Gαs ↑cAMP 
CRTH2 (DP2) Gαi ↓cAMP, ↑Ca
2+, ↑IP3 
PPAR-γ/RXRα - Genomic» 
EP 
EP1 EP1 & variant
R Unknown ↑Ca2+, low ↑IP3 
EP2  Gαs ↑cAMP 
EP3 
EP3: 
1a,1b,II,III,IV,
V, VI, e & f 
Gαs/Gαi/Gαq ↑↓ cAMP, ↑IP3 
EP4  Gαs ↑ cAMP 
FP 
FP-A & FP-B+ Gαq ↑Ca2+, ↑IP3 
FP(s) Unknown Unknown 
TP 
TP: Gαq ↑Ca2+, ↑IP3 
TPα/TPβ Gαs/Gαi ↑cAMP/↓cAMP 
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The first group of prostanoid receptors are spasmogenic or contractile and comprise 
PGF2α, TXA2 and PGE2 acting at FP, TP, and EP1/EP3 respectively.  The second 
group are spasmolytic or relaxant, namely PGD2, PGI2 and PGE2 which interact with 
DP1, IP and EP2/EP4 receptors correspondingly (the series-1 and -3 PGs behave as 
for the series-2 PGs).  Each receptor has its own type of G protein sub-unit α which 
determines the type of second messenger and physiological response obtained as a 
result of receptor activation (refer to Table 1).  DP, IP and EP2/EP4 receptors 
stimulate Gαs coupled with AC leading to cAMP formation and consequently 
inhibition of smooth muscle contraction.  FP, TP and EP1/EP3 receptors couple 
intracellularly with Gαi and Gαq and stimulate the myometrium to contract.  Whilst 
Gαq couples with PLC to catalyse production of DG and IP3, Gαi inhibits cAMP, the 
resultant effect being an increase in intracellular calcium in myocytes. 
As summarised in Figure 1.2a, calcium is essential for myometrial contraction, 
which lends itself mainly to the process of parturition.  EP3 elicits a stimulatory 
response in non-pregnant myometrium (Senior et al., 1991) by AC inhibition 
however, depending upon cell distribution and splice variants, AC stimulation is 
possible (Narumiya et al., 1999).  To take into consideration, is the promiscuous 
action of prostanoids on other receptors, for example, PGI2 and PGD2 are likely to 
have minor stimulatory effects at EP3 or FP receptors (Senior et al., 1992).  PGF2α is 
known to bind EP and TP receptors (Coleman et al., 1984), although in myometrium 
activation of TP response is likely to be minimal (Senior et al., 1992). 
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1.5.3 Prostanoids in the uterus: non-pregnancy 
Prostanoid profiles in the human uterus fluctuate during the menstrual cycle.  
Eicosanoid synthesis also varies according to uterine tissue type.  The prostanoids 
are synthesised by myometrial smooth muscle but PGI2 clearly predominates (Abel 
and Kelly, 1979, Rees et al., 1984), in accord with strong staining of PGIS in uterine 
smooth muscle cells (Battersby et al., 2004).  Conversely, in endometrium the same 
authors showed that PGE2 and PGF2α were most plentiful, which may reflect the 
differences in cell types between both tissues.  PGES and PGE2 are localised mainly 
to the glandular, stromal and endothelial cells, particularly of the dynamic 
functionalis, whereas in the myometrium expression of PGE2 was restricted to 
endothelial cells (Milne et al., 2001a). 
The endometrium is capable of producing 10-fold greater concentrations of PG in 
vitro than myometrium (Rees et al., 1984), corresponding with the more apparent 
cyclical expression of sex steroid receptors (Vienonen et al., 2004) and possibly 
greater exposure to ovarian steroids (Alsbach et al., 1983).  Inactive prostanoid 
metabolites are excreted in the urine at higher concentrations than their precursors 
(Presser et al., 1991, Farker et al., 1997) but have low biological activity at 
prostanoid receptors (Moore, 1982).  The PGD2 metabolite, 15-deoxy-∆
12, 14-PGJ2 
does not activate DP1 receptors in platelets but can activate eosinophils through 
CRTH2 (Monneret et al., 2002).  This metabolite occurs at low picomolar 
concentrations in urine (Bell-Parikh et al., 2003) but has yet to be measured in the 
human myometrium along with other PGD2 metabolites. 
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1.5.4 Prostanoid receptors in the uterus 
Elucidation of the reproductive functional roles of prostanoids depends upon which 
of these receptors are functionally active in the uterus.  A heterogeneous population 
of functional EP receptors exists in myometrium, with an abundance of inhibitory 
EP2 receptors and the predominant excitatory EP subtype being EP3 (Senior et al., 
1991).  Functionally active myometrial DP1, TP, IP and FP receptors were also 
demonstrated by the same authors in a later study (Senior et al., 1992).  The uterine 
vasculature whose network extends throughout the uterus contains abundant TP and 
also IP and possibly EP4 receptors (Baxter et al., 1995).  PGI2 acting via the IP 
receptor may promote uterine vascular homeostasis, whilst maintaining a relative 
degree of quiescence in the myometrium of non-pregnant women.  Disorders of 
menstruation may result from imbalanced PGI2 production, whilst the pregnant 
uterus may depend upon its synthesis to prevent preterm delivery.   
The endometrium expresses the PG receptors IP, EP2/4 and FP, which are able to 
generate second messenger in vitro (Milne et al., 2001a, Milne and Jabbour, 2003, 
Battersby et al., 2004), whilst EP1/3, DP1/2 and TP RNA transcripts although 
expressed (Catalano et al., 2011) are yet to be studied in terms of functionality (e.g. 
measuring second messenger in response to a selective PG agonist).  Prostanoid 
receptor expression changes temporally with localisation mainly to the functional 
layer glands and stroma but also smooth muscle and endothelial cells of blood 
vessels.  PGE2 and PGF2α act at EP2 and FP receptors correspondingly to initiate 
proliferation in Ishikawa cells via Epidermal Growth Factor Receptor 
(EGFR)/Extracellular signal-Regulated Kinase (ERK) 1/2 and PLC pathways 
respectively (Milne and Jabbour, 2003, Sales et al., 2004) and could do the same in 
endometrium to restore the functional layer with each menstrual phase. 
Chapter One: Introduction 
29 
 
1.5.5 Prostanoids and the menstrual cycle 
PGE2 and PGI2 generate most cAMP corresponding with maximal EP4 receptor 
expression during the time of ovarian follicle growth (Milne et al., 2001a, Battersby 
et al., 2004) and thus providing important vasodilatatory action.  Myometrial 
contractions increase in frequency during proliferative phase (Kunz et al., 1998, 
Maslow and Lyons, 2004) coinciding with up-regulation of gap junctions (Saito et 
al., 1987, Wang and Schneider, 1991, Jahn et al., 1995) under the influence of 
oestrogen (MacKenzie et al., 1983).  Uterine contractions travel from the cervix 
towards the fundus (Lyons et al., 1991, Kunz et al., 1996, Ijland et al., 1996), 
corresponding with enhanced responsiveness to spasmogenic PGF2α in isolated, 
lower segment uterine smooth muscle (Fischer, 2010), possibly to aid sperm 
transport. 
Progesterone dependent decidualisation of the endometrium is essential for 
pregnancy maintenance and relies on generation of cAMP (Dunn et al., 2003) 
mediated by a positive feedback loop involving a PGE2-EP2 interaction (Brar et al., 
1997).  Late luteal phase, if implantation has not occurred, sharp withdrawal of the 
steroid support of endometrial structures takes place. Vascular degeneration is 
thought to be induced by a variety of factors inhibited by progesterone including 
PGF2α and TXA2 (Liggins et al., 1980, Rees et al., 1984).  Both mediators act at TP 
receptors (TXA2 being the most potent) in the uterine arteries to produce 
vasoconstriction (Baxter et al., 1995) and contributing to endometrial hypoxia. 
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In vitro uterine PG synthesis increases dramatically between late luteal phase and 
menstruation onset in non-pregnant women (Downie et al., 1974, Singh et al., 1975, 
Willman et al., 1976, Maathuis and Kelly, 1978, Liggins et al., 1980, Rees et al., 
1984, Leaver and Richmond, 1984, Ishihara et al., 1986, Rees and Kelly, 1986) 
consistent with the decline in both sex steroid and their receptors in the endometrium 
(Lessey et al., 1988, Garcia et al., 1988, Snijders et al., 1992, Noe et al., 1999, 
Vienonen et al., 2004).  Prostanoids have been proposed to mediate digestion of 
endometrial tissue by up-regulating chemokines in particular, Interleukin-8 (IL-8 or 
Neutrophil Activating Peptide (NAP-1)) and hence leukocyte infiltration into the 
endometrium (Jones et al., 1997).  To aid with endometrial shedding, uterine 
contractions become antegrade (fundus to cervix) (de Vries et al., 1990) regulated by 
loss of progesterone-PR attenuation of activity in the fundus (Lye et al., 1998, 
Challis et al., 2002) and possibly by alterations in spasmogenic: spasmolytic 
prostanoid receptor ratios topographically. 
1.5.6 Prostanoids in non-cancerous pathology of the uterus: menorrhagia 
PGs are likely exacerbators of menorrhagia, since COX-2 expression correlates 
positively with menorrhagia severity (Milling Smith et al., 2007) and MBL is 
attenuated by the NSAID, ibuprofen (Makarainen and Ylikorkala, 1986a) (for a 
summary of the pharmaceutical agents used to treat this disorder refer to Appendix 
1).  Insufficient production of vasoconstrictory mediators and excessive synthesis of 
vasodilatatory PGs in the endometrial vasculature is likely to worsen symptoms, 
since there is an inverse correlation between the ratio of PGF2α and PGE and blood 
loss in endometrium (Smith et al., 1981a) and synthesis of PGI2 (Smith et al., 1981b) 
(Ylikorkala and Makila, 1985) and nitric oxide (Zervou et al., 1999) are high in 
menstrual blood of sufferers. 
Chapter One: Introduction 
31 
 
1.5.7 Prostanoids, pregnancy and parturition 
In order to maintain uterine quiescence during gestation, PGI2 production is 
abundant (Satoh et al., 1981), whilst the expression of EP3 and FP receptors is down-
regulated to below non-pregnancy levels (Matsumoto et al., 1997).  Maximal uterine 
stretch and pressure from the weight of the foetus in the final weeks of gestation 
could stimulate cervical remodeling ready for dilation, by stimulating the production 
of chemokines such as IL-8 (Loudon et al., 2004).  Moreover, the prostaglandin gel 
(misoprostol a PGE1 analogue, specific for the EP2 and EP3 receptor) applied intra-
vaginally can promote cervical ripening (Aronsson et al., 2005). 
For parturition to occur at term, intrauterine tissues first need to be activated to 
prepare for the work of parturition and then stimulated to initiate labour, whereby the 
functional withdrawal of progesterone restores oestrogen-mediated uterotonin gene 
expression.  As it stands, the whole range of prostanoids have not been measured in 
human myometrial tissues taken from labouring women.  However, COX-2 
expression was enhanced (Cook et al., 2000) and synthesis of the excitatory 
prostanoid PGF2α increased in the amniotic fluid (Reddi et al., 1984) and plasma of 
labouring women (Davidson et al., 1987), with a likely action on the myometrium.  
PGF2α and PGE2 were excitatory in the fundus and without effect on the lower 
portion (Wikland et al., 1984, Wiqvist et al., 1985) and could therefore induce labour 
contractions in a downward direction to aid foetal delivery.  Relaxation of the cervix 
to facilitate dilation is also a crucial step during labour corresponding with limited 
gap junction protein CX-43 (comprising the channel) near to the parturient cervix 
(Sparey et al., 1999). 
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1.5.8 Prostanoids and preterm labour 
To the author’s knowledge, PGs have not been measured in myometrial tissue from 
preterm labouring donors.  However, the myometrial PG receptors have been a focus 
in previous research, whereby EP1 expression was greater at term labour versus 
preterm labour (Astle et al., 2005, Grigsby et al., 2006).  Therefore term and preterm 
labour processes, for example, those which generate uterine contractions are likely to 
involve different PG receptor subtypes and consequent intracellular signalling 
mechanisms.  Concurrently, myometrial PGES-2 and PGES-1 expression was more 
abundant at preterm and term labour (compared with non-labour) respectively (Astle 
et al., 2007).  This highlights the importance of studying both types of labour 
separately to better understand their aetiologies and find suitable targets for tocolysis 
for the treatment of preterm labour syndrome.  A clear increase in amniotic fluid 
PGE2 and PGF2α during preterm labour (Romero et al., 1993, Menon et al., 2011) 
implies that women in preterm labour would benefit from specific PG relaxant 
agonists and PG contractile antagonists delivered locally to the uterus.  This could be 
more beneficial than current forms of tocolytic treatment with detrimental side 
effects and lacking in any considerable efficacy. 
1.6 Chemokines and cytokines in pregnancy and at parturition 
In the lead up to term, neutrophils and macrophages migrate to the human cervix 
(Bokstrom et al., 1997) in response to chemokines such as IL-8, which has been 
shown to increase in cervical fluid during the third trimester of pregnancy 
(Mondestin-Sorrentino et al., 2007). 
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These leukocytes secrete various important chemo-attractant factors for specific 
immune cells such as Monocyte Chemotactic Protein-1 (MCP-1), Regulated upon 
Activation, Normal T-cell Expressed, and Secreted (RANTES) and Endothelial-
Monocyte-Activating Polypeptide-II (EMAP-II) to name a few.  Select chemokines, 
for example, EMAP-II serve multifunctions as both cytokines and angiogenic 
regulators (Tas and Murray, 1996), whilst other mediators such as RANTES 
(Athayde et al., 1999), Macrophage Inflammatory Proteins (MIPs) (Wang et al., 
1993), IL-6 (Romano et al., 1997) and sICAM-I (soluble Intercellular Adhesion 
Molecule-1) (Marvin et al., 1999) help to recruit inflammatory cells. 
Leukocyte migration involves not only chemical stimuli but also factors that allow 
for leukocyte extravasion (escape from blood vessels into tissues) such as a) 
cytokines mediating vasodilatation facilitating increased blood flow in tissues such 
as EMAP-II (Tsai et al., 2004) b) factors for example, Vascular Endothelial Growth 
Factor (VEGF) (Ferrara and Gerber, 2001), which promote permeability by causing 
fenestrations and leaking of the vasculature, resulting in stasis of blood flow to aid 
leukocyte attachment to the endothelium and c) endothelial receptors; Selectins or 
ICAMs that bind to leukocyte cell surface ligands (for example, Lymphocyte 
Function-associated Antigen-1 (LFA-1)) and help these cells to make contact with 
and roll along endothelium (Smith et al., 1989).  Leukocytes then pass through the 
basement membrane and into tissues where they can perform their functions.  
Macrophages deriving from monocytes, with their chemokine and cytokine secretory 
capacity (Stow et al., 2009) and ability to produce the aforementioned degradative 
enzymes (MMPs or Matrix Metalloproteinases) are likely, in part, to mediate 
cervical remodeling (ripening) (Kelly, 2002) and the weakening of foetal membrane 
integrity, which takes place before labour onset (Arikat et al., 2006). 
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The cervix during pregnancy is closed and relies upon a collagen matrix for integrity, 
namely collagen type-1 (Iwahashi et al., 2003).  At term, the cervix effaces (ripens) 
to become softer and thinner (and therefore shortens) in preparation for cervical 
dilation during labour.  Correspondingly, women with a short cervix are at increased 
risk of commencing labour before 37 weeks gestation (Iams et al., 1996).  
Neutrophils which respond to IL-8 secrete collagenase and thus facilitate in breaking 
down the collagen component of the cervix (Kelly, 2002).  This process takes place 
right through into labour so that the cervix dilates, coinciding with increased elastase 
production (Kanayama and Terao, 1991).  Labour is regularly described in the 
literature as an “inflammatory process” involving the up-regulation of genes 
associated with changes to vascular response, such as VEGF (Hassan et al., 2006) 
secreted by neutrophils (Taichman et al., 1997) and those involved in cellular 
trafficking (Bollopragada et al., 2009).  That way, leukocytes capable of secreting 
pro-inflammatory mediators migrate to the uterus. 
Unique to lower segment myometrium and cervix, leukocyte numbers increase 
further with labour onset (Thomson et al., 1999, Young et al., 2002), coinciding with 
chemokine and pro-inflammatory cytokine expression (Young et al., 2002, 
Sennstrom et al., 2000, Osman et al., 2003, Tattersall et al., 2008) and with 
progression of cervical dilation (Winkler et al., 1999a).  Cytokines, such as IL-6 
have important immunomodulatory roles, whose signalling pathways span to include 
the regulation of many different proteins at gene level.  This may include an 
influence on COX based on a study using cytokine receptor knockout mice (Hirsch 
et al., 2006). 
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1.7    Aims and objectives 
The central aim of this thesis was to explore the profile of PGs in uterine tissues 
donated by non-pregnant, pregnant and parturient women, aiming to gain insight into 
the roles they play during non-pregnancy, pregnancy and labour.  Finally, the 
predictive value of Cervico-Vaginal Fluid (CVF) cytokines in the early detection of 
preterm labour was determined.  The rational for these study areas is listed in more 
detail below. 
1.7.1 Lipidomic profiling of uterine tissues obtained from non-pregnant 
women 
1.7.1.1 Utero-specific prostanoid release 
Previous studies, which have analysed uterine prostanoid synthesis in vitro, have 
used predominantly radioimmunoassay (RIA), which is limited to the analysis of 
single, prostanoid metabolites per uterine tissue.  Moreover, detection of PGs using 
RIA (particularly in earlier studies) lacks specificity owing to antibody cross-
reactivity, resulting in over-estimations of metabolite concentrations.  Rees et al 
(Rees et al., 1984) used RIA to compare the production of PGI2, PGE2 and PGF2α 
(but not TXB2) in superfusate collected from minced endometrium versus 
myometrium incubated in solution, rather than tissue homogenate.  Abel et al (Abel 
and Kelly, 1979) measured exogenous, endometrial and myometrial PG release from 
radio-labelled AA and although findings suggest an important homeostatic role for 
PGI2, data do not represent in vivo events.  Another group measured TXB2 
production from endometrial perfusate according to menstrual phase, although did 
not carry out myometrial comparisons (Liggins et al., 1980). 
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Moreover, endometrial messenger RNA (mRNA) expression of TXAS was not 
compared with myometrium (Catalano et al., 2011).  It is hypothesised that like 
PGE2 and PGF2α (Rees et al., 1984), TXB2 is produced more copiously from 
endometrial tissue than myometrium based on similarities in TP and FP receptor 
coupling to the Gαq protein.  LC/ESI-MS/MS profiling of PGs will therefore help to 
clarify whether TXA2 plays an important role in the endometrium in non-pregnancy. 
1.7.1.2  Prostanoid release according to menstrual phase 
PG production in uterine tissues according to menstrual phase has been heavily 
studied for endometrium using mainly bioassay (Pickles et al., 1965, Downie et al., 
1974), RIA (Liggins et al., 1980, Rees et al., 1984, Rees and Kelly, 1986) and Gas 
Chromatography coupled with Mass Spectrometry (GC-MS/MS) (Green and 
Hagenfeldt, 1975, Maathuis and Kelly, 1978, Lumsden et al., 1986).  These findings 
support a role for endometrial PGs in the late-luteal phase through to menstruation, 
however, only a maximum of three PGs at a time have been analysed.  The 
production of multiple PG metabolites, with TXB2 included, from a single, 
homogenised myometrial specimen is yet to be demonstrated.  Without simultaneous 
identification of uterine PG metabolites, it is difficult to reliably pin-point which PGs 
could play important roles in a particular menstrual phase.  Previously, myometrial 
tissue incubates were tested for PGE2, PGF2α (Vijayakumar and Walters, 1981), as 
well as PGI2 (Rees et al., 1984) and PGD2 (Rees and Kelly, 1986) or homogenate for 
PGE2, PGF2α and PGI2 (Lumsden et al., 1986) with conflicting findings.  Data from 
the literature imply the positive and negative regulation of PG synthesis by oestrogen 
and progesterone respectively, based on measurements of COX expression 
(Critchley et al., 1999) and 15-PGDH activity (Hapangama et al., 2002).  It is 
anticipated that LC/ESI-MS/MS study of prostanoid output will support this concept. 
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1.7.1.3  Prostanoid release according to topography 
For the first time, the analysis of uterine prostanoid production in isolated, upper 
compared with lower myometrial segments from non-pregnant women will be 
carried out.  Findings may clarify if and how prostanoids mediate uterine peristalsis 
during the menstrual cycle, which may be defective in cases of pregnancy failure 
(Ayoubi et al., 2003). 
1.7.2 Lipidomic profiling of uterine tissues obtained from pregnant women 
1.7.2.1  Term pregnancy 
There are multiple reports that PGI2 production is increased during pregnancy in 
plasma (Ylikorkala et al., 1981b), amniotic fluid (Mitchell et al., 1979, Ylikorkala et 
al., 1981c), myometrial tissue incubate (Satoh et al., 1981) and myometrial cells 
(Korita et al., 2002) and thus is important for gestation progression.  For the first 
time LC/ESI-MS/MS will allow PGI2 production to be measured and compared with 
other prostanoids in myometrial homogenate from non-pregnant versus pregnant 
women.  This may better indicate myometrial reproductive events in vivo than 
analysing metabolites in plasma or cell culture, for example.  Myometrial TXB2 has 
yet to be measured from pregnant donors, possibly since the RIA technique in the 
1970s and 1980s failed to detect TXB2 as reported by Rees et al (Rees et al., 1984) 
due to a lack of sensitivity of the RIA assay.  LC/ESI-MS/MS detection of 
myometrial PGE2, PGD2, PGI2, TXB2 and PGF2α, together with series-1 and -3 
equivalents, will help to clarify their roles during pregnancy, prior to labour onset.  It 
is unknown whether J2 metabolites are synthesised by myometrium from pregnant 
donors and if they change according to gestational state.  Yet, since another group 
has shown that PPAR (to which 15-deoxy-PGJ2 binds) may be important during 
pregnancy (Marvin et al., 2000a), a role for J2 metabolites may be hypothesised. 
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1.7.2.2  Term parturition 
There is yet to be a comprehensive study of simultaneous prostanoid detection and 
quantitation in human myometrium with labour onset, which is surprising given the 
role of PGs in labour induction (Karim et al., 1968).  Satoh et al (Satoh et al., 1981) 
used RIA to measure PGF2α, PGE2 and PGI2 but not TXB2 or PGD2 from minced 
myometrial tissue incubates, indicating a role for PGF2α.  The mRNA and protein 
expression of a range of prostanoid synthases was analysed in myometrium from 
non-labouring versus labouring donors (Swanson et al., 1992, Giannoulias et al., 
2002, Sooranna, 2006, Astle et al., 2007, Phillips et al., 2010), whereby 
conflictingly, expression increased or showed no change with labour onset.  In 
speculation, TXA2 synthesis could be important for parturition in line with recent 
reports that functional TP but not FP receptors are maintained in lower segment 
myometrium during labour (Fischer et al., 2008).  It is hoped that lipidomics will 
reveal which PGs are most important during labour, by comparing the full range of 
major prostanoids in myometrium from term, pregnant, non-labouring versus 
parturient women, including rare samples from pregnant women whose spontaneous 
or induced labour did not progress. 
Ultimately this data may help to, not only understand the physiological importance 
of PGs in parturition, but also identify potential prostanoid targets for tocolysis, 
which may offer better efficacy and specificity and hence are safer to use in pregnant 
women to delay preterm labour.  It was an additional aim to carry out lipidomic 
profiling of PGs in myometrial biopsies from from preterm labouring donors, 
however only one sample was obtained to anecodotally compare with those from 
women in labour at term (not previously covered in the literature). 
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1.7.3 CVF cytokines as predictive tools for preterm labour 
Preterm labour risk is associated with presence of the marker Foetal fibronectin 
(fFN) in CVF, however testing for this marker in the clinic, does not yield enough 
discriminatory power (Lockwood et al., 1991, Zegels et al., 2010, Chandiramani et 
al., 2011).  Other inflammatory markers, such as chemokines and cytokines show 
promise as predictive indicators, for example, IL-6 in CVF can reliably predict 
preterm labour within 7 days (Marvin et al., 2000b, Coleman et al., 2001, Holst et 
al., 2009).  However, at which point these mediators in CVF increase in the lead up 
to term or preterm labour needs to be addressed, in a manner similar to another group 
who measured antioxidant enzymes e.g. copper, zinc superoxide dismutase (Heng et 
al., 2010).  PGs have been measured in CVF previously (COX et al., 1993) and can 
only be reliably measured in CVF if women have abstained from sexual intercourse 
(semen is rich in PGs, Kurzrok and Lieb, 1930)).  For this study, it was not known if 
CVF donors had abstained from sexual intercourse and therefore PG measurement 
using ELISA/lipidomic applications was not attempted. 
Previous findings show that higher numbers of macrophages (CD14+ cells) but no 
other type of immune cell was present in ripe compared with unripe cervices of term, 
pregnant, non-labouring women (Sakamoto et al., 2005).  This leads to the 
hypothesis that the cervical ripening process may be accelerated by increases in 
chemokines, which chemoattract macrophages e.g. MCP-1, at a particular point of 
term gestation prior to labour onset.  For this reason Interleukin-6 (IL-6), 
Macrophage Inflammatory Protein-1α (MIP-1α), Macrophage Inflammatory Protein-
1β (MIP-1β), MCP-1 and EMAP-II will be assayed in CVF from pregnant donors 
using Luminex® or Enzyme-Linked Immunosorbent Assay (ELISA). 
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Reliant upon patient follow up, CVF cytokines will be compared based on length 
from both preterm and term labour, although observation of the term labour process 
is a good starting point, particularly since most of the women sampled went into 
labour at term.  For the first time, RANTES, VEGF, sICAM-I, eotaxin and elastase 
will be analysed in human CVF samples at different intervals prior to labour onset 1) 
to act as a comparison with the chemotactic stimuli for monocytes and macrophages 
and 2) to show how angiogenic (VEGF) and adhesion molecules (ICAM) and 
neutrophil derived proteins (elastase) are regulated in the cervix prior to labour 
onset, in addition to T cell (RANTES) and eosinophil (eotaxin) homing.  Therefore, 
data will help to understand at what point in time and which subset of immune cells 
flux to the cervix before labour.  Ultimately this may help to pin-point which 
markers (e.g. macrophage, T cell and neutrophil versus angiogenic factors) could 
make suitable predictors of preterm labour risk. 
To achieve our aims we set the following specific objectives: 
- Analyse lipidomic prostanoid profiles according to uterine tissue type, 
topography and menstrual state. 
- Analyse lipidomic prostanoid profiles in relation to pregnancy and 
parturition. 
- Measure cytokine and chemokine concentration in CVF from pregnant 
women according to interval to labour onset. 
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Chapter 2: Materials and Methods 
2.1 Clinical Samples: surgical specimens from human donors 
Human myometrium was excised and donated for research from: 
- Non-pregnant donors with benign uterine disease taken at hysterectomy.  
Uterine sections were longitudinal, anterior and full thickness. 
- Preterm and term pregnant, non-labouring and labouring donors.  Lower 
uterine segments taken at Caesarean section were transverse and anterior. 
Other human tissues donated for research were: 
- Human eutopic endometrium and junctional zone (JZ) from consenting non-
pregnant women with benign uterine pathology.  These biopsies were 
removed from the uterine cavity by laparoscopic excision or hysterectomy 
followed by curettage. 
- CVF specimens collected via high vaginal swabs from consenting preterm 
and term pregnant, non-labouring and labouring donors undergoing clinical 
assessment for pregnancy associated pathology. 
2.1.1 Approval and ethical consent for human tissues 
Ethical approval was obtained from the Local Regional Ethics Committees (LREC): 
the Bradford Hospital NHS Trust and the University of Bradford Ethics Committee.  
In September 2008, ethical approval was obtained by Ethical Tissue at the University 
of Bradford, which has its own Ethical Research Tissue Bank (ERTB) where human 
samples are stored. 
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Ethical Tissue was licensed as a research tissue bank in September 2006 by the 
Human Tissue Authority (HTA) and in 2007 ethical status was granted.  All human 
tissue collected from donors by Ethical Tissue has full ethical approval and is 
handled in accordance with the requirements of the Human Tissue Act 2004 and 
under governance of the HTA licence granted in 2007.  Each donor of uterine tissue 
gave informed written consent prior to surgical procedure.  Specimens from non-
pregnant donors were collected from the Yorkshire Clinic or the Nucleus Theatres at 
the Bradford Royal Infirmary. 
Samples from pregnant donors were obtained from the Maternity unit at the Bradford 
Royal Infirmary.  CVF swabs were collected from pregnant women being assessed 
in the delivery suite assessment unit within the Maternity unit.  Examples of the 
LREC and ERTB consent forms signed by the donor and clinicians, along with 
patient information forms can be found in Appendices: 4-10.  Further information 
regarding study numbers can be found in Appendix 3. 
2.1.2 Uterine tissues 
Uterine smooth muscle taken from non-pregnant donors at hysterectomy was 
different to myometrium obtained from pregnant women at Caesarean section in 
terms of vascularity (refer to Figure 2.1).  Myometrium obtained at pregnancy was 
spongy and soft, in contrast with tissue from non-pregnant women, with the 
vasculature not easily identifiable, possibly due to increased blood flow through the 
uterine arteries during pregnancy (Palmer et al., 1992). 
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Pregnant myometrium also had a ridged appearance across the length of the tissue, 
whereby longitudinal fibres were more prominent and consistent with pregnancy-
associated myometrial remodeling.  Endometrial specimens from non-pregnant 
donors were red, with a mucous like consistency interspersed with small tissue 
clumps. 
The consistency of CVF taken from pregnant women during assessment was 
mucous-like whereby the colour was mostly clear or in some cases white.  CVF 
specimens obtained from pregnant women post-pelvic bleed, which showed evidence 
of blood contamination (and confirmed in the patients’ information) were not 
processed.  In some cases, women were noted to have experienced a pelvic bleed but 
showed no signs of blood upon examination by midwives or in the CVF specimen 
collected.  These samples were processed and compared with those from women 
who had been assessed on the ward for symptoms of preterm labour but were later 
deemed to be not at risk and therefore sent home (refer to pages 160-1).  The reason 
for this comparison was to ensure that there were no differences in cytokine 
concentrations in CVF donated by either group of women, so that data could be 
pooled and analysed according to interval to labour onset. 
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Figure 2.1: Biopsies of a) myometrium taken from non-pregnant women at 
hysterectomy b) myometrium obtained from pregnant, non-labouring women at 
Caesarean section and c) the sterile polyester pathology swab with a Dacron tip, 
Fisher Scientific (Loughborough, UK) used to collect CVF from pregnant women.  
Non-pregnant myometrial samples were considerably larger than pregnant 
specimens, being approximately 5cm long and 3-4cm in width (this size varying 
from patient to patient). 
Myometrium
b)
c)
a)
Polyester pathology swab
Fundal ligature
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2.1.3 Non-pregnant donors of endometrium and myometrium 
Samples were taken from pre-menopausal women undergoing hysterectomy for 
benign uterine pathologies (menorrhagia in all cases and 27.2% were also sufferers 
of dysmenorrhoea and uterine fibroids: mean age of sufferers was 44.2 ± 1.3 years) 
and who were not taking any hormone based therapies.  In this study, patient 
information sheets reported that seventy percent of uterine samples were from 
donors in the follicular phase of the menstrual cycle.  Myometrial and endometrial 
specimens were excised from the anterior corpus, whilst the fundus was tied with a 
ligature for purposes of anatomical differentiation.  The hospital staff would notify 
researchers when samples were available for collection, with the journey to and from 
the hospital taking approximately forty minutes.  During surgery, specimens were 
placed immediately in plastic, sterile, air-tight containers filled with Krebs’ (Krebs’ 
Heinseleit physiological salt) solution.  Samples were collected at room temperature 
owing to specimen collection for immersion study by other group members, 
requiring functional tissue. 
As will be discussed on pages 58-59, degradation of PGs in specimens was not a 
major concern.  Although for lipidomic study, histology was not carried out to 
confirm endometrial viability after removal at surgery, the same samples were 
required by other researchers in our laboratory in viable form to use for cell culture.  
One patient had undergone previous endometrial ablation but was excluded from 
analysis and for samples included in this study, as per patient notes, use of heat 
ablation to collect samples was not noted. 
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2.1.3.1 Inclusion and exclusion criteria for non-pregnant donors of uterine 
tissues 
Inclusion criteria for specimens from non-pregnant women were compromised by 
the diminishing numbers of donations as the time progressed from 2006 to 2010.  
This could have been related to the media coverage regarding misuse of human 
tissues by another establishment, as reviewed by Dewar and Boddington (Dewar and 
Boddington, 2004).  Therefore, for this study, extensive inclusion and exclusion 
criteria were not applicable and instead, all tissues were processed, so long as donors 
were not taking any form of medication.  All non-pregnant donors were 
normotensive (blood pressure was below 140/90 mmHg) and did not suffer from any 
other type of pathology unrelated to the reproductive system.  Samples excluded 
from analysis, were those from women taking hormonal therapy, including that from 
an endometriosis sufferer fitted with the LNG-IUS (Levonorgestrel-intrauterine 
system). 
2.1.3.2 Limitations for use of uterine specimens from non-pregnant women 
In the current study all specimens were donated by menorrhagic women and due to 
sample collection in a clinical setting, one had to rely on any patient information 
given by the clinician performing the surgery, whereby women were stated to have 
menorrhagia.  Diagnosing menorrhagia is quite difficult and often subjective with 
patients describing blood loss very differently.  Nonetheless, according to NICE 
guidelines, clinicians are not to carry out: thyroid testing unless signs of thyroid 
disease are present, serum ferritin measurement or utilise the alkaline haematin 
dilution method but instead rely upon the “woman’s own judgement” (NICE, 2007). 
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Women who routinely undergo laparoscopy/hysterectomy tend to be aged over 40 
and undesiring of pregnancy.  The aim of uterine removal is to alleviate symptoms of 
uterine pathology and so specimens are not deemed to be normal.  For endometrial 
biopsy collection, patients tend to be suffering from various underlying uterine 
pathologies which warranted surgical investigation in the first place, and again, such 
women are likely to be aged over 40 and nearing the menopause.  Despite lacking a 
control group, studies do show that prostanoid receptor (Adelantado et al., 1988) and 
prostanoid output (Smith et al., 1982, Lumsden et al., 1986) are not dependent upon 
age of the donor.  Furthermore, differential expression of ER (Sakaguchi et al., 2003) 
and PR (Noe et al., 1999) exists in premenopausal women versus postmenopausal 
women, so that uterine hormonal regulation in premenopausal women is likely to 
reflect that of healthy younger women.  Indeed the donors of specimens, whose 
tissues were used for thesis work, were still experiencing menstrual cycles. 
2.1.4 Pregnant, non-labouring donors: myometrium 
Segments of myometrium from the upper margin of the incision site in the lower 
section of uterus were obtained from preterm (33+4weeks, the + sign referring to 
number of days) and term (37-39+5weeks), pregnant women carrying one foetus.  
Preterm (<37 weeks gestation) refers to the gestation period before term pregnancy 
begins, whilst term is defined as the period of pregnancy between 37 and 41 weeks 
gestation (postterm being 42 weeks and beyond).  The mean age was 25 and 29.8± 
1.6 years in preterm and term pregnant non-labouring women respectively. 
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Donors were aged between 21 and 40 years undergoing elective, non-emergency 
Caesarean section.  Non-labouring donors had elected for a planned Caesarean 
section.  These types of Caesareans can be reliant on patient request e.g. experience 
of a previous traumatic vaginal birth or indication based e.g. there is a medical 
reason such as a maternal heart condition.  For this study, the reason for Caesarean 
section was undisclosed on the patient’s information sheet, however there was no 
record of serious medical conditions for ten donors, one donor had anaemia and the 
other four were hypertensive (blood pressure >140/90 mmHg, one donor treated with 
the anti-hypertensive atenolol). 
2.1.5 Pregnant, labouring donors: myometrium 
Labouring specimens were collected from pregnant women experiencing regular 
uterine contractions at either preterm (27 weeks) or term gestation (39-41+2 weeks).  
Myometrial biopsies from labouring donors (aged 18-37 years) were excised from 
the upper edge of the lower segment of the corpus during emergency Caesarean 
section, after delivery of the foetus and placenta.  Three labouring donors were given 
entonox (a 1:1 mixture of oxygen and nitrous oxide) to relieve labour pain.  
According to information sheets, primiparous, spontaneously labouring donors had 
no serious medical condition, although one woman had asthma and used a 
salbutamol inhaler.  One multiparous donor was administered the anti-
histamine/sedative phenergan for reasons undisclosed (refer to Appendix 21).  
Women can undergo emergency Caesarean section for reasons such as medical 
conditions, which put both the mother and foetus at risk (preeclampsia) or a failure 
of labour to progress.  A limitation of this study is that it was not clear from the 
patients’ notes the exact reason for Caesarean section, which could be related to the 
design of the information sheets and would need to be amended for future studies. 
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2.1.5.1 Inclusion and exclusion criteria for pregnant donors of myometrium 
Similar to specimen donations from non-pregnant women, those from pregnant 
women declined in number over recent years.  The twice yearly rotation of Senior 
House Officers (SHOs, who carried out the excision of myometrial samples from 
consenting pregnant women) also affected frequency of donations.  It was beneficial 
to give talks at the hospital after new SHOs were recruited, which familiarised them 
with our research aims.  Also, clinical specimens were being used by other 
researchers in our group at the time and therefore it was difficult to apply set 
inclusion criteria when sample donations were low frequency.  Instead, upon tissue 
storage, particular parameters were noted as per patient information sheets, such as 
blood pressure, parity and whether or not the consenting donor smoked.  When data 
had been acquired, comparisons of prostanoid profiles were made based on donor 
characteristics e.g. parity, prior to making non-labour and labour comparisons.  This 
was not ideal, but allowed a degree of control over variables, which could have 
affected production of the metabolites being measured.  Specimens from donors 
carrying twins and donors given general anaesthesia were not included for analysis. 
2.1.6 Pregnant CVF donors 
CVF was collected from pregnant, non-labouring and labouring women (16-37 years 
old and at 20-41 weeks gestation at the time of swabbing).  Dacron swabs were 
placed high in the vagina to collect CVF from pregnant women undergoing 
assessment for pregnancy associated disorders and were then sealed and placed 
immediately in a -20ºC freezer to await weekly collection.  Almost two thirds of 
swabs were collected from women at preterm gestation. 
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Follow ups were routinely carried out on women who donated swabs, to track when 
they went into labour.  Only one donor went into preterm labour 2 weeks after the 
CVF sample was taken (refer to patient details in Appendix 26), with the rest of the 
donors labouring at term.  The latter group of women had normal blood pressure 
with no serious medical condition, as stated on the information sheet. 
2.1.6.1 Inclusion and exclusion criteria for pregnant donors of CVF 
For CVF donors, the main inclusion criteria were that donors should not have any 
type of serious medical condition and that specimens should not contain blood, since 
this can produce false positive readings when using ELISA (through interference 
with the spectrophotometric readings).  The CVF study was in its initial stages and it 
was borne in mind that hospital staff were becoming accustomed to the new 
protocols and incorporating consent of donors and collection of swabs into their 
usual duties.  With time it is hoped that the frequency of CVF specimen donations 
increase, particularly to include better follow up of patients. 
2.2 Preparation and storage of clinical samples for prostanoid analysis 
Surgical specimens used for lipidomic analysis were as follows:  
- Myometrium (including JZ) and eutopic endometrium taken from non-
pregnant, menorrhagic women. 
- Myometrium taken from pregnant, non-labouring and labouring women. 
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Samples were collected in Krebs’ solution at ambient temperature because human 
specimens were shared by other researchers in the laboratory at that time for in vitro 
work, which required tissue to remain functional.  A good level of communication 
between hospital staff and the researcher resulted in quick specimen collection from 
the hospital with no longer than an hour taken to transport samples from the hospital 
back to the university.  Upon arrival at the laboratory tissue dissection was always 
carried out quickly, whilst keeping air exposure and trauma of the tissue to a 
minimum (samples were excised in dissecting dishes filled with Krebs’ solution).  
For every biopsy, three 5 mm x10 mm x 5mm segments of tissue were excised (refer 
to Figure 2.2 for details, page 54) followed by immediate storage in eppendorf tubes 
at -80ºC to await solid phase extraction (described later in section 2.3.7).  All 
equipment such as scissors, dissecting dishes and forceps were cleaned with ethanol 
followed by distilled water prior to dissection to reduce contamination of sample and 
of the HPLC column during sample analysis. 
Longitudinal excision of consistent-sized tissue segments was attempted, although 
any fluctuation in size of uterine sample was normalised using protein content 
estimation (outlined in section 2.3.9).  Tissues analysed using LC/ESI-MS/MS had 
been stored at -80°C with care taken to prevent freeze-thaw effects.  For example, all 
samples were kept in sealed plastic boxes and placed on one designated shelf (each 
shelf had its own door).  Also, prior to semi purification, samples were quickly taken 
out of the freezer and put straight on ice. 
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2.2.1 Uterine tissues from non-pregnant women 
For non-pregnant samples the surgeon took specimens from the length of the uterus 
marking the upper region with a ligature.  Tissue was first split into the most extreme 
fundal (upper), mid and lower segments (refer to Figure 2.2 on the next page), 
followed by further dissection of tissue into three pieces of consistent size.  This 
allowed analysis of prostanoids per uterine region, in triplicate.  Due to eutopic, 
endometrial tissue being of a mucous-like consistency (much bloodier and stretchy 
than myometrium), extra care was taken to try and keep tissue segments equal and of 
consistent size.   
Since it is only possible to accurately identify JZ (the area closest to the 
endometrium) for analysis using ultrasound, for this study, isolation of the JZ had to 
be estimated for preliminary study.  JZ specimens could only be obtained from 
hysterectomy specimens (three were received in total from menorrhagia sufferers), 
of which included a visible margin of endometrium on the inner surface, otherwise it 
would not have been possible to identify the JZ.  The inner-most portion of 
myometrium was identified, the orientation of which was further aided by the 
presence of serosa on the opposite side.  Any remnants of endometrium were 
removed and the margin of the inner myometrium excised from approximately 
0.5cm into the myometrial wall (based on the basic definition of JZ thickness) and 
spanning the mid portion of the myometrium (since the inner wall was most apparent 
in the mid-corpus). 
2.2.2 Uterine tissues from pregnant women 
Human gravid myometrium (only lower segment was donated) was excised in the 
same manner as that described for non-pregnant tissue. 
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2.2.3 Clinical samples used for the analysis of cytokines 
CVF specimens were transported in sealed, sterile tubes from the delivery 
assessment unit at Bradford Royal Infirmary to the laboratory (in a container filled 
with ice) and placed immediately in the -20ºC freezer to await experimental 
procedure (samples were analysed within three months of freezing).  Samples were 
kept a low temperature to ensure specimen stability and prevent degradation of 
proteins on the swab. 
 
 
 
Excision 
Excision 
Excision 
Lower 
Mid 
Fundus 
Figure 2.2: Diagram representing the area of myometrium excised from a full 
length uterine sample from a non-pregnant woman into three segments (outlined by 
the grey box).  This left three pieces of tissue from the fundus, mid and lower 
myometrium, from which three samples of equal size were excised and 
immediately stored in separate, labelled eppendorf tubes for LC/ESI-MS/MS 
analysis at -80°C.  The freezer was checked daily and the temperature logged. 
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2.3 Analysis of prostanoids 
Liquid chromatography coupled with electrospray ionisation mass spectrometry 
(LC/ESI-MS/MS) due to its high sensitivity and high throughput nature was chosen 
to analyse prostanoids in human uterine tissues.  The protocol developed previously 
by colleagues of the same laboratory Masoodi and Nicolaou (Masoodi and Nicolaou, 
2006) to measure eicosanoids and detailed in their published paper was adopted for 
this study.  In terms of eicosanoids, LC/ESI-MS/MS has been used to measure AA 
metabolites, namely Hydroxy-eicosatetraenoic acids (HETEs) (Kempen et al., 2001) 
and PGE2 and PGE3 (Yang et al., 2002) in cultured tumour cells, in addition to 
HETEs in human gestational tissues (Zhang et al., 2007), but as yet, has not included 
prostanoid detection in the human uterine milieu. 
2.3.1 Recovery experiments 
Due to the low frequency of myometrial donations and the high number of 
researchers requiring use of the mass spectrometer, recovery experiments were not 
carried out for uterine samples.  However, Masoodi and Nicolaou carried out three, 
separate estimation of recovery experiments by spiking brain, liver, plasma and urine 
samples with 200 pg of mixed prostanoid standard, which after semi-purification and 
LC/ESI-MS/MS was compared with unspiked tissue samples run in parallel.  Liver 
tissue (which similar to other avascular tissues showed prostanoid recoveries of 
>91% and a limit of detection as low as 0.5pg) is similar to the uterus in terms of 
vascularity e.g. myometrium and endometrium contains uterine arteries and veins, 
whilst the liver contains a central vein and is supplied by the hepatic artery.  
Therefore, both types of tissue contain vascular smooth muscle throughout their 
structures. 
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Both liver and myometrium comprise connective tissue, although there are 
differences in cell types, the liver comprising predominantly hepatocytes and the 
myometrium being principally made up of myocytes. 
2.3.2 Advantages of LC/ESI-MS/MS 
The LC/ESI-MS/MS protocol gives good chromatographic separation of compounds, 
in particular those which ionise to give the same mass parent and daughter ion, 
making it easier to distinguish the E and D prostaglandins.  RIA on the other hand 
relies upon antibody specificity and limited antibody cross-reactivity.  Moreover, 
LC/ESI-MS/MS is a highly sensitive analytical tool allowing not only the 
measurement of quantities as low as 1 pg/ml but also the potential to simultaneously 
identify up to twenty-seven metabolites from a single tissue without requirement for 
the lengthy derivatisation steps associated with GC-MS/MS. 
2.3.3 Limitations of LC/ESI-MS/MS 
2.3.3.1 Risk of contamination 
There are limitations with every scientific methodology, however, and for mass 
spectrometry there is the issue of contamination of the mass spectrometer source 
with residues from previous experiments, which could interfere with sensitivity of 
the assay.  During the duration of the study, care was taken to minimise this risk by 
ensuring the source was cleaned (with the help of a technician) prior to 
experimentation.  Before each run, PG standards (1-2 pg/ml versus 200 pg/m1) were 
analysed, with high baselines indicating contamination of the instrument’s source, in 
which case the source was cleaned by a specialist technician before re-running the 
cocktail of PG standards.  It was observed that the chromatogram for 6-keto-PGF1α 
showed a tailing peak when either standard or biological sample was analysed. 
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2.3.3.2 Tailing of peaks on chromatograms 
As previously discussed by Masoodi and Nicolaou (Masoodi and Nicolaou, 2006), 
this was a result of chromatography and not the presence of biological impurities 
(the badly formed peak was observed in standards).  Although this could interfere 
with reproducibility of the integration, the calibration lines were linear, as 
demonstrated in Figure 2.3.1.5 on page 72.  To overcome the limitation in 
reproducibility, all peaks for 6-keto-PGF1α were integrated in the same fashion (for 
standard and biological sample).  For example, when integrations were applied, only 
the peak for 6-keto-PGF1α was measured and not the tail (refer to Figure 2.3 below). 
 
  
 
 
 
Figure 2.3: Representative spectra of 6-keto-PGF1α standard (100 pg/ml) with the 
retention time of 2.59 minutes.  The red line indicates the cut-off point for 
integration. 
2.3.3.3 Shifts in retention times 
Another limitation is that retention times can fluctuate by up to 10% from 
experiment to experiment.  There are many factors which can alter retention times 
such as subtle changes in pH and temperature of the column.  For one experiment, 
the retention times for prostanoids in standard and biological samples were 2-3 
minutes higher than all other experiments (specimens from non-pregnant versus 
pregnant donors: refer to Figures: 4.2-4.4 in Chapter four and Appendices: 15-17). 
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It is not clear why this occurred, other than routine maintenance checks had been 
carried out in the same month.  There appeared to be no problems with the HPLC 
machine and mass spectrometer, nor was there an adverse effect on linearity of 
standard calibration lines. 
2.3.3.4 Risk of degradation of metabolites in biological samples 
Due to sample collection at room temperature, there was a concern that prostanoids 
would be metabolised and that in vitro concentrations measured using lipidomic 
application may not reflect those in vivo.  Unfortunately samples were collected in 
this manner since the main use of tissue for research in our laboratory was either 
immersion bath study or cell culture.  However, the time samples spent in these 
conditions was kept to a minimum and the excision carried out prior to freezing was 
done very quickly.  To check for lipid stability, measurement of Prostaglandin B2 
(PGB2) in biological samples using LC/ESI-MS/MS was attempted.  For each biopsy 
analysed, the failure to detect PGB2 was taken as a marker that uterine PG 
metabolites had not undergone extensive metabolism, as PGE2 transforms to PGA2, 
PGC2 and then PGB2 (Polet and Levine, 1975).  An example of spectra showing the 
non-detection of PGB2 in myometrium is shown in Figure 2.3.1. 
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2.3.4 Outline of LC/ESI-MS/MS 
To outline the whole process of profiling prostanoids in uterine tissues, prostanoids 
were first extracted and then semi-purified from uterine specimens using solid phase 
extraction (SPE) (described in Figure 2.3.1.1, page 62).  Prostanoid extracts 
containing internal standard were then analysed alongside cocktails of prostanoid 
standards also spiked with internal standard using reverse-phase HPLC (high 
performance liquid chromatography).  By changing the ratio of mobile phases: non-
polar versus polar solvents flowing through the column over a time course of 30 
minutes, individual prostanoids were separated from their mixtures via elution at 
different time points prior to electro-spray ionisation (ESI).  Analytes were passed 
through the mass spectrometer for detection and quantitation on the Multiple 
Reaction Monitoring (MRM) mode following structure specific ion transitions (refer 
to Figures: 2.3.1.2 and 2.3.1.3, pages 63-64). 
a) 
c) 
b) 
Figure 2.3.1: Representative spectra of LC/ESI-MS/MS analysis of PGB2 in 
myometrium from a) a non-pregnant donor b) a term, pregnant donor and c) a term, 
pregnant labouring donor.  A peak for PGB2 would be expected at approximately 
11-12 minutes.  The PGB2 standard spectrum can be found in Figure 2.3.1.8 on 
page 75. 
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2.3.5 Materials for LC/ESI-MS/MS 
Materials and equipment used for SPE were as follows: glass tubes (15ml) purchased 
from VWR International Ltd (Poole, Dorset, UK), Solid Phase Extraction (SPE) 6ml 
cartridges C18-E 500mg, SPE vacuum manifold and drying attachment for the 
manifold, C18 HPLC column (Luna, 5µm, 150 x 2.0mm), Universal Security Guard 
cartridge holder,  Security Guard cartridges (C18 4 x 2.0mm) purchased from 
Phenomenex (Macclesfield, Cheshire, UK), narrow range pH indicator paper strips 
(pH 2.5-4.5) (Merck, Nottingham, UK), Polytron Ystral D-79282 blade homogeniser 
(Ystral gmbh, Ballrechten-Dottingen, Germany), Nitrogen gas (BOC gases, 
Bradford, UK), glass syringes: 10, 50 and 250µl  (SGE, Ringwood, Victoria, 
Australia), graduated cylinders 10-1000ml, Schott Bottles (Fisher Scientific, 
Loughborough, Leicestershire, UK), Gilson pipettes (10-1000µl) (Gilson UK, Luton, 
Bedfordshire), Nylaflo membrane filters (0.45um/47mm) (Sigma Aldrich, Poole, 
UK), Büchner flask and funnel (York Glassware Services, York, UK), vortex (Hook 
and Tucker Instruments Ltd, Croydon, UK), 96 well plates (Corning Incorporated, 
New York, USA), 2ml (12 x 32mm), autosampler amber glass bottles, insert vials 
(100µl), open screw caps (8mm), PTFE 8mm septa purchased from Kinesis Ltd 
(Bedford, UK), Sovrall RT6000B refrigerated centrifuge (Grant Instruments Ltd, 
Cambridge, UK), microplate reader (Labsystems Multiscan RC Ver 6.0) operated 
using Gemini 4.0 software (Labsystems, Helsinki, Finland) and Waters alliance 2695 
HPLC pump with a waters 2690 autosampler coupled to an electrospray (ESI) triple 
quadrupole Quattro Ultima Mass Spectrometer with operating software MassLynxTM 
V4.0 (Waters, Elstree, Hertfordshire, UK). 
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2.3.6 Compounds, reagents and solvents for LC/ESI-MS/MS 
Compounds and solvents used for SPE, HPLC, mass spectrometry and protein 
content assaying were purchased as follows: HPLC-grade ethanol, methanol, hexane, 
acetonitrile (Fisher Chemicals, Loughborough, UK), HPLC-grade glacial acetic acid 
(Merck, Nottingham, UK), HPLC-grade methyl formate, hydrochloric acid (HCI) 
and sodium hydroxide (NaOH) (Sigma Aldrich, Dorset, UK).  In addition, 
prostanoid standards, one of which was deuterated, were purchased individually 
from Cayman Chemicals (Ann Arbor, Michigan, USA): 6-keto-PGF1α, PGE1, PGD1, 
PGF2α, PGF1α, PGD2, PGB2, PGE2, TXB2, PGJ2, PGD3, PGE3, ∆
12-PGJ2, 15-deoxy
12, 
14 PGJ2, 8-iso-15 keto PGF2α, 8-iso-15-keto PGE2, 8-iso-PGF2α, Prostaglandin F3α 
(PGF3α), Thromboxane B3 (TXB3), 13,14-diyhdro-15 keto PGF2α, 13,14-diyhdro-15 
keto PGE2, 13,14-diyhdro-15 keto PGE1, 13,14-diyhdro PGF1α, 13,14-diyhdro PGE1, 
13,14-diyhdro PGF2α and PGB2-d4. 
2.3.7 Prostanoid extraction and semi-purification 
2.3.7.1 Tissue homogenisation 
Tissue homogenization and extraction was performed according to the method 
described by Masoodi and Nicolaou (Masoodi and Nicolaou, 2006).  For each tissue 
biopsy stored in triplicate at -80ºC, each segment underwent homogenisation and 
SPE separately.  Samples were removed from the freezer and allowed to thaw on ice.  
Samples were immediately transferred to a glass tube filled with 3ml ice cold water 
(filtered, deionised, analytical grade water) using clean forceps.  Glass tubes 
containing the samples were always capped and kept on ice to reduce risk of 
bacterial contamination of samples and to prevent oxidisation and degradation of 
prostanoids in samples. 
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Figure 2.3.1.1: Flow chart depicting the steps carried out for solid phase extraction (SPE) and semi-purification of uterine specimens. 
Semi-purification 
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 Figure 2.3.1.2: Flow chart depicting the steps carried out for LC/ESI-MS/MS analysis of prostanoids extracted 
and semi-purified from uterine specimens.  
HPLC and Mass spectrometric analysis 
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Figure 2.3.1.3: Principles of ESI-tandem mass spectrometry (MS/MS). 
 
A polytron blade homogeniser was used until tissue was completely homogenised 
with two sets of 30 seconds up and down stroke actions.  The sample was placed on 
ice in between these bursts to prevent the homogeniser heating the sample.  Since 
non-pregnant tissue was very tough, tissue remnants often remained and after 
cooling on ice had to be further homogenised (for approximately another 30 seconds) 
until they were broken up.  The homogeniser was cleaned in between each sample 
homogenisation by rinsing with both HPLC grade ethanol and water (at least four 
times) to remove non-polar and polar substances, respectively.  A 50µl sample was 
taken from the middle of the homogenate using a calibrated pipette (with the tip 
clipped off to allow for thick sample consistency to be drawn up) and stored in an 
eppendorf tube at -200C, awaiting protein content analysis within the week. 
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Using a 50µl glass syringe, 40µl Internal standard, PGB2-d4 (1ng/µl) (Cayman 
Chemical, Michigan, USA) was added to all standards and biological samples, to 
improve the precision of quantitative analysis.  The concentration chosen was based 
on the previous experiments in this laboratory (Masoodi and Nicolaou, 2006).  
PGB2-d4 was used as internal standard for quantitative analysis.  Absence of a peak 
corresponding to PGB2-d4 elution would also reflect problems with the extraction 
steps.  The homogenate was adjusted to 15% (v/v) methanol by adding 530µl 
methanol to homogenates.  This was to ensure the sample would be retained on the 
C-18 SPE cartridges when applied at a later stage in the protocol.  Resulting 
solutions were kept on ice in the dark for 30 minutes to allow protein precipitation to 
occur.  The homogenate was then centrifuged at 2,500 x g for 35 minutes at 4ºC to 
remove any precipitated proteins.  The supernatant was transferred to a clean glass 
tube using a glass Pasteur pipette and stored on ice away from light ready for SPE.  
All glass tubes and implements used were cleaned in the following manner to 
minimise risk of column contamination.  Each tube was soaked in detergent for half 
an hour, rinsed and then washed again with detergent.  Following thorough rinsing, 
ethanol followed by water was used to rinse the tubes.  This step was repeated a 
second time to ensure all detergent was removed.  Tubes were then left to dry in a 
heated unit. 
2.3.7.2 Activation of SPE cartridges 
C18-SPE cartridges were attached to a 12 position vacuum manifold and then 
conditioned prior to use.  SPE cartridges were activated in turn by washing with 
20ml methanol followed by 20ml water.  A vacuum of 5 mmHg was applied so that 
drop-wise flow of solvent was maintained to avoid channelling effects. 
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Air was prevented from passing through the cartridges to prevent the solid phase 
from drying out and causing the formation of channels, which could reduce the 
efficiency of the extraction procedure. 
2.3.7.3 SPE extraction procedure 
The pH of each specimen was adjusted to 3 by adding 0.1M (Molar) HCI to the 
sample in a drop-wise manner using a glass Pasteur pipette and the pH was 
confirmed using narrow range indicator paper.  Samples were then immediately 
transferred to activated SPE cartidges and drop-wise flow of sample through the 
cartridges was maintained by adjusting the manifold vacuum control.  SPE cartridges 
were washed with 20ml 15% (v/v) methanol to remove unbound material, 20ml 
water to remove polar molecules and then 10ml hexane to remove water from the 
cartridge.  Washing with 10ml methyl formate eluted prostanoids from the cartridge 
into clean glass tubes.  A fine stream of nitrogen gas was applied to samples in the 
dark, in order to evaporate methyl formate to dryness. 
The resulting clear lipid residue was dissolved in 100µl of HPLC-grade ethanol and 
using a glass syringe, immediately transferred to 100µl glass insert vials situated 
within glass amber HPLC vials (Phenomenex, Macclesfield, UK).  Glass tubes were 
centrifuged (maximal setting, 5,000 x g for 30 seconds) and sample remnants were 
transferred to relevant labelled insert vials, capped with Teflon septa and sealed with 
open screw caps and stored at -20°C (for no longer than 1 week) awaiting LC/ESI-
MS/MS analysis.  All samples were kept on ice in the dark, de-capped for as short as 
time as possible and treated in exactly the same manner as not to affect in vitro 
prostanoid production.   
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2.3.8 LC/ESI-MS/MS analysis of prostanoids 
2.3.8.1 Preparation of stock solution of prostanoid standard 
Prostanoids were quantified using calibration lines of commercially available 
standards (Cayman Chemicals, Ann Arbor, MI, USA).  Ice cold ethanol was used to 
create stock standard solutions (10 ng/µl), from which a 400 pg/µl cocktail of the 
various standards was made.  6-keto PGF1α, PGE1, PGD1, PGF2α, PGF1α, PGD2, 
PGB2, PGE2 and TXB2 were purchased as dry powder in individual vials (1mg 
each).  Ice cold ethanol (1ml) was added to each vial to make a final solution at a 
concentration of 1 µg/µl.  PGJ2 was supplied as 500µg in 100µl ethyl acetate.  Ethyl 
acetate was evaporated under a fine stream of nitrogen and 500µl ice cold ethanol 
was added to the vial to prepare a final solution of PGJ2 at a concentration of 1 
µg/µl.  PGD3, PGE3, ∆
12-PGJ2, 15-deoxy
12,14 PGJ2, 8-iso-15-keto PGF2α, 8-iso-15-
keto PGE2, 8-iso-PGF2α, PGF3α, TXB3, 13,14-diyhdro-15-keto PGF2α, 13,14-
diyhdro-15 keto-PGE2, 13,14-diyhdro-15-keto PGE1, 13,14-diyhdro PGF1α, 13,14-
diyhdro PGE1 and 13,14-diyhdro PGF2 α were purchased as 1 µg/µl solutions. 
A 10µl volume of each solution (1 µg/µl) was transferred to an amber glass vial and 
diluted with 990µl ice cold ethanol to give a final concentration of 10 ng/µl.  With 
all vials on ice, 40µl of each standard (10 ng/µl) was transferred to a single new 
amber glass vial and the volume adjusted to 1ml with HPLC-grade ethanol.  The 
final concentration of the composite stock solution was thus 400 pg/µl.  Aliquots 
(100µl) of this solution were taken and stored in separate amber glass vials.  All of 
these stock solutions were stored at -80ºC.  
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2.3.8.2 Preparation of prostanoid composite standards 
Composite prostanoid standard solutions were prepared by mixing and diluting the 
stock solution (400 pg/µl) to give final concentrations of 180 pg/µl, 160 pg/µl, 100 
pg/µl, 80 pg/µl, 40 pg/µl and 8 pg/µl, 4 pg/µl and 2 pg/µl as shown in Table 2.3.  
PGB2-d4 (internal standard) was prepared in ethanol (1 ng/µl, working 
concentration) and 40µl added to all composite standards to give a final 
concentration of 400 pg/µl. 
Table 2.3: Preparation of prostanoid composite standard solutions (100µl) using 
HPLC-grade ethanol, prostanoid standard stock solution and internal standard 
solution. 
Final 
concentration of 
composite 
standard (pg/µl) 
Volume (µl) 
Composite stock 
solution 
(400pg/µl) 
PGB2-d4 (IS) 
(1ng/µl) 
Ethanol 
180 45 40 15 
160 40 40 20 
100 25 40 35 
80 20 40 40 
40 10 40 50 
8 2.0 40 58 
4 1.0 40 59 
2 0.5 40 59.5 
 
Composite standards were always analysed at equal intervals amongst biological 
sample injections to check that retention times had not shifted day to day during the 
experimental run.  Sensitivity of the mass spectrometer was tested by making sure 
that 2 pg/µl of various prostanoid standards were detected with minimal levels of 
background activity, prior to the commencement of each experiment.  Standards 
were analysed in duplicate to check instrument precision and bracketed with ethanol 
blanks to check for sample carry over (refer to Figure 2.3.1.4 on the next page). 
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Figure 2.3.1.4: Representative spectra of LC/ESI-MS/MS analysis of prostanoids in 
ethanol blanks.  In this case, ethanol was analysed subsequent to a cocktail of 
prostanoid standards (200 pg/ml).  The non-detection of prostanoids in ethanol 
blanks verified that prostanoid standard was not being carried over.  Spectra for 
prostanoid standards are shown in Figures: 2.3.1.6-2.3.1.8 on pages 73-75. 
a) 
b) 
c) 
d) 
PGE2 and PGD2 undetected at 4-6 minutes 
PGB2-d4 (Internal standard) undetected at 
12 minutes 
TXB2 undetected at 3 minutes 
6-keto-PGF1α undetected 
at 2-3 minutes 
PGF2α undetected at 3-4 minutes 
e) 
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2.3.8.3 Quantitation using calibration lines 
All peaks were integrated using MassLynxTM V4.0 software (detailed in section 
2.3.5) and calibration lines were constructed by plotting normalised peak area versus 
concentration.  The line of best fit was plotted according to the least squares linear 
regression method, which allowed for r2 determination (accepted at greater than 
0.9500, usually r2 was between 1 and 0.9800).  Mathematical substitution (utilising 
Microsoft Office Excel to display the equation of the calibration line) was adopted to 
quantify uterine prostanoids per biological sample, whereby the ratio of peak area for 
prostanoid versus internal standard in biological sample was compared to that 
displayed in Figure 2.3.1.5 in order to determine the amount of prostanoid in 10µl 
biological sample on the column in pg.  Dilution factors were considered (x100 
during reconstitution after drying) and pg metabolite expressed per mg of protein 
present in the original 3ml tissue homogenate to normalise data further (accounting 
for variability in vasculature and cell heterogeneity between triplicate samples of the 
same biopsy).  The Lowry method was used to estimate protein content (refer to 
section 2.3.9). 
2.3.8.4 Liquid chromatography 
Chromatographic analysis was performed performed on a C18 column (Luna, 5µm, 
150 x 2.0 mm) using reverse phase HPLC.  The injection volume for samples was 
10µl so that 4ng internal standard was loaded onto the column.  The sample chamber 
temperature of the autosampler was kept at 8ºC and the column was maintained at an 
ambient temperature, whilst the flow rate was maintained at 0.2 ml/min.  
Chromatographic separation of prostanoids was achieved using a gradient system 
composed of two HPLC-grade mobile phase solvents (Table 2.3.1). 
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Solvent A with composition acetonitrile: water: glacial acetic acid, 45: 55: 0.02 
(v/v/v) and solvent B with composition acetonitrile: water: glacial acetic acid, 90: 
10: 0.02 (v/v/v) over the gradient shown in Table 2.3.1 were used as described 
previously (Masoodi and Nicolaou, 2006).  Water was analytical grade, filtered, and 
deionised.   
Table 2.3.1: Gradient system for the analysis of prostanoids 
Time (min) 
Mobile phase A Mobile phase B 
450ml Acetonitrile: 550ml 
water: 200µl acetic acid 
900ml Acetonitrile: 100ml water: 
200µl acetic acid 
0 100 0 
8.00 100 0 
8.10 50 50 
12.00 50 50 
12.10 30 70 
20.00 30 70 
21.00 100 0 
30.00 100 0 
 
The total run time was 30 minutes including a 10 minutes wash cycle.  Prior to 
sample runs, the column was equilibrated with mobile phase A, switching to 50/50 
proportions of solvent A and B at least an hour before the run and covering 20 
column volumes. 
2.3.8.5 Multiple Reaction Monitoring assay 
For analysis of prostanoids the instrument was operated in the negative mode.  The 
capillary voltage was set at 3.0 KV, cone voltage: 3.5eV, RF lens 1: 0.3, aperture: 
0.3, RF lens 2: 1.0, source temperature: 120ºC and desolvation temperature: 360ºC.  
The collision energy was optimised for each compound to achieve maximum 
sensitivity using argon as collision gas.  Figure 2.3.1.3 (refer back to page 64) 
describes the formation of daughter from parent ions in the collision cell. 
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Figure 2.3.1.5: Representative set of standard calibration lines carried out for each consecutive experiment.  Calibration lines were linear over 
the range of 2-200 pg/mg. 
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Figure 2.3.1.6: Representative spectra obtained from a typical experiment, whereby 200 pg/mg prostanoid and isoprostane standard was analysed. 
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Figure 2.3.1.7: Representative spectra obtained from a typical experiment, whereby 200 pg/mg prostanoid and isoprostane standard was analysed. 
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Figure 2.3.1.8: Representative spectra obtained from a typical experiment, whereby 200 pg/mg prostanoid and isoprostane standard was analysed. 
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Dwell times were 0.2s with a 0.1s inter-scan delay.  The cone gas flow was 40 L/hr 
and the desolvation gas flow was 400 L/hr.  For optimal results the multiplier was set 
at 650 V and the collision cell pressure was 6.98e-4 mbar.  The MRM cycle time was 
3.38s for the prostanoid assay.  Transitions used for the MRM assay of prostanoids 
were as follows: 
13,14 dihydro-15-keto-Prostaglandin F2α (15-keto PGF2α) m/z 353>113; 13,14 
dihydro-15-keto-Prostaglandin E2 (15-keto PGE2) m/z 351>333; 8-iso-PGE2 m/z 
351>315; 8-iso-15-keto PGF2α  m/z 351>315: PGE2 m/z  351>271; PGD2 m/z 
351>271; PGF3α m/z 351>193; PGE3 m/z 349>269; PGD3 m/z 349>269; 8-iso-15-
keto PGE2 m/z 349>113; PGB2-d4 m/z 337>179; PGJ2 m/z 333>271; ∆
12-PGJ2 m/z 
333>271; PGB2 m/z 333>175; 15-deoxy-∆
12,14 PGJ2 m/z 315>271; TXB2 m/z 
369>169; 6-keto-PGF1α m/z 369>163; TXB3 m/z 367>169; 13,14 dihydro PGE1 m/z 
355>337; PGF1α m/z 355>311; 13,14 dihydro PGF1α m/z 355>311; 13,14 dihydro-15-
keto-Prostaglandin F1α (15-keto PGF1α) m/z 355>193; 13,14 dihydro-15-keto-
Prostaglandin E1 (15-keto PGE1) m/z 353>335; PGE1 m/z 353>317; PGD1 m/z 
353>317; PGF2α m/z 353>193; 8-iso-PGF2α m/z 353>193. 
2.3.9 Protein assay 
The BioRad DC protein assay is a colourimetric assay for the quantitation of protein 
concentration following detergent solubilisation and is based on the Lowry method 
(Lowry et al., 1951).  Under alkaline conditions divalent copper ions form a complex 
with peptide bonds in a biological sample to form a monovalent copper ion.  The 
monovalent copper ion and the radical groups of tyrosine, tryptophan, and cysteine 
react with Folin reagent to produce an unstable product (chromophore) that becomes 
reduced to molybdenum/tungsten blue, from which absorbance can be recorded. 
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2.3.9.1 Sample preparation 
All frozen, human, non-pregnant and pregnant human uterine tissue samples, which 
were stored post-homogenisation during SPE, were used for protein content 
estimation.  Tissue homogenate (50µl) was mixed with an equal volume of 0.5M 
NaOH and vortexed to ensure all material had dissolved.  A further 3 dilutions were 
made from this solution using 0.5M NaOH as diluent in order to cover a range of 
protein content estimations.  The following myometrial and endometrial dilutions 
were made: 1 in 2, 1 in 4, 1 in 6 and 1 in 12. 
2.3.9.2 Protein assay procedure 
Bovine Serum Albumin (BSA) (BioRad laboratories, Herts, U.K.) was serially 
diluted using 0.5M NaOH (Sigma Aldrich, Poole, U.K.) to give a range of 
concentrations (0.25, 0.5, 0.75, 1.0 and 1.5 mg/ml as shown in Table 2.3.2) and after 
step-wise addition of reagents according to the Lowry method, absorbance of all 
samples was measured.  This enabled a standard calibration line of BSA to be 
constructed (Figure 2.3.1.9) and tissue protein content to be estimated. 
Table 2.3.2: Serial dilution of 1.5 mg/ml BSA stock standard with 0.5M NaOH, in 
order to perform a calibration line by plotting absorbance against concentration (also 
refer to Figure 2.3.1.9). 
Volume (µl) Final BSA concentration 
(mg/ml) BSA (1.5 mg/ml stock) 0.5M NaOH 
0 150 0 
25 125 0.25 
50 100 0.5 
75 75 0.75 
100 50 1.0 
150 0 1.5 
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Using Gilson pipettes, 5µl of each BSA standard and biological sample was added to 
a 96 well plate, in triplicate.  Solution AS comprised 20µl surfactant (S) mixed with 
1ml alkaline copper tartrate solution (A).  Reagents were added to the wells in the 
following order; 25µl (AS) followed by 200µl (B).  The plate was left in the dark for 
20 minutes to allow a blue coloured product to form (proportional to the 
concentration of protein in samples).  A microplate reader was used to measure the 
absorbance of ultraviolet light at 650nm wavelength in each well.  
 
 
 
 
 
 
 
 
Figure 2.3.1.9: A standard calibration line for BSA.  Calibration lines were 
constructed plotting the absorbance of BSA solutions versus concentration (mg/ml).  
Using the least squares linear regression method, the mean concentration of protein 
in each biological sample was estimated, whilst accounting for dilution factor. 
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2.3.10 Statistical analysis 
Data groups, which included samples from four or more donors were statistically 
analysed, whereby normality testing was carried out (on all data sets) by analyzing 
P-Plots, frequency distribution curves and the Kolmogorov-Smirnov test.  For data 
groups comprising an n of three, it was not possible to carry out normality testing 
reliably and hence data were treated as non-parametric. 
Lipidomic data grouped according to menstrual state and tissue type (non pregnancy) 
or donor characteristics and gestational state (pregnancy) were compared first using 
One-Way Analysis of variance (ANOVA) or Kruskal-Wallis (three or more groups 
in the sample) dependent upon Gaussian distributions.  A p value of <0.05 led to 
testing of sub-groups using the Mann-Whitney or Student’s t-test for non-parametric 
and parametric data respectively.  Paired tissue data (non-pregnant, upper versus 
lower segment myometrium) were analysed using the Wilcoxon signed-rank test. 
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2.4 Measurement of cytokines 
2.4.1 Enzyme-Linked Immunosorbent Assay (ELISA) 
In this study, four different human antigens were tested for using ELISA: EMAP-II, 
IL-6, sICAM-I and elastase.  These cytokines (and the other six detected using 
Luminex® as outlined on pages 92-93) were selected for analysis based on 1) 
literature showing their possible roles in cervical ripening 2) their potential to predict 
a short interval to preterm labour (as detailed in the aims section) 3) CVF data being 
scarce, namely for EMAP-II and VEGF and 4) the void in studies on CVF cytokines 
in relation to varying intervals to labour onset.  Wells coated with monoclonal 
antibody specific for human antigen were filled with samples of serially diluted 
standard, positive control (Foetal Bovine Serum: FBS), negative control (standard 
diluent) or CVF collected from pregnant women. 
During the first incubation, human antigen in the clinical samples bound to the 
immobilised, solid phase capture antibody on one site, after which excess unbound 
fractions were washed away.  Biotinylated monoclonal secondary antibody was 
added and incubated, whereby solution phase biotinylated antibody bound to human 
antigen on a second site.  Excess biotinylated antibody was removed during washing 
followed by addition of the enzyme Streptavidin-HRP (Horseradish Peroxidase 
conjugated to Streptavidin), which bound with high affinity to biotin conjugated to 
the secondary antibody to complete the four-member sandwich.  After incubation 
and washing to remove excess unbound enzyme, substrate solution (chromogen) was 
added.  HRP catalysed the production of coloured product from chromogen, the blue 
colour of which was directly proportional to the concentration of antigen present in 
the original samples.  CVF samples were routinely filtered and diluted prior to 
analysis by ELISA to prevent opaqueness affecting data acquisition. 
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2.4.2 Materials  
Table 2.4:  The items used for elution of CVF from swabs and their subsequent 
analysis by ELISA, were purchased as follows: 
Material Manufacturer Town County Country 
Plastic shaft with 
dacron dry swab 
Medical Wire 
and equipment 
Corsham Wiltshire UK 
Sterile Costar® 
Spin-X® 2ml 
centrifuge tube 
with filters 16000 
x g max (0.22µm 
pore, cellulose 
acetate 
membrane) 
Fisher 
Scientific 
Loughborough Leicestershire UK 
Fresco17 mini-
centrifuge 
Thermo Fisher 
Scientific 
Loughborough Leicestershire UK 
TubeOneTM 
RNase, DNase, 
DNA and 
Pyrogen free 
pipette tips 
Star Lab 
Milton 
Keynes 
Buckinghamshire UK 
RNase, DNase, 
DNA and 
Pyrogen free 
polypropylene 
1.5ml 
minicentrifuge 
tubes 
Star Lab 
Milton 
Keynes 
Buckinghamshire UK 
Bio-Tek Elx800 
Universal 
Microplate reader, 
capable of reading 
at 450nm 
wavelength 
LabTech Lewes Sussex UK 
Gen5ELISA 
software 
LabTech Lewes Sussex UK 
Vacuboy aspirator 
system 
Fisher 
Scientific 
Loughborough Leicestershire UK 
Calibrated Gilson 
pipettes including 
multichannel 
 
Gilson UK Luton Bedfordshire UK 
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2.4.3 Kit components and reagents 
CVF was eluted from swabs and mixed with carbonate-bicarbonate buffer capsules, 
Sigma Aldrich (Dorset, UK) ready for ELISA.  ELISA kits were purchased to detect 
and quantify proteins in CVF specimens from pregnant women.  Tables 2.4.1, 2.4.2 
and 2.4.3 detail the components of ELISA kits purchased from Invitrogen Biosource 
(CA, USA); whilst the elastase assay was based on individual components purchased 
from Sigma Aldrich (Dorset, UK) (Table 2.4.4). 
Table 2.4.1:  Human EMAP-II ELISA kit  
Catalogue Number KHC1581 
Kit Components Volume per bottle 
1 Human EMAP-II standard 2 vials (0.5ml per vial) 
2 Standard diluent buffer 1 bottle (25ml) 
3 Human EMAP-II Antibody-coated wells 96 wells 
4 Human EMAP-II biotin conjugate 1 bottle (11ml) 
5 Streptavidin-peroxidase (HRP) concentrate (100x) 1 vial (125µl) 
6 Streptavidin-peroxidase (HRP) diluent 1 bottle (25ml) 
7 Wash buffer concentrate (25x) 1 bottle (100ml) 
8 Stabilised chromogen tetramethylbenzidine (TMB) 1 bottle (25ml) 
9 Stop solution 1 bottle (25ml) 
10 Plate Covers Adhesive strips x 3 
 
Table 2.4.2:  Human Ultra Sensitive IL-6 ELISA kit 
Catalogue Number KHC0064 
Kit Components Volume per bottle 
1 Human IL-6 ultra sensitive standard  2 vials (0.5ml per vial) 
2 Standard diluent buffer  1 bottle (25ml) 
3 Antibody coated wells (12x8 well strips) 96 wells 
4 Human IL-6 ultra sensitive Biotin Conjugate 
(Biotin-labelled anti-IL-6) 
11ml per bottle 
5 Streptavidin-HRP (100X) 0.125ml per vial 
6 Streptavidin-HRP diluent  1 bottle (25ml) 
7 Wash buffer concentrate (25X) 1 bottle (100ml) 
8 Stabilised Chromogen (TMB) 1 bottle (25ml) 
9 Stop solution  1 bottle (25ml) 
10 Plate Covers Adhesive strips x 3 
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Table 2.4.3:  Human sICAM-I ELISA kit components 
 
Catalogue Number KHS5411 
Kit Components Volume per bottle 
1 sICAM-I monoclonal antibody-coated wells (murine 
to human) 
96 wells 
2 sICAM-I standard (10ng/ml) 2 vials (0.5ml per vial) 
3 Sample diluent buffer (buffered protein matrix) 1 bottle (50ml) 
4 Murine HRP-conjugated anti-sICAM-I monoclonal 
antibody, (60x concentrate) 
1 vial (0.2ml) 
5 Assay buffer (20x concentrate, PBS with 1% Tween 
20 and 10% BSA)  
1 vial (5ml) 
6 Wash buffer concentrate (20x, PBS with 1% Tween 
20) 
1 bottle (50ml) 
7 Stabilised chromogen (TMB) 1 vial (15ml) 
8 Stop solution (1M phosphoric acid) 1 vial (15ml) 
9 Plate Covers Adhesive strips x 3 
 
Table 2.4.4:  Human Polymorphonuclear leukocyte Elastase (PmnE) Immunoassay 
components 
 
Components Manufacturer 
Catalogue 
number 
1 Human PmnE standard Sigma Aldrich, (Dorset UK) E8140 
2 Carbonate-bicarbonate buffer 
capsules pH 9.6 
Sigma Aldrich, (Dorset UK) C3041 
3 0.01M PBS pH 7.2 Sigma Aldrich, (Dorset UK) P5368 
4 0.05% Tween 20 Sigma Aldrich, (Dorset UK) P2287 
5 Bovine serum albumen for ELISA Sigma Aldrich, (Dorset UK) A7030 
6 Anti-Neutrophil Elastase Rabbit 
PmnE 
Calbiochem 
(Nottinghamshire, UK) 
481001 
7 HRP conjugated goat anti-rabbit 
IgG (Immunoglobulin G) 
Sigma Aldrich, (Dorset UK) A6154 
8 TMB horse-radish peroxidase 
substrate 
Sigma Aldrich, (Dorset UK) T0440 
9 1M HCI Sigma Aldrich, (Dorset UK) H1758 
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2.4.4 Elution of CVF from swabs 
To prepare CVF swabs for ELISA analysis, swabs were thawed and all visible fluid 
was collected from the swab plastic case and transferred to a Spin-X® tube.  The 
swab was clipped off at the head and the cotton tip placed in the Spin-X® tube.  
Carbonate-bicarbonate buffer capsules were added to 100ml deionised water to yield 
a final concentration of 0.05M.  Carbonate bicarbonate (300µl) was added to the 
eppendorf tube, which was then incubated with the swab tip for 30 minutes in the 
dark at 4ºC.  CVF was eluted from the swab using a Gilson pipette and transferred to 
a new Spin-X® eppendorf filter tube, along with the 300µl carbonate bicarbonate 
bathing the swab.  Dry swabs were discarded and the samples were centrifuged at 9 
000 x g for 5 minutes at 4ºC.  Carbonate bicarbonate (300µl) was added to the insert 
once more and centrifuged at 9 000 x g for 5 minutes at 4ºC.  The Spin-X® insert 
filter was discarded and the fluid which had passed through the insert filter was 
vortexed to ensure thorough mixing of CVF in carbonate bicarbonate buffer.  
Samples were collected in triplicate (200µl per eppendorf) and stored at -20ºC to 
await ELISA.  A sub-sample was used to estimate protein content as previously 
described in section 2.3.9. 
2.4.5 Preparation of solutions 
2.4.5.1 Standard for ELISA 
Human EMAP-II standard was diluted with standard diluent buffer to give a final 
concentration of 20 ng/ml, which was mixed gently and left to stand for 10 minutes 
before being serially diluted (1:1) to give the following concentrations;10, 5.0, 2.5, 
1.25, 0.625, 0.312 ng/ml.   
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Human IL-6 standard (2.5ng/ml) was diluted to give 10 pg/ml, which was then 
serially diluted 1:1 to give the following concentrations; 5.0, 2.5, 1.25, 0.625, 0.312, 
0.156, 0.078 pg/ml.  Human sICAM-I standards were prepared directly in 96 well 
plates (refer to section 2.4.6).  Human elastase standard was prepared by adding 
1.2ml 0.1M carbonate-bicarbonate buffer to a 6µg vial for a stock concentration of 
5000 ng/ ml.  The vial of elastase was mixed gently and left to stand for 10 minutes 
to ensure complete reconstitution.  For a working concentration of 1000 ng/ml, 50µl 
of stock elastase was diluted in 200µl carbonate bicarbonate solution.  Serial 
dilutions were prepared as follows: 500, 250, 125, 64, 32, 16 and 0 ng/ml. 
2.4.5.2 Wash buffer for ELISA 
Wash buffer (comprising 1% Tween 20, preventative of non-specific antibody 
binding) was made fresh before each experiment at a ratio of 1 volume of wash 
buffer to 24 volumes of deionised water (50ml wash buffer was diluted up to 1.25L 
with deionised water).  The wash buffer used to analyse sICAM-I was made fresh 
before each experiment at a ratio of 1 volume of wash buffer to 19 volumes of 
deionised water (50ml wash buffer was diluted up to 1L with deionised water).  The 
wash solutions were all stored at 4ºC and mixed gently before use.  Wash solution 
(PBS-T) for the elastase assay consisted of 0.01M Phosphate Buffered Saline (PBS) 
pH 7.2 with 0.05% Tween 20 (T).  
Chapter Two: Materials and Methods 
86 
 
2.4.5.3 Streptavidin-HRP for ELISA 
For EMAP-II and IL-6 assays, Streptavidin-HRP concentrate was allowed to reach 
room temperature and gently mixed and diluted 1:100 (10µl HRP in 990µl 
Streptavidin-HRP diluent for each 8 well strip).  For sICAM-I analysis, Streptavidin-
HRP concentrate was gently mixed and added to a clean plastic tube prior to 60-fold 
dilution (100µl HRP in 5.9ml Streptavidin-HRP diluent for a maximum of 12 wells 
(and used within 30 minutes of preparation)).  Goat anti-rabbit HRP conjugate for 
the elastase assay was diluted 1:1000 in antibody diluent (1% BSA) in PBS-T as per 
manufacturers’ instructions. 
 
2.4.6 Plating biological sample and reagents for ELISA 
CVF samples were thawed and diluted 5-fold in sample diluent prior to assaying.   In 
duplicate, 100µl standard diluent was added to zero wells as blanks and the 
chromogen blank wells were left empty. Freshly prepared standard serial dilutions 
and FBS (diluted 1:10) as positive control (100µl) were added to the appropriate 
microplate wells.  Standard diluent buffer (50µl) followed by 50µl of sample were 
pipetted into the same well, followed by gentle tapping to mix plate contents.  For 
IL-6 ELISA the same steps as for EMAP-II ELISA were followed except samples 
were diluted 1:10 before 100µl addition to wells.   
The sICAM-I assay was identical as before, except for wells were washed twice with 
300µl wash buffer immediately prior to sICAM-I measurement.  Preparation of 
standards also differed, whereby after leaving two wells for sample diluent only and 
another two empty wells, 100µl sample diluent was added to the next four wells in 
duplicate.   
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Soluble ICAM-I standard (10 ng/ml, 200µl) was added to two empty wells with 
100µl standard transferred to the next two wells to give a final concentration of 5 
ng/ml in duplicate and 100µl from the 5 ng/ml standard wells were pipetted into the 
next two wells to give a final concentration of 2.5 ng/ml.  This step was repeated 
twice to give a standard range of 10-0.625 ng/ml and 100µl from the 0.625 ng/ml 
well was discarded to leave a volume of 100µl.   
Figure 2.4.1 and 2.4.2 on pages 89-90 and the schematic of the antibody sandwich in 
Appendix 11 outlines the subsequent step-wise procedures that were followed for 
ELISA analysis of EMAP-II, IL-6, sICAM-I and elastase human antigens as well as 
potential limitations of the assays.  The elastase protocol differed in that plates 
containing samples were incubated for 2 hours at 21oC.  For the elastase ELISA 
wash steps, liquid was completely aspirated from all wells and then filled with 100µl 
of diluted wash solution.  This was left for 15 to 30 seconds before the liquid was 
aspirated once more.  This step was then repeated twice. 
 
Wells were then incubated with 100µl/well blocking agent (3% heat-deactivated 
BSA in PBS-T) for 1 hour at 21oC followed by another three washes.  Anti-
neutrophil elastase rabbit antibody (100µl) was added to each well at a concentration 
of 1:1000 in antibody diluent (1% BSA in PBS-T) as per manufacturers’ instructions 
and in contrast with other ELISAs, which had antibody already bound to the plate’s 
surface.  After 1 hour incubation at 21ºC, three wash steps followed prior to the 
addition of HRP conjugated goat anti-rabbit antibody (100µl).  The plate was then 
incubated for another hour at room temperature followed by the wash step. 
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2.4.7 Conversion of substrate to detectable colour 
For EMAP-II and IL-6 ELISAs stabilised chromogen substrate (100µl TMB) was 
added to each well, turning the liquid in the wells to a blue colour. The plates were 
incubated for no more than 25 minutes in the dark (as not to exceed limits of 
detection), after which point 100µl stop solution was added to each well (liquid 
turned a yellow colour).  Absorbance was measured at 450nm using a microplate 
reader, after gentle shaking of the plate on a rotator to mix contents and having 
referenced the plate reader against a chromogen/stop solution well.  Aluminium foil 
or metalized mylar was not used to cover the plate at any point during experiments 
as per manufacturer advice. 
For both sICAM-I and elastase assays, 100µl TMB substrate solution was pipetted 
into all wells including the blank wells and plates were covered and incubated at 
room temperature for 10 minutes in the dark.  The colour development was 
monitored and the reaction stopped when the 10 ng/ml standard turned a dark blue 
colour.  For the sICAM-I ELISA, 100µl stop solution was added to each well to stop 
the reaction.  One molar HCI (100µl) was used as stop solution for the elastase assay 
before plate agitation to ensure uniform distribution of stop solution.  Absorbance 
was measured at 450nm using a microplate reader following reference blanking on 
the machine. 
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Figure 2.4.1: Schematic demonstrating differences in the step-wise processes of 
EMAP-II and sICAM-I ELISA.  Invitrogen described that a limitation of their 
assay was that degradation of EMAP-II had not been tested, which could be an 
issue considering sample incubations were carried out at 37°C.  However, the 
recovery rate for EMAP-II was high at 98% in tissue culture medium. 
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Figure 2.4.2: Schematic demonstrating differences in the step-wise processes of 
IL-6 and elastase ELISA (IL-6 but not elastase purchased as an ELISA kit).  
Invitrogen described that a limitation of their assay was that degradation of IL-6 
had not been tested, which could be an issue considering sample incubations were 
carried out at 37°C.  However, the recovery rate for IL-6 was high at 98% and 
113% in tissue culture medium and individual serum respectively. 
 
 
 
 
 
 
Chapter Two: Materials and Methods 
91 
 
2.4.8 LUMINEX® assay 
Invitrogen’s Human Chemokine multiplex assay is designed for the simultaneous in 
vitro quantitative determination of Eotaxin, MCP-1, MIP-1α, MIP-1β and RANTES 
in serum, plasma, and tissue culture supernatant.  For this study, Luminex® was 
used to analyse chemokines simultaneously in CVF from pregnant women.  The 
singleplex VEGF kit was utilised in combination with the 5-plex assay for higher 
multiplexing of results. 
The concept of Luminex® is similar to ELISA except the solid phase does not 
comprise antibodies adsorbed to the bottom of each plate well; rather spectrally 
encoded antibody-conjugated beads moving freely act as the solid support.  
Multiplex kits allow beads conjugated by specific antibodies to be mixed with other 
antibody-conjugated beads for high-through put data analysis.  The technology uses 
5.6 µm polystyrene beads, which are internally dyed with red and infrared 
fluorophores of differing intensities.  Each bead is given a unique number, or bead 
region, allowing differentiation of one bead from another.  Like, ELISA, the assay is 
performed in a 96-well plate format but analyzed with a Luminex® 100™ 
instrument, which monitors the spectral properties of the capture beads while 
simultaneously measuring the quantity of associated fluorophore.   
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2.4.8.1 Outline of the Luminex® process 
 
1. Beads of defined spectral properties are conjugated to protein-specific 
capture antibodies and added along with samples (including standards, 
control samples, and test samples), into the wells of a filter-bottom 
microplate.  Human antigens bind to the capture antibodies over the course of 
a 2 hour incubation (refer to Figure 2.4.3). 
 
2. After washing the beads, using a manifold system, antigen-specific 
biotinylated detector antibodies are added and incubated with the beads for 1 
hour.  
 
3. After removal of excess biotinylated detector antibodies, Streptavidin 
conjugated to the fluorescent protein, R-Phycoerythrin (Streptavidin-RPE) is 
added and incubated for 30 minutes.  
 
4. The Streptavidin-RPE binds to the biotinylated detector antibodies associated 
with the immune complexes on the beads and each bead fluoresces to varying 
extents.   
 
5. After washing to remove unbound Streptavidin-RPE, the beads are analyzed 
with the Luminex® detection system.  
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Figure 2.4.3: Schematic representing the step-wise process of Luminex®. 
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2.4.8.2 Materials 
Table 2.4.5: Details of the supplies used for the multiplex assay and their sources. 
Material Manufacturer Town County Country 
Luminex® 
xMAP® system 
with data 
acquisition and 
analysis 
Software 
Invitrogen 
Biosource 
Camarillo California USA 
Filtration vacuum 
manifold for bead 
washing 
Pall 
Corporation 
Ann Arbor Michigan USA 
Orbital shaker 
Fisher 
Scientific 
Loughborough Leicestershire UK 
96-well plate 
cover 
Invitrogen 
Biosource 
Camarillo California USA 
TubeOneTM 
RNase, DNase, 
DNA and Pyrogen 
free pipette tips 
Star Lab 
Milton 
Keynes 
Buckinghamshire UK 
Calibrated Gilson 
pipettes including 
multichannel 
 
Gilson UK Luton Bedfordshire UK 
Graduated 
cylinders 
Fisher 
Scientific 
Loughborough Leicestershire UK 
RNase, DNase, 
DNA and Pyrogen 
free polypropylene 
1.5ml 
minicentrifuge 
tubes 
Star Lab 
Milton 
Keynes 
Buckinghamshire UK 
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2.4.8.3 Kit components and reagents 
Table 2.4.6:  Human chemokines 5-plex panel kit, Invitrogen Biosource (CA, USA): 
Catalogue Number LHC0005 
Kit Components Volume per bottle 
1 Human Chemokine 5-Plex Antibody Bead 
Concentrate (10X) 
1 vial (0.25ml) 
2 Hu 5-plex biotinylated Ab concentrate (10x) 1 vial (1ml) 
3 Hu 14-plex lyophilised standard 2 vials 
4 Wash solution concentrate (20x) 1 bottle (15ml) 
5 Assay diluent 1 bottle (15ml) 
6 Incubation buffer 1 bottle (12ml) 
7 Biotin diluent 1 bottle (12ml) 
8 Streptavidin-RPE concentrate (10x) 1 vial (1ml) 
9 Streptavidin-RPE diluent 1 bottle (12ml) 
10 96 well plate  1 x 96 well plate 
11 Filter bottom plate  1 x filter bottom plate 
 
Table 2.4.7:  Human VEGF singleplex bead kit, components of which were 
combined with those in the LHC005 kit, Invitrogen Biosource (CA, USA): 
 
Catalogue Number KHG0111 
Kit Components Volume per bottle 
1 Human VEGF beads 0.25ml per bottle  
2 Rabbit anti-human VEGF biotin 1ml per bottle 
 
 
2.4.8.4 Preparation of wash solution 
1 part 20X wash solution concentrate (comprising 0.1% sodium azide) was brought 
to room temperature to dissolve precipitate and was mixed with 19 parts deionised 
water and refrigerated. 
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2.4.8.5 Preparation of antibody bead concentrate 
Immediately before dispensing, 10X 5-Plex Antibody Bead Concentrate and 10X 
VEGF singleplex bead concentrate were wrapped in aluminium foil to protect from 
light and vortexed for 30 seconds followed by sonication in a sonicating water bath 
for 30 seconds.  Each well required 25µl of diluted 1X beads from a total volume of 
2.4ml.  Therefore, to combine both 1X bead types, 240µl of 10X 5-Plex beads and 
240µl 10X VEGF beads were added to 2160µl using 1X wash solution as diluent 
(dilution factor 1:11 as per manufacturer’s advice for extra pipetting volume). 
2.4.8.6 Preparation of lyophilized standards 
For use of 2 vials of human standard together, 0.5ml assay diluent was used to 
reconstitute standards in each vial followed by gentle mixing.  From each vial, 300µl 
was combined and mixed gently.  The vial stopper was replaced and the vial left to 
stand for 10 minutes, after which the vial was gently swirled and inverted 2 to 3 
times and allowed to sit at room temperature for 5 minutes.  The following proteins 
were present at pg/ml concentrations in reconstituted human standard antigen 
mixture: VEGF (125), RANTES (7,200), Eotaxin (1,440), MIP-1α (15,700), MIP-1β 
(6,300) and MCP-1 (23,900).  Series dilutions of reconstituted human standard 
mixture were made as shown in Table 2.4.8 and used within 1 hour of preparation. 
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Table 2.4.8:  The volume of human reconstituted standard added to assay diluent to 
yield 3-fold series dilutions. 
 
Human Standards (µl) 
Assay diluent 
(µl) 
1 Stock solution (Step 1) 0 
2 1 (150) 300 
3 2 (150) 300 
4 3 (150) 300 
5 4 (150) 300 
6 5 (150) 300 
7 6 (150) 300 
0 0 300 
1:3 dilutions at each step 
2.4.8.7 Preparation of biotinylated antibody 
The 10x biotinylated antibody concentrate was diluted 11-fold as described under 
preparation of antibody beads (section 2.4.8.5) per manufacturer’s advice.  Each well 
required 100µl of 1X beads and therefore for 96 wells, 960µl 10X 5-Plex biotin 
concentrate and 960µl 10X VEGF biotin stock was added to 8.64ml biotin diluent 
and mixed gently. 
 
2.4.8.8 Preparation of Streptavidin-RPE 
The Streptavidin-RPE was supplied as a 10X concentrate and diluted to yield a 1X 
working solution prior to use.  For 96 wells, 960µl 10x Streptavidin-RPE concentrate 
was diluted in 9.6ml Streptavidin-RPE diluent.  
 
2.4.8.9 Washing method using vacuum manifold 
The filter plate was placed on the vacuum manifold and the liquid aspirated with 
gentle vacuum.  Vacuum was controlled by ensuring low level suction before 
samples were applied and not exceeding 5mmHg mercury during the wash.  As soon 
as the wells were empty, vacuum pressure was stopped. 
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The filter plate was lightly pressed onto clean paper towels to remove excess fluid 
from the bottom of the filter plate.  Care was taken to not invert the plate.  Following 
the last aspiration and plate taps, the bottom of the filter plate was blotted with a 
clean absorbent towel before addition of next liquid phase or data acquisition step.  
The plate was never left on an absorbent surface when adding liquid phase. 
2.4.8.10 Capture of analyte 
Plates were pre-wetted with 200µl working wash solution and incubated for 15-30 
seconds at room temperature.  Fluid was removed from wells by aspiration with the 
vacuum manifold and the 1X bead solution vortexed for 30 seconds and sonicated 
for 30 seconds immediately prior to use.  Bead solution (25µl) was pipetted into each 
well with care to protect the plate from light.  Liquid was removed from wells by 
aspiration with the vacuum manifold and washed with 200µl of working wash 
solution.  
Beads were soaked for 15 to 30 seconds and then aspirated with the vacuum 
manifold.  This washing step was then repeated (refer to washing method, section 
2.4.8.9) followed by blotting of the plate’s base.  Incubation buffer (50µl) was 
pipetted into all wells followed by addition of 100µl standard dilutions, assay diluent 
(zero blanks), samples and positive FBS control (samples and FBS: comprising 50µl 
assay diluent and 50µl sample).  Samples were thawed followed by 5-fold dilution in 
assay diluent and gentle mixing prior to assaying. 
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Capture bead incubation was carried out in the dark on an orbital shaker for 2 hours 
at room temperature followed by another washing step as previously described.  
Prior to the end of incubation, 1X biotinylated detector antibody was prepared, 100µl 
of which was added to each well before incubation for 1 hour at room temperature 
on an orbital shaker to keep the beads suspended (500-600 rpm).  Meanwhile, the 
Luminex® 100™ instrument was prepared and along with 1X Streptavidin-RPE 
working solution. 
 
2.4.8.11 Data acquisition 
The same washing step as before was repeated and 1X Streptavidin-RPE (100µl) 
was pipetted into each well.  This was followed by incubation for 30 minutes at 
room temperature on an orbital shaker.  Liquid was removed from wells by 
aspiration with the vacuum manifold and beads were washed by adding 200µl 
working wash solution to the wells; allowing the beads to soak for 10 seconds before 
aspiration.  This was repeated three times.  After excess wash solution was removed 
by blotting the bottom of the plate on an absorbent towel, working wash solution 
(100µl) was added to each well and shaken for 2-3 minutes to resuspend beads.  The 
plate was uncovered of foil and inserted into the XY platform of the Luminex® 
100™ instrument for analysis.  Curve fitting software was used to measure 
concentration of antigen in samples. 
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3.1     Results 
This chapter will focus on the lipidomic profiling of prostanoids in human uterine 
tissues taken from non-pregnant (NP), menorrhagic women (age range: 32-53 yrs) in 
different phases of the menstrual cycle, to clarify the role of prostanoids in 
reproductive processes.  To readdress previous studies: in the human, non-pregnant 
uterus, there has been simultaneous detection and quantitation of PGI2, PGE2, PGD2, 
PGF2α, but not TXB2 produced from exogenous substrate using thin layer 
chromatography coupled with mass spectrometry (Abel and Kelly, 1979).  In another 
study, due to the limitations of RIA, prostanoids were not measured simultaneously 
(Rees et al., 1984).  To reiterate the aims stated earlier in Chapter two, the analysis of 
full prostanoid profiles per uterine biopsy using LC/ESI-MS/MS should help to 
elucidate the role of uterine prostanoids during the follicular, luteal and menstruation 
phase of the menstrual cycle. 
The expression of a broad range of prostanoid synthase enzymes has been recently 
studied in endometrium from non-pregnant women according to menstrual phase 
(Catalano et al., 2011), although analysis of in vitro prostanoid production in 
endometrium or myometrium was not carried out.  To the author’s knowledge, 
prostanoid synthesis by uterine junctional zone (JZ) tissue is yet to be studied in 
humans and animals and therefore has been analysed in this chapter, given that 
endometrial wave-like activity appears to originate in the JZ (Brosens et al., 1995).  
Data will hopefully show how the uterine hormonal milieu and tissue structure 
relates to prostanoid synthesis in the endometrium and myometrium of menorrhagic, 
premenopausal women. 
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Metabolite 
Prostanoid production in isolated human non-pregnant uterine tissues (pg/mg) 
Endometrium 
(n=9) 
Junctional 
Zone (n=3) 
Upper 
Myometrium 
(n=16) 
Mid 
Myometrium 
(n=6) 
Lower 
Myometrium 
(n=15) 
PGE2  89.4 ± 43.8
a 7.9 ± 3.2 13.9 ± 5.3 9.6 ± 4.8 13.7 ± 4.4 
PGD2 53.0 ± 17.3 9.5 ± 3.9 32.1 ± 9.1 36.9 ± 11.6 63.5 ± 12.9
d 
TXB2 63.6 ± 18.5
b 17.5 ± 4.5 19.8 ± 7.3 16.9 ± 7.8 20.8 ± 3.4 
6-keto-PGF1α 31.8 ± 8.4 14.6 ± 7.2 29.8 ± 8.0 31.9 ± 11.5 41.0 ± 9.6 
PGF2α 168.6 ± 105.3
c 9.3 ± 7.5 14.2 ± 6.1 7.9 ± 2.6 18.9 ± 4.4 
Table 3.1: Prostanoids produced by uterine tissues taken from menorrhagic, pre-menopausal donors not taking 
any form of hormonal therapy.  Data are expressed as arithmetic means of metabolite (pg/mg protein) ± S.E.M 
when cases are ≥ 3 and ± Standard Deviation (S.D) when cases are equal to 2.  Statistical analysis was carried out 
using the Kruskal-Wallis test and Mann-Whitney test as appropriate: a endometrium versus upper, mid, lower 
region myometrium and junctional zone (p<0.05); b endometrium versus junctional zone, upper and mid segment 
myometrium (p<0.05); c endometrium versus junctional zone, upper, mid and lower myometrial biopsies 
(p<0.05); d compared with upper segment myometrium (p<0.05). 
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Figure 3.1: Representative spectra of the prostanoids: PGB2-d4 (internal 
standard), PGD2, PGE2, TXB2, 6-keto-PGF1α and PGF2α detected by 
LC/ESI-MS/MS in a) endometrium and b)  junctional zone obtained from 
consenting, pre-menopausal women and also the c) cocktail of prostanoid 
standards (100 pg/ml). 
Endometrium Junctional zone 
PGE2 
PGD2 
PGF2α 
a) b) c) 
TXB2 
6-keto-PGF1α 
PGD2 
PGE2 
PGB2-d4 
6-keto-PGF1α 
PGF2α 
PG standard cocktail 
PGB2-d4 (internal standard) 
TXB2 
Spectra for LC/ESI-MS/MS analysis of prostanoids in upper, mid and 
lower segment myometrium are included in Figure 3.2. 
TXB2 
6-keto-PGF1α 
PGF2α 
8-iso-PGF2α 
PGB2-d4 
PGE2 
PGD2 
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3.1.1 Prostanoid release from human eutopic endometrium, upper versus 
lower segment myometrium and junctional zone 
When all the data from Chapter three was grouped together, regardless of menstrual 
status of NP donors, production of PGD2 and 6-keto-PGF1α predominated in 
myometrium in contrast with endometrium, the latter of which synthesised 
significantly greater concentrations of PGF2α (most abundant), PGE2 and TXB2 than 
the fundus and JZ (p<0.05, Table 3.1).  In spite of a 3.4-fold attenuation in PGD2 
production in JZ compared with upper, mid and lower segment myometrium, this 
result did not reach significance, whilst in vitro PGE2, TXB2, 6-keto-PGF1α and 
PGF2α production was constant between both tissue types.  Unique to the JZ, TXB2 
was the most abundantly produced prostanoid (Table 3.1). 
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Myometrial 
Metabolite 
 
PG synthesis in isolated human myometrium (pg/mg) 
Follicular (n=2-6) Luteal (n=2) Menstruation (n=3) 
 Upper Mid Lower Upper Lower Upper Lower 
PGE2 20.9 ± 7.9
d, e 24.4 ± 4.9 12.6 ± 3.9b,c 5.6 ± 0.4 19.9 ± 14.3 1.7 ± 0.3 24.8 ± 20.0 
PGD2 38.4 ± 11.3
a 65.6 ± 17.4 76.0 ± 14.9 25.0 ±15.1 120.7 ± 83.6 16.1 ± 8.5 36.4 ± 10.1 
TXB2 22.7 ± 9.6
d 21.3 ± 0.2 26.5 ± 3.6b, f 9.0 ± 3.3 31.8 ± 20.1 7.6 ± 1.8 11.5 ± 2.9 
6-keto-PGF1α 56.9 ± 16.1 64.7 ± 33.9 57.3 ± 15.1
f 18.4 ± 2.3 50.6 ± 20.5 17.2 ± 3.3 13.3 ± 2.7 
PGF2α 18.1 ± 8.6
d 7.5 ± 10.7 22.9 ± 7.2b,c 1.3 ± 1.9 26.6 ± 27.4 3.3 ± 2.7 20.2 ± 12.4 
Table 3.2: The prostanoids produced by human isolated upper, mid and lower segment myometrial samples taken from women who were in the 
follicular, luteal and menstrual phase of the menstrual cycle and suffering from menorrhagia.  Donors were pre-menopausal and not taking any 
form of hormonal therapy.  Data are expressed as arithmetic means of metabolite (pg/mg protein) ± S.E.M when cases are ≥ 3 and ± S.D when 
cases are equal to 2.  Statistical analysis was carried out using the Kruskal-Wallis, Mann-Whitney test and Wilcoxon signed-rank test as 
appropriate; a PGD2 upper versus lower segment (p<0.05);
 b PGE2, TXB2, PGF2α versus PGD2 lower segment (p<0.05); 
c PGE2 and PGF2α versus 
6-keto-PGF1α lower segment (p<0.05); 
d PGE2, TXB2, PGF2α versus 6-keto-PGF1α upper segment (p<0.05), 
e follicular compared with 
menstruation phase upper segment tissue (p<0.05), f follicular compared with menstruation phase lower segment tissue (p<0.05). 
 
Spectra are shown in Figures: 3.2-3.5.  Follicular phase, upper and lower segment myometrium represent n=6. 
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Figure 3.2: Representative spectra of lipidomic analysis of prostanoids (labelled accordingly) in isolated a) fundus b) mid segment and c) lower segment 
myometrium donated by a non-pregnant woman in the follicular phase of the menstrual cycle.  Refer to Figure 3.3 on the following page for representative 
spectra of prostanoid standards run alongside follicular phase samples. 
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Figure 3.3: Representative spectra of lipidomic analysis of 
prostanoid standards (100 pg/ml) run alongside follicular phase 
myometrial samples shown in Figure 3.2. 
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Figure 3.4: Representative spectra of lipidomic analysis of prostanoids (labelled accordingly) in a) isolated, upper segment myometrium donated by a non-
pregnant woman in the luteal phase of the menstrual cycle b) the standard cocktail (100 pg/ml) and c)isolated, lower segment myometrium from the same 
luteal phase donor. 
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Figure 3.5: Representative spectra of lipidomic analysis of prostanoids (labelled 
accordingly) in isolated, upper and lower segment myometrium donated by non-
pregnant women (donors 1 and 2 shown) in the menstruation phase of the 
menstrual cycle. 
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PGF2α undetected 
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3.1.2 Prostanoid release from human myometrium and endometrium in 
relation to topography and menstrual state 
Sub-grouping of data show that prostanoid production differs according to the region 
from which the myometrial biopsy is excised and menstrual status of the tissue 
donor.  Upon closer inspection of the data, in upper segment tissue, 6-keto-PGF1α 
production was most abundant and significantly higher (p<0.05, Table 3.2) than 
other series-2 PGs, except for PGD2.  Concentrations of 6-keto-PGF1α and PGD2 
were similar in mid section myometrium taken from menorrhagic sufferers in the 
follicular phase (Table 3.2).  However, in lower segment myometrium, PGD2 
production predominated and was higher than the other series-2 eicosanoids, apart 
from 6-keto-PGF1α (p<0.05, Table 3.2).  Synthesis of 6-keto-PGF1α in lower segment 
biopsies was significantly higher than PGE2 and PGF2α (p<0.05, Table 3.2). 
Production of PGE2, TXB2, 6-keto-PGF1α and PGF2α in vitro did not significantly 
differ in NP, lower versus fundal, follicular phase myometrium obtained from 
menorrhagic women (Table 3.2).  Lower segment myometrium, however, produced 
1.9-fold more PGD2 than the fundus (follicular phase p<0.05, Table 3.2) and when 
all myometrial samples were analysed, irrespective of menstrual phase, in vitro 
synthesis of PGD2 but no other prostanoid was more abundant in lower versus upper 
segments (Table 3.1 and Appendix 12 for paired samples, p<0.05). 
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Although n numbers were too small to compare follicular and luteal phase 
myometrial data statistically, it was possible to show that PGE2 production in 
isolated fundus was more abundant during the follicular than menstruation phase 
(p<0.05, Table 3.2).  Production of 6-keto-PGF1α in lower segment myometrium 
from menstruating donors was variable (refer to spectra in Figure 3.5).  Nonetheless, 
TXB2 and 6-keto-PGF1α was synthesised at greater concentrations in lower segment 
myometrium from follicular phase compared with menstruating women (p<0.05, 
Table 3.2). 
Prostanoid production was maintained at follicular phase levels in lower segment 
myometrium obtained from donors in the luteal phase and suffering from 
menorrhagia, except for PGE2 and PGD2, concentrations of which were 1.6-fold 
higher in luteal phase versus follicular phase, lower segment myometrium (Table 
3.2).  Unlike follicular phase specimens, topographical gradients in prostanoid 
production were apparent in luteal and menstruation phase biopsies, owing to the 
attenuation of fundal but not lower segment myometrial prostanoid production 
(Table 3.2).  In lower segment myometrium from a menstruating donor with 
menorrhagia, PGE2 was the only prostanoid whose production was higher than that 
in equivalent biopsies from two donors in the luteal phase, although the S.E.M was 
large.  In vitro synthesis of all other prostanoids was attenuated in menstruation 
versus luteal phase, lower segment myometrium (Table 3.2). 
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Metabolite 
Pg/mg 
Early follicular phase Late follicular phase 
γ
 Menstruating 
PGE2 41.8 ± 29.7 208.2 ±106.4 18.2 ± 9.2 
PGD2 65.4 ± 41.3 77.0 ± 29.3 16.6 ± 4.8 
TXB2 80.3 ± 49.7 88.3 ± 17.8 22.2 ± 3.8 
6-keto-PGF1α 30.1 ± 12.2 42.1 ± 21.8 23.3 ± 11.8 
PGF2α 30.4 ± 20.2 440.0 ± 277.9
a 35.4 ± 13.8 
Table 3.3: The effects of menstrual phase on endometrial prostanoid output in vitro (n=3 for all groups).  Endometrial 
donors were premenopausal and not taking medication.  Data are expressed as arithmetic means of metabolite (pg) per 
mg of protein ± S.E.M.  Statistical analysis was performed using the, Kruskal-Wallis and Mann-Whitney test as 
appropriate: a PGF2α late follicular versus early follicular and menstruation phase (p=0.05: not significant). 
γ As per patient information sheet (possible ovulation).  Spectra are shown in Figure 3.6. 
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Figure 3.6: Representative spectra of lipidomic analysis of prostanoids (labelled accordingly) in endometrial biopsy obtained from a consenting donor with 
menorrhagia and in the a) early follicular b) late follicular phase c) menstruation phase. 
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Production of endometrial TXB2 predominated, followed closely by PGD2 and PGE2 
in the early follicular phase and was at least 2.3-fold higher in early follicular phase 
compared with menstruation phase endometrium (not statistically significant, Table 
3.3).  In rare cases, endometrial but not myometrial specimens were donated by 
women specified to be in the late follicular phase.  Data in Table 3.3 show each 
prostanoid increased in late versus early follicular phase endometrium (not 
significant), except for 6-keto-PGF1α, which remained constant.  In vitro synthesis of 
PGE2 and PGF2α was most abundant late follicular phase (5.0- and 14.5-fold 
increases respectively for late follicular versus early follicular and menstruation 
phase, p=0.05 and non-significant for PGF2α, Table 3.3).  In endometrium obtained 
from menstruating menorrhagia sufferers, PGF2α, TXB2 and 6-keto-PGF1α synthesis 
was similar (Table 3.3). 
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3.2     Discussion 
3.2.1   Utero-specific postanoid release 
LC/ESI-MS/MS simultaneous lipid profiling is a relatively new technique and hence 
previous studies have mainly focused on analysis of PGE2 and PGF2α using RIA.  
PGF2α was a major metabolite in human endometrium, in agreement with other 
groups studying humans (Singh et al., 1975, Liggins et al., 1980, Rees et al., 1984, 
Lumsden et al., 1986) and rhesus monkeys (Eldering et al., 1990), occurring at 
higher quantities than myometrium (Rees et al., 1984).  Also, data show that 6-keto-
PGF1α synthesis was predominant in human myometrium corresponding with other 
findings from humans (Abel and Kelly, 1979, Rees et al., 1984) and rodents 
(Fenwick et al., 1977).  Another study reported an endometrial concentration of 
PGE2 higher than PGF2α (Abel and Kelly, 1979) and this could be due to 
measurement of prostanoids from exogenous rather than endogenous AA and not 
truly representative of events in vivo.  The concentration at which PGF2α, for 
example, was produced in endometrial specimens detected by LC/ESI-MS/MS, 
correlated well with other groups who used chromatography and densitometry 
(Singh et al., 1975) and GC-MS/MS (Green and Hagenfeldt, 1975, Maathuis and 
Kelly, 1978, Lumsden et al., 1986).  However, previous studies have not compared 
TXB2 concentrations in endometrium and myometrium, along with simultaneous PG 
profiles, which would offer greater clarification of the roles of PGs in uterine 
physiology. 
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Interestingly, Liggins (Liggins et al., 1980) pointed out that in the studies which used 
mass spectrometric analysis of uterine tissues, pg/mg concentrations were very 
similar, with large variations (by a factor of ten in some cases) between GC-MS/MS 
(Green and Hagenfeldt, 1975, Maathuis and Kelly, 1978) and bioassay/RIA 
techniques (Pickles et al., 1965, Downie et al., 1974, Willman et al., 1976, Rees et 
al., 1984). 
Thesis data demonstrate the tissue-specific synthesis of prostanoids reflecting 
differences in cell morphological characteristics of the uterus.  The uterotonic 
prostanoids PGE2, TXB2 and PGF2α were significantly more abundant in 
endometrium than myometrium regardless of menstrual phase.  Given the heavy 
glandular component unique to the endometrium, in which PGES (Milne et al., 
2001a), AKR1C3 or PGFS (Catalano et al., 2011) and TXAS (Swanson et al., 1992) 
but not PGI2 synthesis (Lumsden et al., 1984) was identified, endometrial lipidomic 
profiles were unsurprising.  In support of thesis findings, Milne et al (Milne et al., 
2001a) showed that both PGES and PGE2 immunoreactivity was stronger in the 
functionalis layer of the endometrium than the myometrium.  In accord, endometrial 
epithelial cells produced a greater concentration of PGE2 and PGF2α compared with 
stromal cells (Lumsden et al., 1984, Smith and Kelly, 1988).  Data which showed the 
greater concentration of oestradiol in endometrium (550-3460 pg/g) compared with 
myometrium (380-1710 pg/g) (Alsbach et al., 1983) and higher histoscores of ER in 
endometrial glands versus stroma (Mertens et al., 2001), could explain why 
endometrial PG synthesis in vitro is abundant.  Correspondingly another group found 
that oestradiol stimulated prostanoid synthesis in the glandular but not the stromal 
cells of the endometrium (Schatz et al., 1987). 
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Studies support a proliferative function for PGE2 via EP2 (Sales et al., 2004), whilst 
PGF2α might stimulate endometrial epithelial proliferation via the FP receptor whose 
expression peaks mid follicular phase (Milne and Jabbour, 2003, Catalano et al., 
2011) and downstream signalling can induce proliferation in Ishikawa cells (Milne 
and Jabbour, 2003).  A role for TXA2 has been implicated in endometrial cancer 
(Aitokallio-Tallberg, 1990) and so it would follow that TXA2-TP signalling is able to 
induce proliferation of endometrial cells and hence facilitate the formation of the 
functionalis layer of the endometrium in the lead up to ovulation.  Furthermore, 
research showed the TP antagonists EP092, AH23848 and BM 13.505 prevented the 
oestradiol-induced increase in uterine dry weight in hypertensive rats (Kerr et al., 
1991).  Therefore, TP downstream effects could influence oestrogen-mediated 
uterine growth, possibly by targeting oestrogen-stimulated growth factors, such as 
Epidermal Growth Factor (EGF) (Uchiyama et al., 2009), to indirectly stimulate 
endometrial epithelial cell proliferation.  There is a possibility that abundance of 
TXA2 in endometrial versus myometrial biopsy is related to the pathology that is 
menorrhagia (whereby the endometrium is persistently proliferative (Smith et al., 
1982)) and not physiological reproductive function.  However, uterine tissues from 
disease-free women were not donated for study to act as a comparison with those 
from menorrhagic women and so data must be interpreted with caution. 
Prostacyclin and PGD2 might be regarded as homeostatic regulators of uterine 
function, since thesis data show that in vitro production was constant in 
endometrium, JZ and upper, mid and lower myometrial sections.  This corroborates 
with other groups who demonstrated endometrial-myometrial comparisons, although 
did not analyse PGs simultaneously (Abel and Kelly, 1979, Rees et al., 1984).  
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Predominance of spasmolytic PGI2 and PGD2 in myometrium but not endometrium 
may be owing to the vast number of myocytes comprising the bulk of the 
myometrium, which abundantly express PGIS and PGDS (Moonen et al., 1986, 
Giannoulias et al., 2002, Phillips et al., 2010) and reflects the mechanisms by which 
the myometrium is maintained in a relatively hypocontractile state.  PGI2 is likely to 
serve an important vasodilatatory and anti-aggregatory role (Smyth and FitzGerald, 
2002) within the myometrial vasculature (Baxter et al., 1995), in order to sustain 
adequate blood flow to the myometrium. 
Thesis data for the first time showed abundant PGD2 synthesis, similar to PGI2, in 
sixteen human myometrial samples.  In other studies, which analysed myometrial 
prostanoid production from NP women suffering various uterine benign pathologies; 
one did not measure PGD2 (Lumsden et al., 1986), another measured this metabolite 
but did not compare PGD2 production simultaneously with that of other prostanoids 
(Rees and Kelly, 1986), whilst PGD2 production second to prostacyclin and equal to 
PGE2 and PGF2α was reported (Abel and Kelly, 1979).  The discrepant findings 
between this study and that of Abel and Kelly (Abel and Kelly, 1979) could be 
related to differences in methodologies.  The prostanoids, excluding PGD2, have 
been measured in cervical biopsies after administration of 14C-AA (Ellwood et al., 
1980, Christensen and Bygdeman, 1985), whilst the in vitro synthesis of PGD2, or 
any other PG for that matter, has not been analysed in terms of topography in the 
human uterus previously. 
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These new findings suggest that PGD2 production in lower segment myometrium 
may be physiologically important, possibly to aid immunoprotection via a CRTH2 
dependent mechanism.  For example, PGD2 chemoattracts Th2 cells, which express 
the CRTH2 receptor on their surface (Nagata and Hirai, 2003).  Of particular interest, 
is data which showed higher numbers of T helper cells in the lower versus upper 
segment myometrium (Thomson et al., 1999), whilst Th2 cells are present in the 
cervix as well as the vagina (Johansson et al., 1999).  Correspondingly, the core 
proteome of cervical tissue is related to immune defence (Dasari et al., 2007). 
Data show that prostanoid synthesis did not increase from myometrium-to-JZ-to-
endometrium, instead there was a sharp contrast between high prostanoid output in 
endometrium and lower level JZ and myometrial PG production, which is not 
surprising considering JZ structure in a similar manner to myometrium, is distinct 
compared to endometrium (Fusi et al., 2006).  Propagation of highly specialized 
contraction waves in the uterus originate exclusively from the JZ and participate in 
the regulation of diverse reproductive events, such as sperm transport, embryo 
implantation, and menstrual shedding (Fusi et al., 2006).  The predominance of 
TXB2 in the JZ suggests that functional TP receptors may be present in the JZ to 
enhance contractile activity.  However, data showed no difference in synthesis of 
prostanoids in the JZ compared with myometrium in vitro (possibly related to low 
sample number). 
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3.2.2    The menstrual cycle 
In endometrial tissue, PGE2, PGD2 and TXB2 production was more abundant in the 
early follicular versus menstruation phase (no luteal phase specimen donated), 
however, this thesis result did not reach significance, possibly as only three 
endometrial specimens per group were analysed.  In another study, PGF2α, TXB2 and 
6-keto-PGF1α production was more abundant in endometrial perfusate from early 
follicular versus luteal phase women (PGE2 and PGD2 not analysed) (Liggins et al., 
1980).  In accord, thesis data show that series-2 PG synthesis was most abundant in 
follicular versus luteal phase myometrium, although owing to the low frequency of 
tissue donations from the latter group, statistical comparisons could not be drawn.  A 
major limitation of this study is that the menstrual phase of uterine tissue donors was 
not confirmed by histological technique and instead based on the gynaecologist’s 
notes.  Also, serum measurement of sex steroid hormones could not be carried out in 
donors of uterine tissues.  This is due to the high cost of assaying hormones and the 
challenges involved in being granted ethical approval to carry out this type of study 
and also to obtain consent to collect blood from donors.  Therefore, it is with 
extreme caution that thesis menstrual data are interpreted.  Follicular and 
menstruation phase comparisons (this study) showed that PGE2 production in 
isolated fundus was significantly more abundant in the follicular than menstruation 
phase.  However, data from previous studies, which did not carry out simultaneous 
PG profiling according to uterine topography, are conflicting.  For example, selected 
PGs (PGF2α, PGD2 and 6-keto-PGF1α) are produced at lower level in the follicular 
phase (Rees et al., 1984, Rees and Kelly, 1986) or show differences in output, which 
support thesis data, notably PGE2 (Vijayakumar and Walters, 1981, Lumsden et al., 
1986). 
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The differences in findings between research groups could be related to analysis of 
superfusate versus homogenised tissue.  PGE2 synthesis in the upper segment of 
myometrium may be required for paracrine action on the dominant ovarian follicle 
before and during ovulation, since ova from EP2 receptor knockout mice fail to 
undergo fertilisation (Tilley et al., 1999).  Alternatively there may be a 
vasodilatatory or angiogenic role for PGE2 in the fundus prior to ovulation, given the 
effects of PGE2 in isolated uterine arteries (Baxter et al., 1995) and reports of 
increased myometrial PGE2 binding sites and PGE2 binding affinity in the fundus 
compared with the cervix (Giannopoulos et al., 1985, Adelantado et al., 1988).  
Importantly, future work is necessary to differentiate between the effects of 
menorrhagia and normal physiology on prostanoid concentrations in follicular phase 
myometrial segments by comparing samples from women with and without 
menorrhagia. 
During the follicular phase, uterine prostanoid synthesis could increase due to the 
positive oestrogen influence on uterine PLA2, as demonstrated in the human 
(Bonney, 1985, Bonney et al., 1987, Periwal et al., 1996) and rat (Dey et al., 1982, 
Pakrasi et al., 1983) as for COX-2 (Dong et al., 1996, Catalano et al., 2011).  Such 
effects are speculated to occur via ER because in ovariectomized mice, ICI-182780 
(which acts as a selective oestrogen receptor modulator, to wit an ER antagonist) 
significantly decreased the level of oestrogen-induced COX-2 expression (Wu et al., 
2007).  However, there are other factors to take into consideration, such as cytokines 
and various inflammatory cascades.  For example, IL-1 can induce synthesis of PGE2 
and COX-2 in human myometrial cells, which involves not only activation of the 
p38 mitogen-activated protein kinase (MAPK) cascade but also nuclear factor kappa 
B (NFκB) (Bartlett et al., 1999, Hertelendy et al., 2001). 
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Data from this study show an abundance of myometrial TXB2 (not previously 
measured) and 6-keto-PGF1α in follicular versus menstruation phase lower segment 
myometrium, whereby PGI2 could maintain vasodilatation of myometrial arteries 
and thereby prevent tissue ischaemia, when uterine activity increases (Kunz et al., 
1998, Maslow and Lyons, 2004).  The enhanced TXA2 synthesis in the lower 
segment myometrium may help to reverse the fundo-cervical peristaltic pattern 
observed at menstruation (Lyons et al., 1991, Kunz et al., 1996, Ijland et al., 1996).  
The change in uterine peristaltic activity is likely to be preparatory for the facilitation 
of sperm transport towards the ovum at ovulation.  This is based on a study by Kunz 
et al (Kunz et al., 1996), who traced the speed of movement of microscopic particles 
equal to the size of sperm from the follicular phase cervix to the Fallopian tubes. 
Thesis data show that PGF2α predominated in endometrium taken at the late 
follicular phase and although in vitro concentration peaked in the late compared with 
early follicular phase, this was not statistically significant.  Such a result could be 
due to the large variation in PGF2α between the samples analysed, although it is 
possible that low n numbers contributed to this effect.  Another group showed that 
there was variation in PGE2 and PGF2α production from human endometrium in the 
early luteal but not in the follicular phase using RIA (Rees et al., 1984), whilst Singh 
et al (Singh et al., 1975) who used thin layer chromatography, showed very little 
variation in endometrial PG output.  Similar to thesis data, Liggins et al (Liggins et 
al., 1980) found that PGF2α synthesis at 188 pg/mg/min from endometrial perfusate 
was almost three times more abundant late versus early follicular phase.  
Furthermore, expression of endometrial AKR1C3 (one of the PGFS enzymes) was 
elevated early luteal phase (day 14 up to the window of implantation) compared with 
other menstrual phases (Catalano et al., 2011). 
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Elevations in uterine PGF2α production could explain why peristalsis increased in 
frequency and pressure in the late follicular phase (van Gestel et al., 2003), 
consistent with in vivo ultrasound recordings in NP women (Bulletti et al., 2000).  
Extending the current study to analyse a greater number of endometrial biopsies in 
the early versus late follicular phase may support a role for PGF2α in ovulation.  
Unfortunately no endometrial samples from luteal phase donors were donated for 
analysis, however, myometrial data from two specimens show prostanoid synthesis 
in vitro was attenuated, particularly in the upper segment myometrium obtained from 
luteal versus follicular phase donors.  This data cannot be relied upon with great 
certainty, however, since only two samples were donated and analysed.  
Nonetheless, preliminary findings are consistent with other studies comparing PLA2 
concentration (Hayashi et al., 2000) and PGE2, PGF2α and 6-keto-PGF1α in follicular 
and early-mid luteal phase uteri (Lumsden et al., 1986, Kelly and Smith, 1987, Milne 
et al., 2001a).  In addition, data from this study show attenuation of prostanoid 
output in upper but not lower segment myometrium taken from women in the luteal 
phase, which could be explained by presence of more PR in the fundus compared 
with lower segment myometrium (Vollmer et al., 1990, Challis, 2000).  However, 
further study is required to interpret luteal phase, lipidomic data more reliably. 
Thesis data show that endometrial and myometrial prostanoid production did not 
increase at menstruation, which contrasts with other reports of abundant endometrial 
prostanoid production (not simultaneously measured) late luteal phase through to 
menstruation (Downie et al., 1974, Singh et al., 1975, Willman et al., 1976, Maathuis 
and Kelly, 1978, Liggins et al., 1980, Rees et al., 1984, Leaver and Richmond, 1984, 
Ishihara et al., 1986, Rees and Kelly, 1986). 
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The unexpected finding could relate to a number of factors, such as low n number, 
inadequate confirmation of menstrual status and hormonal changes.  Myometrial 
prostanoid data was unsurprising considering that unlike the functionalis, PR does 
not decline and hence a functional progesterone withdrawal fails to take place in the 
myometrium and stroma/basalis layer during the luteal phase (Garcia et al., 1988, 
Lessey et al., 1988, Snijders et al., 1992, Noe et al., 1999).  Other groups showed no 
significant increase in myometrial PGI2 and PGE2 production with menstruation 
versus other menstrual phases in vitro (Rees et al., 1984, Milne et al., 2001a) but did 
not measure a range of prostanoids.  Problematically, other similar studies have not 
analysed menstruation phase myometrium (Vijayakumar and Walters, 1981, 
Lumsden et al., 1986), nor is it possible to show to what extent thesis data reflects 
normal physiological processes compared with menorrhagia.  Hyperperistalsis is 
associated with heavy MBL (Chalubinski et al., 1993), which could be related to 
imbalanced spasmolytic and spasmogenic prostanoid production in the myometrium.  
However, further study is required to clarify differences between uterine prostanoid 
profiles in menstruating women with or without menorrhagia. 
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4.1     Results 
To the author’s knowledge, so far, only one group have carried out the simultaneous 
quantitation of a maximum of two prostanoids from Isotope-labelled AA (PGE2 and 
PGF2α) in human, pregnant myometrium at term gestation, using GC-MS/MS 
(Dimov et al., 1983).  Studies have focused mainly on quantitation of prostanoids in 
other human intrauterine tissues.  For example, in amniotic fluid (Dray and Frydman, 
1976, Mitchell et al., 1979, Nieder and Augustin, 1983, Romero et al., 1993, 
Steinborn et al., 1995, Helliwell et al., 2006), foetal membranes (Mitchell et al., 
1982, Wetzka et al., 1993),  placenta (Mitchell et al., 1982, Steinborn et al., 1995) 
and deciduas (Mitchell et al., 1982, Wetzka et al., 1993, Steinborn et al., 1995), 
whereby RIA was used to measure all five primary prostanoids in each tissue, 
although not together. 
Regarding parturition, the rate of release of myometrial PGE2, PGF2α and 6-keto-
PGF1α but not TXB2 and PGD2 from myometrial incubate before and after labour 
onset were measured using RIA (Satoh et al., 1981).  With this in mind, 
simultaneous lipidomic profiling of prostanoids was carried out in human 
myometrium from pregnant women before and after labour onset to elucidate which 
PGs play a pivotal role in prolonging gestation to term and helping labour to 
progress so that the foetus is delivered.  Also included in the present study were case 
studies comprising pregnant women whose 1) labour had not progressed 
(hypocontractile, n=2) 2) oxytocic induction of labour had failed (n=3) and 3) labour 
started preterm (n=1), to see if and how PG production is affected when pregnancy is 
abnormal.  The ultimate goal of this chapter is to show which PGs could make 
suitable tocolytic targets. 
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4.1.1 Prostanoid production in isolated lower segment uterine specimens 
obtained from pregnant women: effect of donor characteristics 
In vitro PGE2 production in human, gravid, non-labouring myometrium was 
relatively uniform regardless of donor characteristic (4.5-11.6 pg/mg), as was PGF2α 
(14.2-34.0 pg/mg) (Table 4.1).  Concentration of the thromboxane metabolite, TXB2 
was 2.6-fold higher in hypertensive donors compared with women with normal 
blood pressure.  This was owing to the myometrium of one donor with high 3-fold 
higher TXB2 output than other hypertension sufferers and therefore, data from this 
biopsy were analysed separately (refer to Appendix 21) to data presented in Table 
4.3.  Production of the stable metabolite of prostacyclin, 6-keto-PGF1α was more 
variable, ranging from 101.4-233.9 pg/mg and did not differ significantly among 
donor groups, despite 1.8-fold lower production in donors who had given birth twice 
previously compared with nulliparous women.  Similar to 6-keto-PGF1α, production 
of PGD2 was variable ranging from 21.8-82.7 pg/mg and was attenuated 1.9-fold in 
non-labouring, hypertensive versus normotensive myometrium.  This result, 
however, did not reach significance as was the case for PGD2 concentration 
according to the other donor characteristics presented in Table 4.1. 
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Non-labouring donors 
Metabolite (pg/mg) 
PGE2 6-keto-PGF1α TXB2 PGF2α PGD2 
Blood pressure       
Normal blood pressure (n=11) 6.4 ± 1.4 150.0 ± 42.2 13.8 ± 3.3 18.9 ± 5.4 41.3 ± 13.6 
Hypertensive (n=4) 11.6 ± 3.7 157.2 ± 28.6 36.1 ± 17.9 14.2 ± 4.7 21.8 ± 3.2 
      
Smoking       
Non-smoker (n=12) 5.5 ± 2.0 207.6 ± 112.0 25.4 ± 8.8 23.8 ± 16.9 65.9 ± 46.1 
Smoker (n=3) 8.4 ± 1.8 138.0 ± 30.0 18.3 ± 6.7 16.1 ± 3.6 28.7 ± 6.5 
      
Parity      
0 (n=2) 6.0 ± 2.6 181.4 ± 135.0 11.0 ± 5.0 20.2 ± 16.6 51.6 ± 22.9 
1 (n=4) 5.2 ± 1.1 174.9 ± 97.8 15.1 ± 8.9 20.8 ± 12.7 55.6 ± 34.7 
2+ (n=4) 8.3 ± 3.7 101.4 ± 49.8 15.4 ± 3.7 20.1 ± 6.5 30.5 ± 13.9 
      
Previous Caesarean Section      
No (n=3)  4.5 ± 1.4 233.9 ± 111.1 18.3 ± 11.7 26.3 ± 16.1 74.7 ± 41.7 
Yes (n=7) 7.5 ± 2.1 109.4 ± 45.8 12.7 ± 2.7 17.8 ± 5.5 32.0 ± 10.8 
      
Ethnicity      
White British (n=3) 9.7 ± 4.3 169.2 ± 130.9 24.0 ± 9.3 34.0 ± 13.9 82.7 ± 40.8 
British (n=5) 4.7 ± 1.3 133.2 ± 58.9 11.5 ± 3.5 14.3 ± 6.2 31.0 ± 12.0 
Pakistani British (n=2) 6.7 ± 4.8 149.6 ± 142.2 7.0 ± 1.5 15.2 ± 16.4 22.5 ± 8.9 
High blood pressure (hypertension) defined as: systolic >140 and diastolic >90 mmHg. 
Table 4.1: The effect of donor characteristics on prostanoid production in isolated, lower segment smooth muscle obtained from pregnant, non-
labouring women at term gestation (38.7 ± 0.2 weeks).  Data are expressed as arithmetic means of metabolite ± S.E.M (pg/mg) where cases are 
n ≥ 3 and ± S.D where cases are n=2.  Statistical comparisons were carried out using the Kruskal-Wallis and Mann-Whitney test as appropriate.   
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Labouring donors  
Metabolite (pg/mg) 
PGE2 6-keto-PGF1α TXB2 PGF2α PGD2 
Parity      
Primiparous (n=7) 25.7 ± 4.6 521.0 ± 129.5a  34.6 ± 6.5 41.3 ± 12.5 98.2 ± 45.4 
Parity 2 (n=3) 378.7 ± 270.6 98.5 ± 29.3 87.4 ± 29.4 712.2 ± 378.7 184.4 ± 83.3 
      
Previous Caesarean Section      
No (n=8) 48.3 ± 22.9 461.4 ± 135.8 43.1 ± 10.9 130.4 ± 95.9 129.1 ± 53.4 
Yes (n=2)+ 464.8 ± 628.3 125.8 ± 25.8 80.0 ± 69.8 691.3 ± 926.3 103.9 ± 53.0 
      
Ethnicity      
White British (n=5) 58.7 ± 37.0 438.4 ± 194.6 50.3 ± 14.2 179.9 ±144.2 186.4 ± 69.2 
Pakistani British (n=3) 29.8 ± 10.8 479.7 ± 171.6 36.6 ± 10.1 55.9 ± 13.6 70.7 ± 35.8 
Table 4.2: The effect of donor characteristics on prostanoid production in isolated, lower segment myometrium donated by 
term, pregnant, labouring women (41 ± 0.2 weeks gestation).  Data are expressed as arithmetic means of metabolite ± 
S.E.M (pg/mg) where cases are n ≥ 3 and ± S.D where cases are n=2.  Statistical comparisons were carried out using the 
Mann-Whitney test; a Primiparous versus parity 2, p<0.05; + sample size too small to be included in statistical analysis. 
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Figure 4.1: Representative spectra for the LC/ESI-MS/MS analysis of prostanoids (labelled as appropriate) in 
isolated myometrium from a term, labouring (halfway point of cervical dilation) a) primiparous and b) 
multiparous donor. 
PGE2 PGE2 PGD2 
PGD2 
TXB2 TXB2 
6-keto-PGF1α 6-keto-PGF1α 
PGF2α PGF2α 
a) b) 
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Term labouring (TL) women with a parity of 2 produced 1.9-, 2.5-, 14.7- and 17.2-
fold greater PGD2, TXB2, PGE2 and PGF2α respectively compared with women 
experiencing their first labour, however, due to the large sample variation as is often 
the case with labouring women, these differences were not statistically significant 
(Table 4.2).  In the myometrium of multiparous donors, however, 6-keto-PGF1α 
concentration was significantly attenuated compared with primiparous women 
(p<0.05, Table 4.2).  There was also no effect of labouring donors’ ethnicity on 
myometrial prostanoid profiles (Table 4.2), as was the case for blood pressure and 
gravidity (Appendix 14). 
4.1.2 Lipidomic profiles of prostanoids in isolated lower segment non-gravid 
and gravid non-labouring and labouring uterine specimens 
Lipidomic analysis of isolated myometrium revealed a decline and increase of PGE2 
and 6-keto-PGF1α production respectively in myometrium from term, pregnant 
compared with non-pregnant (NP) donors (statistically significant for 6-keto-PGF1α, 
p<0.05, Table 4.3).  Production of the series-1 prostanoids: PGF1α, PGE1 and PGD1 
were enhanced at least 2.3-fold (p<0.05 for PGF1α and PGE1), whilst in contrast 
PGJ2 production was significantly lower in myometrium from gravid versus non-
gravid women (p<0.05, Table 4.3) as reflected by attenuated production of the PGJ2 
precursor: PGD2 during pregnancy.  PGJ2, Δ
12-PGJ2 and 15-deoxy-∆
12, 14 PGJ2 was 
either undetectable or barely detectable in biopsies from term, pregnant women 
(refer to spectra in Figure 4.3 and Appendix 19).  The mean concentration of 
myometrial 6-keto-PGF1α was 1.6-fold higher at term versus preterm gestation and 
non-pregnancy (Appendices: 21 and 23). 
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Metabolite 
PG production in isolated, human myometrium (pg/mg) 
Non-pregnant (n=6) Non-labour (n=14) 
Spontaneous labour
  
(n=7) 
Failed labour 
(n=2) 
IOL (n=3) 
PGE2 19.5 ± 10.0 8.2 ± 1.6
b 52.2 ± 26.1 15.8 ± 8.1 99.6 ± 66.3 
PGD2 61.8 ± 24.6 46.1 ± 11.2 113.7 ± 43.8
c 18.6 ± 11.0 298.5 ± 17.7 
15-deoxy-∆12,14 PGJ2 - 0.4 ± 0.3 - - - 
∆12-PGJ2 - 0.5 ± 0.2 - - 54.1 ± 54.1 
PGJ2 2.4 ± 1.1
a 0.3 ± 0.2 - - 146.3 ± 139.3 
TXB2 19.9 ± 5.6 21.5 ± 4.4
b 47.9 ±10.5 13.0 ± 0.6 44.8 ± 25.7 
6-keto-PGF1α 26.7 ± 8.6
a 247.4 ± 69.3 456.8 ± 149.4c 131.0 ± 73.4 2158.8 ± 370.4 
PGF2α 20.3 ± 7.9 31.5 ± 11.6 144.7 ± 102.2
 14.4 ± 2.3 118.1 ± 36.0 
PGF1α 2.4 ± 1.4
a 9.2 ± 1.9 14.8 ± 5.3 3.5 ± 2.3 30.4 ± 16.9 
PGE1 2.4 ± 0.8
a 7.6 ± 1.5 12.4 ± 3.1 6.8 ± 2.4 68.1 ± 44.7 
PGD1 6.5 ± 2.4 14.9 ± 4.1 32.2 ± 9.9
c 6.6 ± 4.6 117.8 ± 11.5 
PGE3 - 0.3 ± 0.1 1.3 ± 0.7 - 0.6 ± 0.1 
PGD3 - 2.0 ± 1.8 2.4 ± 1.8 - 0.9 ± 0.9 
TXB3 0.1 ± 0.1 1.1 ± 1.0 0.8 ± 0.4 - 0.4 ± 0.4 
15-keto PGE2 12.0 ± 4.8
a 0.5 ± 0.2 8.0 ± 4.5 0.8 ± 0.3 22.4 ± 19.2 
Table 4.3: Lipidomic analysis of prostanoid metabolites produced by isolated, lower segment, human myometrium taken from non-pregnant (NP) 
donors (n=6) and pregnant donors at term gestation of whom were not in labour (n=14), in spontaneous labour (n=7), whose labour had failed 
(hypocontractile, n=2) or had induction of labour with syntocinon (IOL, n=3).  Myometrium from pregnant women was excised from the lower 
margin of the incision at elective Caesarean Section (donors who were not in labour) or emergency Caesarean Section (labouring donors).  Uterine 
smooth muscle was obtained from consenting, NP donors during hysterectomy.  Data are expressed as arithmetic means ± S.E.M (pg/mg).  
Statistical analysis was carried out using the Kruskal-Wallis and Mann-Whitney test as appropriate; a compared to non-labour (p<0.05), b versus 
spontaneous labour (p<0.05); c compared to IOL, (p<0.05). 
Spontaneous labour: mean cervical dilatation of 5.5 ± 1.1 cm, Failed labour: mean cervical dilation of 1.8 ± 1.0 cm and IOL: mean cervical dilatation of 5.5 ± 2.5 
cm.  Donors whose labours did not progress did not receive IOL with oxytocin, although one donor received prostaglandin agent (unspecified) and reached 0.5 
cm cervical dilation.  Representative spectra for LC/ESI-MS/MS analysis in Figures: 4.2-4.6 can be found on the following pages. 
15-keto PGE2: 13,14 dihydro-15-keto-Prostaglandin E2. 
Chapter Four: Pregnancy 
133 
 
Time2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00 22.00 24.00 26.00 28.00
%
100
369 > 163
2.47e3
2.91
Time2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00 22.00 24.00 26.00 28.00
%
100
351 > 271
3.81e4
6.59
5.49
Time2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00 22.00 24.00 26.00 28.00
%
100
369 > 169
1.75e4
3.93
Time2.00 4.00 6.00 8.00 10.0012.0014.0016.0018.0020.0022.0024.00 26.0028.00
%
100
333 > 271
4.47e4
5.67
4.82
Time2.00 4.00 6.00 8.00 10.0012.0014.0016.0018.00 20.0022.0024.00 26.0028.00
%
100
369 > 163
4.01e4
2.88
Time2.00 4.00 6.00 8.00 10.0012.0014.0016.0018.0020.0022.0024.00 26.0028.00
%
100
353 > 193
9.28e3
3.96
Time2.00 4.00 6.00 8.00 10.0012.0014.0016.0018.0020.0022.0024.00 26.0028.00
%
100
369 > 169
2.85e4
3.58
Time2.00 4.00 6.00 8.00 10.0012.0014.0016.0018.0020.0022.0024.0026.0028.00
%
100
353 > 193
1.07e4
4.48
Non-pregnancy Term non-labour 
PGF2α 
PGF2α 
6-keto-PGF1α  
6-keto-PGF1α  
TXB2  
TXB2  
PGD2  PGD2  
PGE2  PGE2  
Figure 4.2: Representative spectra of LC/ESI-MS/MS analysis of PGE2, PGD2, 6-keto-PGF1α, TXB2 and PGF2α in 
myometrium obtained from a consenting a) non-pregnant and b) term pregnant donor.  Refer to Appendix 15 for spectra 
representing prostanoid standards, which were analysed alongside biological samples from non-pregnant and pregnant 
women. 
a) b) 
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Figure 4.3: Representative spectra of LC/ESI-MS/MS analysis of PGJ2, ∆
12-PGJ2, 15-deoxy-∆
12, 14 PGJ2, 15-keto PGE2 and PGB2-
d4 (Internal standard) in myometrium obtained from a consenting a) non-pregnant and b) term pregnant donor.  Refer to 
Appendix 16 for spectra representing prostanoid standards, which were analysed alongside biological samples from non-pregnant 
and pregnant women.  Additional representative spectra for the J2 metabolites in gravid biopsies are shown in Appendix 19. 
a) b) 
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Figure 4.4: Representative spectra of LC/ESI-MS/MS analysis of PGF1α, PGE1, PGD1, PGE3, PGD3 and TXB3 in myometrium 
obtained from a consenting a) non-pregnant and b) term, pregnant donor.  Refer to Appendix 17 for spectra representing 
prostanoid standards, which were analysed alongside biological samples from non-pregnant and pregnant women. 
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Figure 4.5: Representative spectra of LC/ESI-MS/MS analysis of PGE2, PGD2, 6-keto-PGF1α, TXB2 and PGF2α in myometrium from three pregnant donors at term 
gestation.  One donor was in spontaneous labour (3cm cervical dilation), another donor’s labour failed to progress (3cm cervical dilation) and a third donor required 
induction of labour (IOL) with oxytocin (8cm cervical dilation). 
For an example of representative spectra for PG standards refer to Appendix 18 and Appendix 20 for spectra from a labouring donor at 1.5cm cervical dilation. 
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Figure 4.6: Representative spectra of LC/ESI-MS/MS analysis of PGJ2, ∆
12-PGJ2, 15-deoxy-∆
12, 14 PGJ2, PGF1α, 
PGE1 and PGD1 in myometrium from a term pregnant donor in a) spontaneous labour and b) whose labour was 
induced with oxytocin.  *Refer to Appendix 19 for magnified version of spectra for PGJ2. 
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PGE1 
PGD1 
PGE1 PGD1 
a) b) 
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With the onset of spontaneous labour at term gestation, PGE2 and TXB2 increased, 
which was statistically significant (p<0.05, Table 4.3).  In specimens from term, 
spontaneous labouring women, increased synthesis of 6-keto-PGF1α, PGD2, PGD1, 
PGE1, PGF2α and PGF1α by 1.8, 2.5, 1.6, 2.0, 4.6 and 1.6-fold correspondingly, was 
not significant (Table 4.3).  In comparison with biopsies from donors in spontaneous 
labour, specimens from women who were not experiencing uterine contractions 
produced PGE2, PGD2, TXB2, 6-keto-PGF1α and PGF2α at concentrations which were 
3.3, 6.1, 3.7, 3.5 and 10.0 times lower respectively (Table 4.3). 
During pregnancy, the myometrial concentration of the metabolite of PGE2: 15-keto 
PGE2 reflected the concentration of its precursor, which decreased at late gestation 
compared with non-pregnancy (p<0.05, Table 4.3).  However, 15-keto PGE2 then 
increased at labour onset and further with induction of labour (IOL) with oxytocin 
(the reverse being observed for donors whose labours failed to progress, Table 4.3).  
In pregnant myometrium, in vitro concentrations of the series-3 prostanoids: TXB3, 
PGE3 and PGD3 were low occurring at 0.3-2.0 pg/mg, whereas in tissues from non-
gravid women PGD3 and PGE3 were undetectable and TXB3 barely detectable 
(Table 4.3). 
Prostanoid profiles in specimens taken from women after IOL with oxytocin differed 
to biopsies obtained from spontaneous labouring donors in that PGD2, 6-keto-PGF1α, 
and PGD1 production was significantly augmented (p<0.05, Table 4.3).  Production 
of TXB2 and PGF2α was constant in biopsies from women in spontaneous or induced 
labour, whilst PGE2, PGF1α and PGE1 production was enhanced at least 1.9-fold in 
myometrium from women whose labours were induced (Table 4.3).  Table 4.4 on the 
following page summarises myometrial PG data for hypocontractile donors and 
those receiving IOL with oxytocin compared with spontaneously labouring women. 
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Failure of labour to progress at term 
Abnormality of functional progesterone withdrawal? 
Failure to progress to active phase  IOL with oxytocin  
PGE2 - PGE2 + 
PGF2α --- PGF2α 
PGI2 - PGI2 ++ 
TXB2 - TXB2 
PGD2 -- PGD2 ++ 
PGD1- PGD1 ++ 
Table 4.4: A summary of the changes in prostanoid quantities in vitro when labour 
progression fails or requires induction with oxytocin.  This further supports a role for 
PRA in preventing progesterone attenuation of spasmogenic PG synthesis, since 
PRB was the dominant PR isoform in decidua obtained from a non-contractile donor 
and active labour contractions were associated with a change in the PRA: PRB ratio 
(Goldman et al., 2005).  Data shown in Chapter four implies that labour contraction 
may depend on stimulation of the myometrium by spasmogenic prostanoids. 
+ Indicative of increase and - indicative of reduction of the following comparisons: 
Hypocontractile versus spontaneous, progressive, term labour and IOL with oxytocin 
versus spontaneous, progressive, term labour. 
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The PGD2 metabolites: PGJ2 and ∆
12-PGJ2 were undetected in myometrium taken 
from donors in spontaneous labour, whilst in samples from induced labouring 
donors, PGJ2 (although with a high level of variability), in line with PGD2 synthesis, 
was greater than 100 pg/mg and production of ∆12-PGJ2 reached >50 pg/mg (Table 
4.3). 
4.1.3  Lipidomic profiles of prostanoids in isolated, preterm and term gravid 
gestational tissues: rare cases 
In brief, TXB2 concentration was 16pg/mg higher in myometrium from the preterm 
labouring (PTL) donor versus a donor at mid-stage labour, whilst the PTL versus 
term, mid labouring comparison showed a reduction in 6-keto-PGF1α and PGD2 by 
7.7- and 8.5-fold respectively in tissue from the PTL donor (Appendix 21).  These 
differences were still apparent but lesser, particularly for PGD2 when compared with 
seven other TL donors (Table 4.3). 
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4.2     Discussion 
4.2.1     Pregnancy 
LC/ESI-MS/MS was used to measure prostanoids in human, gravid, lower segment 
myometrium to gain further understanding of how prostanoids are regulated during 
pregnancy.  Indeed, results indicate a role for PGE1 and PGF1α in addition to PGI2 at 
term pregnancy, which will be discussed in the following pages (refer to Figure 
4.2.1, page 147 for summary).  It is interesting that myometrial lipidomic profiles of 
prostanoids closely match the mRNA expression of their respective synthases.  For 
example, abundant PGIS, intermediate PGDS/PGFS and low level PGES (Phillips et 
al., 2010).  Also, lipidomic analysis of prostanoid production  showed a large degree 
of inter-sample variation, although a similar effect was observed in other studies, 
whereby PGE2, 6-keto-PGF1α and PGF2α were measured in pg/mg quantities using 
other methods, to wit, RIA in other human gestational tissues (Helliwell et al., 2006), 
myometrial smooth muscle cells in culture (Korita et al., 2002, Astle et al., 2007) 
and incubate collected from minced myometrium (Satoh et al., 1981). 
Data from this study, which showed that synthesis of PGE2, PGF2α and TXB2 in vitro 
did not increase in myometrium from gravid versus non-gravid donors, indicates that 
their respective synthases are attenuated by the progestogenic milieu of pregnancy 
and not other factors such as gravidity, parity or smoking, the latter factors of which 
had no bearing on lipidomic profiles in myometrium at late gestation.  Progesterone-
mediated PG inhibition, however, does not account for the significantly higher PGI2 
production in gravid myometrium, which is consistent with other groups who tested 
myometrial incubate (Satoh et al., 1981), myocytes (Korita et al., 2002), urine 
(Goodman et al., 1982) and plasma (Greer et al., 1985). 
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Another group has shown that RU486 administered to women resulted in increased 
endometrial PGIS expression (Catalano et al., 2007), whilst PGIS mRNA increased 
late luteal phase consistent with progesterone withdrawal (Catalano et al., 2011).  
Whether this is true regarding the myometrium during pregnancy is yet to be 
demonstrated, however, progesterone had null effect on uterine prostacyclin 
synthesis, in contrast with the inhibition of PGF2α (Peplow, 1991).  The increased 
myometrial PGI2 production in the gravid state, may occur as a result of the 
oestrogen priming, which takes place in pregnancy (Kofinas et al., 1990) as 17β-
oestradiol can up-regulate protein expression of both COX-1 and PGIS in myocytes 
from pregnant women (Korita et al., 2004).  Also, uterine stretch to accommodate 
the growing foetus may affect PGI2 synthesis.  For example, mechanical stretch 
stimulated PGIS expression and therefore the quantity of its product: prostacyclin 
formed in myometrial cells, through activation of the AP-1 site (Korita et al., 2002), 
a finding which was replicated in myometrial strips (Hurd et al., 2008). 
Novel thesis data show that myometrial 15-keto PGE2 production was significantly 
lower at term pregnancy than non-pregnancy, which is likely to reflect lower 
concentration of the precursor PGE2 or the reduced expression of 15-PGDH in 
isolated, human myometrium at term pregnancy (Phillips et al., 2010).  Previously, 
quantitation of prostanoid production from human uterine biopsies obtained from 
pregnant women has been demonstrated via prostanoid synthase expression in 
myometrium or prostanoid production from myocytes.  PGE2 measurement by RIA 
in two different studies (Korita et al., 2002, Astle et al., 2007) showed an 
approximate 10-fold difference in concentration, although there was a 6 hour 
difference in cell incubation time. 
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Moreover, ex vivo concentrations of PGs in cell culture were higher (approximately 
30 pg/ml, (Astle et al., 2007) and 300 pg/ml, (Korita et al., 2002)) than those 
quantified using LC/ESI-MS/MS (this study: <10 pg/mg) and GC/MS (5-30pg/mg 
(Dimov et al., 1983)).  Such differences could be related to the type of methodology 
used, for example, Astle et al and Korita et al incubated myometrial cells at 37°C to 
mimic PG synthesis under physiological conditions, whilst lipidomic analysis relied 
on keeping samples below 4°C, thus minimising PG synthase activity. 
Data from this study show for the first time, that PGD2 production does not differ 
between pregnancy and non-pregnancy in humans.  Even though H-PGDS mRNA, 
whose expression was lesser than the L-type, increased significantly with pregnancy 
in myometrium (Phillips et al., 2010), this does not reflect PGDS protein levels or 
enzyme activity.  Phillips et al (Phillips et al., 2010) did not measure H-PGDS 
protein, although PGES mRNA expression had considerably less variation than the 
protein measurement.  Also thesis data show that PGD2 remained the second most 
abundant prostanoid produced by term, gravid myometrium.  Functional DP1 
receptors reside in pregnant myometrium (Senior et al., 1993) and therefore PGD2 
could serve to potentiate the myometrial quiescence induced by predominantly 
occurring PGI2.  Secondary to this role, PGD2, which has an eight times lower 
affinity for CRTH2 than DP1 receptors, could chemoattract Th2 cells (Nagata and 
Hirai, 2003) to gain immunity from infection, to some extent, during the preparatory 
phase for labour.  The effects of PGD2 are further complicated by metabolism to 
other bioactive mediators. PGD2 also spontaneously forms PGJ2, which converts to 
∆12-PGJ2 and then 15-Deoxy-∆-
12, 14 PGJ2 (Bullo et al., 2005). 
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In the myometrium of pregnant women, the mean concentration of ∆12-PGJ2, 15-
Deoxy-∆12, 14 PGJ2 and PGJ2 was barely detectable at <1 pg/mg, in agreement with 
urine measurements presented by a different author (Bell-Parikh et al., 2003).  
Whilst 15-Deoxy-∆12, 14 PGJ2 is a highly potent anti-inflammatory mediator 
(Lindstrom and Bennett, 2005), the concentration at which it occurs in the human 
uterus is <0.5 pg/mg (and also absent with labour onset).  Therefore, 15-Deoxy-∆12, 
14 PGJ2 and ∆
12-PGJ2 are unlikely to play an important role during pregnancy and 
labour.  This is despite activation of PPAR-γ by 15-Deoxy-∆12, 14 PGJ2 (Forman et 
al., 1995, Marvin et al., 2000a) and the ability of both 15-Deoxy-∆12, 14 PGJ2 and ∆
12-
PGJ2 to act as agonists at the DP1 and CRTH2 receptors (Monneret et al., 2002, 
Nagata and Hirai, 2003).  Interestingly, data show that myometrial PGJ2 production 
was significantly lower with pregnancy and corresponds with the reduced catabolism 
of prostaglandins via 15-PGDH (Phillips et al., 2010) and unaltered synthesis of 
PGD2 at term gestation. 
The PPAR-γ receptor is expressed in human gestational tissues at late pregnancy 
(Marvin et al., 2000a), whereby PGD2 metabolite was able to bind to and activate the 
PPAR-γ receptor in JEG3 choriocarcinoma cell transfects, although not yet 
demonstrated in gravid myometrium from humans or animals.  Both PGJ2 and the 
PPAR-γ agonist, rosiglitazone inhibited proliferation of glioblastoma cell lines by 
inducing apoptosis (Morosetti et al., 2004), although this has yet to be shown in the 
myometrium.  Attenuation of myometrial PGJ2 production at late gestation, in 
theory, could prevent PPAR-γ-induced apoptosis of myocytes.  This may not 
necessarily support myometrial proliferation as this occurs early pregnancy 
(Shynlova et al., 2006) but could possibly maintain integrity of lower segment 
myometrium when the cervix begins to ripen. 
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Myometrial series-1 prostanoids, PGE1, PGD1 and PGF1α also occurred at greater 
concentrations with pregnancy (significant for PGE1 and PGF1α), whose synthesis is 
dependent upon the prevalence of their precursor fatty acids, through dietary intake 
(Fischer, 1989).  Regardless of dietary influence, the rising oestrogenic influence late 
pregnancy could explain the increase in COX-1 mRNA (Korita et al., 2002) and 
protein expression (Phillips et al., 2010), which in turn might account for elevations 
in synthesis of series-3 and series-1 PGs.  Nonetheless, series-2 PG production is 
favoured over series-1 and -3 equivalents, the latter of which were produced at low 
level (< 15 pg/mg) in pregnant myometrium, an effect possibly attributed to 
depletion of maternal PUFA tissue stores to aid foetal growth, which is potentiated 
with multiple pregnancy (Hornstra, 2000).  Thesis data show that PGE1 and PGD1 
are produced as natural products at low pg/mg concentrations in isolated 
myometrium obtained from pregnant women.  Until this point, PGE1 and PGD1 in 
women were theoretical metabolites of DGLA metabolism via COX.  Similar to data 
from this study, PGE1 was detectable at a very low level (picomolar) in plasma from 
men (Cawello et al., 1997, Hammes et al., 1999).  The 3.2-fold increase in PGE1 with 
pregnancy, was statistically significant, the mean concentration of which (7.6 pg/mg) 
may be enough to exert potent, anti-inflammatory effects in the myometrium.  PGE1 
might prevent the aggregation of platelets to the same extent as PGI2 (Whittle et al., 
1978) through both EP and IP receptors (Miller and Gorman, 1979, Negishi et al., 
1993).  Accordingly, PGE1 reduces expression of potent inflammatory cytokines 
(Ishikawa et al., 1998).  In myometrium from human, pregnant donors, PGE1 is 
stimulatory on the upper segment (Embrey and Morrison, 1968) and unsurprisingly 
is able to induce labour in women (Wing et al., 1995). 
Chapter Four: Pregnancy 
146 
 
In speculation, PGE1 could promote cervical ripening and possibly mediate Braxton-
Hick’s contractions prior to labour.  Data from this study show that PGD1 
predominated over PGE1 and PGF1α in human myometrium, regardless of clinical 
profile and corresponding with abundant synthesis of PGD2.  This could reflect the 
higher activity of the PGDS enzyme over PGFS and PGES in human myometrium 
and supported by the PG synthase measurements of Phillips et al (Phillips et al., 
2010).  Also, thesis data show that although myometrial PGF1α occurs at a 
concentration of < 10 pg/mg in vitro, the increase in pregnancy compared with non-
pregnancy was significant.  PGF1α can elicit contraction of human, gravid, 
myometrium similar to PGF2α (Embrey and Morrison, 1968), however the low level 
synthesis of this eicosanoid is unlikely to threaten myometrial quiescence late 
pregnancy, particularly since PGF1α binds to the ovine corpus luteal FP receptor at 
8% the potency of PGF2α (Balapure et al., 1989).  Uterine PGF1α has not been 
measured by other groups and the functional role of PGF1α in the uterus and other 
body systems is unknown, requiring further study. 
Regarding the prostanoids derived from EPA, thesis data show that although PGE3 
and PGD3 became detectable and TXB3 production enhanced (although < 2 pg/mg) 
in myometrium from pregnant donors, this was not significant.  Nonetheless, the 
inflammatory actions of n-3 PUFAs, to wit TXB3, are potent (Gryglewski et al., 
1979, Knapp et al., 1986), which in combination with the abundance of PGI2 during 
late gestation, may serve a haemodynamic function, for example, by regulating blood 
flow to the pregnant uterus (Baxter et al., 1995) when ventilation increases by 40% 
(Girling, 2004).  Whether or not changes to maternal diets during pregnancy could 
be beneficial to pregnancy maintenance (if oily fish containing EPA for example, are 
consumed within safe limits) remains to be tested. 
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Figure 4.2.1: Schematic representing the changes which could be taking place within the myometrium and cervix as a consequence of 
prostanoid signalling during the third trimester of pregnancy (based on the literature and thesis data, the latter is shown in red).  Refer to 
Chapter five for analysis of mediators in CVF in relation to impending labour 
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4.2.2     Term labour 
Simultaneous lipidomic profiling revealed increases in all the prostanoids detected in 
human gravid myometrium with labour onset, corresponding with demonstrations of 
augmented expression of COX-2 (Sparey et al., 1999, Sooranna, 2006, Astle et al., 
2007, Tattersall et al., 2008, Phillips et al., 2010) and COX-1 in human, pregnant 
labouring myometrium (Sparey et al., 1999) but also uterine myocytes from 
parturient rats (Dong et al., 1996).  However, it was particular prostanoids which 
increased significantly with term labour onset.  Upper segment myometrium is hard 
to obtain from pregnant donors for ethical reasons and therefore analysis in this 
chapter will focus upon the lower myometrial segment. 
LC/ESI-MS/MS has for the first time, enabled the pin-pointing of which PGs could 
be most important in the labour process and hence which PG signalling pathway 
could be targeted for tocolysis (to wit, the PGE2 and TXA2 signalling pathway).  It 
must be taken into consideration, however, that although the labouring women who 
consented to donate tissue for this study did not suffer from any serious type of 
medical condition, three received pain relief (entonox) and another took an inhaler to 
treat asthma, which may have affected data.  Unfortunately, the low frequency of 
sample donation at emergency Caesarean section meant that it was not possible to 
pick out and process biopsies from women nil of entonox.  Data show for the first 
time that TXB2 production increased significantly at labour onset and so the 
importance of its precursor TXA2, a potent lipid mediator within the myometrium at 
parturition, may have been previously overlooked. Concurrent with myometrial 
metabolite data, TXAS qualitative immunostaining scores were increased with 
labour at both preterm and term gestation in human myometrium (Swanson et al., 
1992). 
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In accord, TXB2 increased in amniotic fluid with progressive cervical dilation (Reddi 
et al., 1984) and in foetal membranes at parturition (Wetzka et al., 1993).  TXB2 
production has been measured in myometrium and gestational tissues from the 
Rhesus monkey at term pregnancy, although no labouring comparisons were carried 
out (Mitchell et al., 1978).  Responsiveness to the thromboxane mimetic U46619 
was significantly greater in lower segment myometrium at labour versus non-labour 
when compared to PGF2α in vitro (Fischer et al., 2008).  This would implicate TXA2 
as the main inducer of myogenicity in lower segment myometrium to help efface the 
cervix during labour.  TXA2 may also mediate effects in the upper segment alongside 
PGF2α during labour (refer to Figure 4.2.2, page 152 and the summary schematic in 
Figure 4.2.4, page 156). 
Thesis data show that the only other myometrial PG to increase significantly with 
labour onset was PGE2.  It is unsurprising that the measurement from this study was 
3.8-fold lower than that recorded by Satoh et al (Satoh et al., 1981) who measured 
PGE2 release from myometrial incubate.  However, the latter study did not report a 
significant increase in PGE2 with labour onset, which could be related to smaller n 
numbers compared with thesis data.  Thesis data indicates an important role for 
PGE2 in the parturition process, which would depend on the functional EP receptor 
subtypes present in labouring myometrium.  Previous studies in this laboratory 
showed that PGE2 evoked the inhibition of myometrial activity in labouring 
specimens (Fischer, 2010) and thus EP2/4 receptors predominate in lower segment 
myometrium during labour.  Data showed that butaprost dose-dependently attenuated 
myogenic activity, whilst demonstrating poor EP4 receptor-effector coupling in early 
labouring myometrium (Fischer, 2010), although in contrast with EP4 mRNA 
changes with labour onset (Astle et al., 2005, Grigsby et al., 2006). 
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This strongly indicates that functional EP2 receptors dominate in the lower uterus 
during labour and therefore PGE2 is likely to act on this EP subtype to maintain 
quiescence in lower portion myometrium and thus facilitate cervical dilation as 
parturition progresses.  In addition, myometrial PGE2 could act in a paracrine fashion 
on cervical fibroblasts to alter cervical structure (Schmitz et al., 2001), which is an 
important part of the cervical ripening process. 
The steroid hormone changes which take place prior to labour are likely to dictate 
the timing of when concentrations of prostanoids change and to what extent.  Similar 
to the human endometrium at menstruation, labour is characterised by a “functional 
progesterone withdrawal” whereby progesterone levels do not change (Yannone et 
al., 1969, Turnbull et al., 1974), or in part are required for normal labour (Lofgren 
and Backstrom, 1997).  However, myometrial PRA known to repress PRB function 
(Vegeto et al., 1993, Pieber et al., 2001) increases with parturition onset (Pieber et 
al., 2001, Mesiano et al., 2002, Merlino et al., 2007).  In addition, decreased 
progesterone binding to its PR response element in deciduas was observed after 
labour onset (Henderson and Wilson, 2001) and so increases in another protein 
binding to progesterone is able to reduce free ligand.  Cortisol was also shown to 
compete with progesterone for CRH gene regulation in placental cell culture (Karalis 
et al., 1996), therefore an increase in cortisol might also mediate progesterone 
withdrawal.  Furthermore, NFκB increases in pregnant myometrium with labour 
(Chapman et al., 2004) and may also contribute to progesterone withdrawal (Allport 
et al., 2001).  Moreover, κB sites are essential for COX and IL-8 expression in 
myometrial cells (Belt et al., 1999) and could explain not only why all PGs increased 
at labour onset (thesis data), but also why IL-1β, an inducer of PG synthesis, 
increases in lower segment myometrium during labour (Maul et al., 2002). 
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In addition, interactions between PGE2 and chemokines, as part of a bigger local 
inflammatory reaction, could sustain PGE2 production during labour, although 
whether or not this is true for TXA2 requires further study.  There is evidence for a 
positive feedback loop between IL-1β, COX-2 and PGES in myometrial smooth 
muscle cells from pregnant women (Sooranna et al., 2005, 2006, Astle et al., 2007, 
Tattersall et al., 2008).  Also, PGE2 is able to regulate IL-8 in the cervix (Denison et 
al., 1999), IL-8 of which chemoattracts inflammatory cells such as neutrophils.  
Neutrophils and macrophages increase predominantly in lower segment myometrium 
with parturition onset (Thomson et al., 1999) and upon degranulation secrete PGs, 
MMPs and other hydrolytic enzymes (Winkler et al., 1999b).  Interestingly, the 
major PG metabolites of neutrophils are PGE2 and TXB2 (Pouliot et al., 1998), which 
may explain why these mediators increased significantly in the myometrium during 
labour whilst other PGs did not.  Findings demonstrate that although PGF2α 
production was augmented almost 5-fold with spontaneous labour onset, this result 
was not significant, possibly owing to the large inter-donor variation due to unrelated 
variants and the sub-grouping of parturition into stages.  This was similar to another 
group’s findings, whereby PGF2α was measured in myometrial superfusate (Satoh et 
al., 1981).  In other studies, PGF2α was a major prostaglandin in amniotic fluid taken 
from pregnant women during labour (Romero et al., 1989), infusion with PGF2α of 
which has successfully induced labour in women at or near term (Karim et al., 1968).  
It is surprising that mRNA expression of the PGFS synthases, AKR1B1 and 
AKR1C3 did not change with term labour onset in human myometrium and nor did 
the protein expression of AKR1C3 (Phillips et al., 2010), although AKR1B1 protein 
expression was not analysed. 
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Figure 4.2.2: Schematic representing prostanoids and their receptors in 
myometrium at term early labour based on thesis data (red boxes) and the 
literature (e.g. Fischer et al., 2008).  In summary contraction is mediated in upper 
segment whilst lower segment remains quiescent, both actions of which could 
facilitate cervical dilatation and sensitise the myometrium ready for the “active 
phase.”  Schematic adapted from (Tseng, 2012). 
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4.2.3 Special cases: parous women, failed IOL and preterm labour 
The significantly reduced production of relaxatory PGI2 in multiparous compared 
with primiparous myometrium is likely to permit stronger contraction to take place, 
resulting in a shorter labour in the former group.  This could explain why during 
early labour, uterine contractions are approximately 8-9 hours for primiparous and 5 
hours on average for multiparous women (Klossner, 2006), whilst the frequency of 
instrumental delivery was lower in multiparous than in primiparous women 
(Bremme and Bygdeman, 1980).  Data show that PGE2 and PGF2α production was 
greater in biopsies donated by multiparous compared with primiparous women but 
this was not statistically significant.  Another group found significantly higher 
concentrations of PGE2 and PGF2α in maternal plasma from parous than primigravid 
women (Johnston et al., 1993) although PGI2 metabolite was not measured. 
In this study, myometrial samples from three donors who had received intravenous 
infusion of oxytocin to induce labour produced significantly higher levels of PGI2, 
PGD2 and PGD1 compared with women who laboured spontaneously.  Oxytocin 
used for IOL, is a stimulator of the COX-2 enzyme in human myocytes (Molnar et 
al., 1999), helps to liberate AA, stimulate PGF2α synthesis (Soloff et al., 2000) and 
may be able to stimulate prostanoid production by means of MAPK activation of 
cytosolic PLA2 (Ohmichi et al., 1995).  Despite this, in myometrium from women 
after IOL and Caesarean section, prostacyclin production reached 2 ng/pg, which 
was 48-fold higher than TXB2 production in the same biopsies and 4.7-fold higher 
than for spontaneous labour.  This is a phenomenon which is unlikely to result from 
oxytocin stimulation.  It may be that for these women, oxytocin was required to 
counteract the over-production of the uterine smooth muscle relaxants: PGI2 and 
PGD2 in order to start labour contractions. 
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PGD2 metabolites, in line with abundant PGD2 synthesis, were also detected at 
higher quantities in myometrium after IOL with oxytocin but showed high variation. 
Whether or not in cases of failed labour such metabolites could interact with DP1 
receptors to activate Gαs signalling requires further analysis.  Also, findings from 
this study show that myometrium from two latent phase donors, whose labours failed 
to progress from the latent to active phase, showed a paucity of myometrial 
prostanoid production, to wit, PGF2α, which was in contrast to tissues obtained from 
donors experiencing normal spontaneous labour.  However, n numbers are too low to 
draw scientifically sound conclusions.  Concurrent with this case study data, other 
studies demonstrated that failed labour induction was associated with substantial 
reductions in COX and TXAS in human, pregnant myometrium (Faber et al., 1996) 
and PGF2α metabolite in maternal plasma (Johnston et al., 1993). 
To refer to the syndrome of preterm labour (summary in Figure 4.2.3), analysis of 
the only myometrial specimen donated by a preterm non-labouring and labouring 
donor, is included for brief, tentative observations.  In speculation, nifedipine, which 
was administered to the PTL myometrial donor, may have caused the unexpected 
reduction in prostanoid synthesis, including the void in PGF2α, making it challenging 
to understand which PGs drive preterm labour.  Thesis data show that TXB2 was the 
most abundantly occurring excitatory lipid in PTL myometrium (similar to term 
levels), in accord with enhanced myometrial TXAS immunostaining with PTL 
(Swanson et al., 1992) and elevated urinary TXB2 with threatened preterm labour 
(Kurki et al., 1992).  Also, data show that PGD2 and PGI2 in isolated myometrium 
are lacking at preterm labour versus term labour, corresponding with measurements 
in amniotic fluid (Menon et al., 2011).  Future work is necessary to measure PGs in 
myometrium from women who go into preterm labour, which has no known cause.
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Figure 4.2.3: Schematic representing the differences between preterm labour (PTL) and term labour (TL) regarding myometrial prostanoid production based on 
thesis data (shown in red) and receptor profiles based on current literature.  As shown, preterm labour could involve augmented prostanoid production and 
changes in prostanoid receptor expression to favour myometrial contraction.  Based on literature, increased EP3 and EP1 expression is implied in PTL and TL 
respectively, whilst PTL might involve an additional down regulation of EP2 receptors in the fundus which is not apparent at TL.  Unfortunately studies have not 
tested functionality of prostanoid receptors at PTL and TL (Brodt-Eppley and Myatt, 1999, Astle et al., 2005, Grigsby et al., 2006).  Involvement of FP receptor 
signalling in PTL is speculative, whilst elevated mPGES expression could facilitate premature cervical remodeling.  Myometrial TXB2 may be another factor 
involved in PTL initiation. 
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Figure 4.2.4: Schematic representing the changes which could be taking place within the myometrium and cervix as a consequence of 
prostanoid signalling during labour (based on the literature but mainly thesis data, shown in red). 
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5.1     Results 
Parturition is a multifaceted process, involving not only prostanoid action on the 
uterine smooth muscle, but also a complex interplay of many different signalling 
molecules, for example, cytokines and chemokines.  Such signalling extends to other 
intrauterine tissues, namely the cervix (Kelly, 2002), with the downstream pathways 
only partially understood.  Therefore, the final section of this thesis is dedicated to 
the investigation of various inflammatory mediators (eotaxin, EMAP-II, IL-6, MIP-
1α, MIP-1β, MCP-1 and RANTES) angiogenic factor (VEGF), leukocyte adhesion 
molecule (sICAM-1) and protease (neutrophil elastase) in CVF sampled from 
pregnant women at different intervals (20-1 weeks) before term labour.  The less 
intrusive and easy collection of CVF specimens compared with cervical/myometrial 
biopsy, amniocentesis and collection of blood samples has allowed researchers to 
measure chemokines and cytokines previously.  However groups have focused on 
measurement of a limited number of inflammatory markers (IL-6 and MCP-1), 
whereby they analysed either CVF from non-labouring and labouring women (Cox 
et al., 1993, Jacobsson et al., 2003) or those with threatened preterm labour who did 
or did not go into labour within 7 days (Lockwood et al., 1994, Marvin et al., 2000b, 
Coleman et al., 2001, Kurkinen-Räty et al., 2001). 
Holst et al (Holst et al., 2009) carried out a multiplex chemokine assay similar to this 
study but did not analyse samples according to varying intervals (weeks) to labour 
onset, which could help to more reliably pin-point potential predictors of premature 
birth.  For this study, midwives were unable to follow up all donors, therefore, term 
specimens were more heavily relied upon to understand the complexity of cervical 
changes in relation to pregnancy and parturition and to try and determine the 
suitability of specific inflammatory proteins as markers of preterm labour. 
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5.1.1 Inflammatory markers in CVF specimens from pregnant women: effects 
of donor characteristics 
Table 5.1 shows the pg/mg concentrations of elastase, IL-6, MIP-1α, MIP-1β, MCP-
1, RANTES and VEGF measured in CVF specimens taken from women at 20-36 
weeks of pregnancy and analysed using ELISA or Luminex®.  It was not possible to 
carry out Luminex® analysis of MIP-1α, MIP-1β, MCP-1, RANTES and VEGF in 
samples obtained from donors with cervical incompetence (whereby the cervix needs 
to be sutured to prevent premature dilation), however, for this group of women 
elastase (pg/mg) was not significantly different from donors with or without other 
types of medical complaint.  Moreover, the medical complaint due to which the CVF 
swab was taken had no statistically significant bearing on in vitro concentrations of 
the other metabolites measured. 
Unfortunately, the effect of the occurrence of a previous vaginal bleed and cervical 
incompetence on elastase and IL-6 concentration in CVF respectively, could not be 
statistically determined, although values were similar to when women had no 
pathology (Table 5.1).  As shown in Appendix 25, blood pressure had no effect on 
concentrations of elastase, IL-6, MIP-1α, MIP-1β, MCP-1, RANTES or VEGF and 
this included other donor characteristics such as gravidity, parity and BMI.  
Attenuated concentration of elastase in women with parity 1-2 versus parity 0 and 
enhanced concentration of elastase and IL-6 in women with a BMI greater than 25 
did not reach statistical significance (Appendix 25). 
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Medical complaint 
Metabolite (pg/mg) 
Elastase IL-6 MIP-1α MIP-1β MCP-1 RANTES VEGF 
       
No pathology (n=9-12)++ 9.3 ± 3.4 47.4 ± 16.3 23.5 ± 9.5 15.9 ± 5.7 30.9 ± 9.8 21.5 ± 8.7 7.7 ± 2.4 
Abdominal pain (n=7-11) 13.0 ± 3.3 34.9 ± 7.3 15.5 ± 2.3 13.9 ± 2.6 40.6 ± 15.3 19.3 ± 5.5 6.3 ± 1.4 
Per vaginal bleed (n=2-5) 4.8 ± 1.7+ 41.1 ± 20.4 6.3 ± 3.0 10.0 ± 1.6 24.6 ± 4.4 14.9 ± 6.1 7.4 ± 2.5 
Cervical incompetence (n=6) 6.1 ± 3.4 Not tested Not tested Not tested Not tested Not tested Not tested 
Vaginal infection (n=3-8) 10.6 ± 6.3 28.9 ± 13.7 11.0 ± 3.0 11.3 ± 2.2 22.4 ± 4.5 9.9 ± 2.8 7.9 ± 2.2 
Table 5.1: Profiles of molecular markers of inflammation in cervico-vaginal secretions donated by pregnant women who were swabbed between 20 
and 36 weeks gestation due to specific medical complaints as noted on patient information sheets.  Data are expressed as arithmetic means of 
metabolite ± S.E.M (pg/mg) where cases are n ≥ 3 and means of metabolite ± S.D (pg/mg) where cases are n=2.  Statistical comparisons per 
metabolite were carried out using the One-Way ANOVA test as appropriate, except for elastase, which was analysed using the Kruskal-Wallis test; 
+sample size was too small for statistical analysis. 
++Patients were queried to be in preterm labour at the time the swab was taken but upon examination showed no sign of SROM.  Moreover, bleeding, 
abdominal pain or infection was not noted in the patients’ information sheets and donors continued with their pregnancies, later giving birth at term 
gestation.  Vaginal infection: confirmation of yeast or haemolytic streptococci on the swab.  Per vaginal bleed: patient information showed women had 
experienced bleeding but upon examination showed no sign of bleeding or blood contamination within the CVF specimen collected. 
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Donor characteristics 
Metabolite (ng/mg) 
sICAM-I EMAP-II 
Medical complaint   
No pathology (n=9-18) 2.6 ± 0.9 52.2 ± 24.4 
Abdominal pain (n=7-15) 3.1 ± 0.9 32.1 ± 6.2 
Per vaginal bleed (n=4-6) 1.1 ± 0.6 56.6 ± 32.9 
Cervical incompetence (n=7) 1.2 ± 0.5 Not tested 
Vaginal infection (n=6-10) 3.1 ± 1.5 38.0 ± 23.3 
Blood pressure    
Normal blood pressure (n=17-36) 2.7 ± 0.6 39.3 ± 11.6 
Pre/Hypertensive (n=1-4) 1.5 ± 0.8 18.2+ 
Smoking   
Non-smoker (n=17-44) 2.9 ± 0.6 49.2 ± 14.4 
Smoker (n=3-7) 2.9 ± 1.3 28.3 ± 17.6 
Gravidity & Parity   
Primagravida, Parity 0 (n=5-12) 3.0 ± 0.8 32.2 ± 8.9 
Multigravida, Parity 0 (n=5-10) 3.1 ± 1.5 55.7 ± 34.6 
Multigravida, Parity 1 (n=4-10) 2.0 ± 0.8  58.4 ± 36.3 
Multigravida, Parity 2 (n=6-12) 3.3 ± 1.5 41.4 ± 23.2 
Body Mass Index   
15-25 (n=13-32) 2.7 ± 0.6 46.2 ± 15.8 
26-34 (n=6-16) 3.4 ± 1.3 45.9 ± 22.0 
Table 5.2: Concentration of sICAM-I and EMAP-II in cervico-vaginal secretions 
donated by pregnant women who were swabbed between 20 and 36 weeks 
gestation due to various medical complaints as noted on patient information 
sheets.  Data are expressed as arithmetic means of metabolite ± S.E.M (ng/mg) 
where cases are n ≥ 3.  Statistical comparisons were carried out using the One-
Way ANOVA test or the Student’s t-test as appropriate; except for smokers 
versus non-smokers, data of which was analysed using the Mann-Whitney test; 
+sample size was too small for statistical analysis. 
Normal blood pressure defined as: systolic <130, diastolic <80 mmHg and high 
blood pressure (pre or hypertensive): systolic >130 and diastolic >80 mmHg; 
Vaginal infection: confirmation of yeast or haemolytic streptococci on the swab.  
Per vaginal bleed: patient information showed women had experienced bleeding 
but upon examination showed no sign of bleeding or blood contamination within 
the CVF specimen collected. 
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Concentrations of sICAM and EMAP-II were detectable in the ng/mg range in CVF 
donated by gravid women between 20-36 weeks gestation (Table 5.2).  EMAP-II and 
sICAM-I concentrations were relatively uniform and not significantly different 
regardless of donor characteristic.  It was not possible to determine the effects of  
blood pressure on EMAP-II production from CVF in vitro, however, allowing for 
S.E.M of the normotensive group, the level of EMAP-II differed by 9.5 ng/mg when 
compared with the hypertensive donor (Table 5.2). 
5.1.2 Inflammatory markers in CVF specimens from pregnant women: effects 
of donor ethnicity 
Concentration of elastase was similar in Asian and White donors, however, the mean 
concentration of MIP-1α, MIP-1β, MCP-1 and RANTES was greater in CVF from 
pregnant Asian compared with White donors (p<0.05, Table 5.3).  Mean IL-6 
concentration was 1.7-fold greater in specimens from Asian compared with White 
donors, the latter group having large S.E.M for IL-6 and therefore this difference was 
not statistically significant.  A similar trend was apparent for VEGF (Asian versus 
White donors, not significant: p=0.05, Table 5.3).  As demonstrated in Table 5.4, 
EMAP-II concentration in CVF was higher in Asian versus White donors (p<0.05, 
Table 5.4).  Soluble ICAM-I was 1.9-fold higher in CVF from Asian compared with 
White women, although this difference was not statistically significant (Table 5.4).  
Based on these findings, the Asian donor data set was excluded from the subsequent 
data analysis presented in Table 5.5 and 5.6. 
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Ethnicity  
Metabolite (pg/mg) 
Elastase IL-6 MIP-1α MIP-1β MCP-1 RANTES VEGF 
White (n=3-21) 9.3 ± 3.9 39.8 ± 11.0 11.3 ± 2.4a 13.9 ± 3.6 a 27.7 ± 7.8a 15.6 ± 3.3a 7.2 ± 1.6b 
Asian (n=3-7) 11.0 ± 3.4 71.1 ± 20.0 49.0 ± 19.3 34.7 ± 10.7 56.3 ± 7.6 50.4 ± 16.6 15.7 ± 3.9 
Ethnicity 
Metabolite (ng/mg) 
sICAM-I EMAP-II 
White (n=14-25) 2.4 ± 0.5 21.4 ± 3.7a 
Asian (n=3-10) 4.5 ± 1.6  135.4 ± 45.5 
Table 5.3: Concentration of inflammatory markers in cervico-vaginal secretions donated by pregnant women of different ethnicities swabbed 
between 20 and 36 weeks gestation.  Data are expressed as arithmetic means of metabolite ± S.E.M (pg/mg).  Statistical comparisons were carried 
out using the Mann-Whitney test as appropriate; a compared with Asian donors, p<0.05; b versus Asian women (p=0.05). 
Table 5.4: Concentration of sICAM-I and EMAP-II in cervico-vaginal secretions donated by gravid women of 
different ethnicities swabbed between 20 and 36 weeks gestation.  Data are expressed as arithmetic means of 
metabolite ± S.E.M (ng/mg).  Statistical comparisons were carried out using the Mann-Whitney test as appropriate; a 
compared with Asian donors, p<0.05. 
 
White donors were born in either Europe or Britain and Asian donors were of Pakistani origin.  All donors were normotensive (blood pressure 
<130/80 mmHg) and recorded to have no other medical conditions. 
White donors were born in either Europe or Britain and Asian donors were of Pakistani origin.  All donors were 
normotensive (blood pressure <130/80 mmHg) and did not suffer from any medical conditions. 
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5.1.3 Inflammatory markers in CVF specimens: indicators of labour onset 
The rank order of proteins detected in CVF from pregnant women was as follows 
ranked from highest to lowest concentration (based on the range between gestational 
states): EMAP-II, sICAM-I (Table 5.6), MCP-1, RANTES, IL-6, MIP-1α, MIP-1β, 
elastase and VEGF (Table 5.5).  Eotaxin was tested for in CVF but went undetected 
in the majority of samples and therefore was not presented in the results section of 
this thesis.  Data show that in the week before term labour onset seven out of nine 
markers were elevated (Table 5.5 and 5.6), three of which (IL-6, MIP-1α and MCP-
1) were enhanced significantly compared with 2.5-7 weeks before labour (p<0.05, 
Table 5.5).  MIP-1β and MCP-1 (pg/mg) in CVF remained constant from 20-2.5 
weeks before increasing 5.9- and 22.2-fold correspondingly, 1 week before labour 
onset (significant only for MCP-1: 2.5-7, 8-14 and 15-20 weeks before labour onset 
versus 1 week, p<0.05, Table 5.5). 
RANTES followed a similar trend between 20-2.5 weeks and increased 8.6-fold 1 
week before labour (not significant and with large sample variation).  Elastase 
remained constant (5-5.8 pg/mg) in CVF from women swabbed 8-14, 2.5-7 and 1 
week before labour onset.  MIP-1α (pg/mg) was enhanced 6.7-fold in CVF from 
donors swabbed 1 week compared to 2.5-7 weeks before labour onset (2.5-7 and 15-
20 weeks compared with 1 week prior to labour, p<0.05, Table 5.5).  IL-6 
concentration was 2.8-fold greater in specimens taken from women swabbed 
between 15-20 than 8-14 or 2.5-7 weeks before labour (not significant).  However, 1 
week before labour onset, mean IL-6 CVF concentration was 5.7-fold higher 
compared with donors swabbed between 8-14 and 2.5-7 weeks prior to labour onset 
(p<0.05, Table 5.5). 
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Number of wks prior to 
Term Labour 
Metabolite (pg/mg) 
Elastase IL-6 MIP-1α MIP-1β MCP-1 RANTES VEGF 
15-20 (n=2-3) 13.2 ± 13.6+ 32.8 ± 24.6 7.3 ± 4.5 10.1 ± 2.6 18.9 ± 3.4 8.8 ± 5.8 3.8 ± 2.1 
8-14 (n=4-5) 5.2 ± 1.7 11.6 ± 6.3 17.5 ± 8.2 9.8 ± 3.0 29.6 ± 13.7 17.4 ± 8.3 6.6 ± 2.1 
2.5-7 (n=4-10) 5.8 ± 1.9 16.5 ± 6.7 8.5 ± 1.7 7.9 ± 0.5 17.5 ± 2.5 17.6 ± 5.0 5.0 ± 1.4 
1 (n=6-8) 5.0 ± 1.3 93.8 ± 27.6a 56.6 ± 16.2b 46.4 ± 11.0 389.0 ± 115.9c 151.6 ± 130.2 5.7 ± 0.9 
Table 5.5: In vitro concentration of inflammatory markers in cervico-vaginal secretions donated by women who were swabbed 15-20, 8-14. 2.5-7 
weeks (wks) and 1 week before term labour (as per patient follow up).  Data are expressed as arithmetic means of metabolite ± S.E.M (pg/mg) 
where cases are n ≥ 3 and ± S.D where cases are n=2.  Statistical analysis was carried out using the Kruskal-Wallis and Mann-Whitney test where 
appropriate: a compared with 2.5-7 wks and 8-14 wks, p<0.05; b versus 15-20 and 2.5-7 wks, p<0.05; c compared with 15-20, 8-14 and 2.5-7 wks, 
p<0.05; + sample size too small for statistical analysis. 
 
All donors were normotensive and did not suffer from any medical conditions. 
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Number of wks prior to Term 
Labour 
Metabolite (ng/mg) 
sICAM-I EMAP-II 
15-20 wks (n=3) 1.4 ± 0.9 61.7 ± 46.0 
8-14 wks (n=5-6) 2.6 ± 1.5 27.0 ± 9.4 
2.5-7 wks (n=6-10) 2.1 ± 0.6 21.2 ± 5.1 
1 wk (n=7-10) 5.9 ± 2.0 52.9 ± 10.3 
Number of wks prior to Preterm 
Labour: case study 
  
2 α (n=1) 6.8 30.4 
Table 5.6: In vitro concentration of sICAM-I and EMAP-II in cervico-vaginal secretions donated by women who were swabbed 15-20, 8-14. 
2.5-7 weeks (wks), 1 week before term labour and 2 wks prior to preterm labour onset (as per patient follow up).  Data are expressed as 
arithmetic means of metabolite ± S.E.M (ng/mg).  Statistical analysis was carried out using the Kruskal-Wallis test where appropriate; + sample 
size was too small for statistical analysis. 
 
α Donor was swabbed at 33 wks and went into labour at 35 wks gestation (tested negative for yeast 
or bacterial vaginosis). 
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Data from a case study included in the Appendix show that IL-6 was more abundant 
in CVF collected from a donor 2 weeks prior to preterm labour than that collected 
from a donor 2 weeks prior to term labour (Appendix 26).  VEGF in CVF from 
donors swabbed 2.5-7 weeks prior to labour onset was similar to that from donors 
swabbed 1 week before labour, a concentration which did not vary more than 1.9 
pg/mg compared with donors swabbed 20-14 weeks before labour onset (Table 5.5). 
Table 5.6 shows that sICAM-I (ng/mg) was constant in CVF from donors swabbed 
at 15-20, 8-14 and 2.5-7 weeks prior to term labour onset and increased by 2.8-fold 1 
week before term labour (not statistically significant).  In CVF donated by a woman 
swabbed 2 weeks before preterm labour onset, concentration of sICAM-I was 3.2-
fold higher than that in CVF obtained from six women swabbed between 2.5 and 7 
weeks before term labour (Table 5.6).  EMAP-II concentration was no different in 
CVF donated 15-20 weeks compared with 1 week prior to term labour but doubled 
the week before labour onset versus 2.5-7 weeks before labour at term (not 
significant).  EMAP-II measured in CVF collected two weeks prior to preterm or 
2.5-7 weeks before term labour onset was similar (Table 5.6). 
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5.2     Discussion 
Data from this study show elevated chemokine concentrations in CVF 1 week versus 
2-20 weeks before labour onset, which may reflect augmented leukocyte homing to 
the cervix close to labour onset.  In accord, the myometrium does not appear to 
chemoattract leukocytes until labour onset (Thomson et al., 1999), whilst in cervical 
tissue, this immune cell flux occurs before the onset of labour (Bokstrom et al., 
1997).  Such trends may be unrelated to PG synthesis but instead the result of the 
weight of the foetus pressing down on the cervix and inducing changes in cytokine 
and chemokine expression in response to tissue damage.  According to Moore et al 
(Moore et al., 2006), non-labouring foetal membranes have a zone of weakness 
overlying the cervix, which contains biochemical markers of both collagen 
remodeling and apoptosis, such as IL-1β and TNF-α, which act to weaken the foetal 
membranes, possibly through a pre-programmed mechanism.  Correspondingly, such 
cytokines were demonstrated to induce apoptosis of human foetal membranes 
(Fortunato and Menon, 2003) and are further stimulated as a result of membrane 
rupture (El-Shazly et al., 2004).  It is possible that the CVF chemokines, which 
increased near to labour onset and correlating with the rising oestrogenic hormonal 
milieu in the uterus at this time, also mediate foetal membrane rupture.  ER-β 
expression is elevated in the late gestational cervix and ER-β is present on 
neutrophils (Wang et al., 2001) although it is unclear if oestrogen-ER interaction 
potentiates chemokine and cytokine production prior to labour onset to promote 
cervical remodeling prior to parturition. 
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Data in Chapters 4 and 5 suggest that before labour onset the low myometrial 
concentrations of PGD2 and PGE2 may not be enough to stimulate immune cell flux 
into the myometrium but may facilitate cervical ripening secondary to inflammatory 
mediators such as chemokines.  During labour, increased uterine smooth muscle PG 
production could not only stimulate contraction but also induce chemotaxis of 
leukocytes into lower segment myometrium.  Such immune cells could enter cervical 
tissue and assist in the later stages of ripening by stimulating collagenolysis and 
dilation of the cervix.  Interestingly the process of cervical ripening, characteristic of 
the cervical structure before labour, appears to take place in the lower-most segment 
of myometrium during labour (Granstrom et al., 1989). 
For this study, it would have been logical to include PG analysis in CVF fluid, 
particularly to correlate with chemokine concentrations at defined time points before 
labour onset.  For example, PGs are secreted by the immune cells involved in 
cervical ripening, e.g. neutrophils, which secrete TXB2 and PGE2 (Pouliot et al., 
1998).  However, this would have proved challenging considering that donors would 
need to abstain from intercourse prior to swabbing.  Cox et al (Cox et al., 1993) 
demonstrated that there are considerable differences in PG concentrations in CVF 
from women who have abstained from intercourse versus women post-coitus.  For 
this study, most consenting donors of CVF who were attending the clinic and 
experiencing symptoms of labour at 20+ weeks of gestation (most women were 
experiencing false alarms and sent home) may or may not have had intercourse. 
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Of note, is data showing that vaginal infection had no bearing on the inflammatory 
mediator concentrations measured in CVF.  This could be because donors were not 
diagnosed with infection of the gestational membranes, which has previously 
correlated with enhanced uterine chemokine and cytokine production (Keelan et al., 
2003).  CVF from preterm, pregnant Asian donors contained greater concentrations 
of RANTES, VEGF, IL-6, MIP-1α, MIP-1β, EMAP-II and sICAM-I but only the 
concentrations of MIP-1α, MIP-1β, MCP-1, EMAP-II and RANTES were 
significantly higher compared with equivalent inflammatory markers in CVF from 
White donors.  Other donor characteristics had no bearing on cytokine 
concentrations (thesis data).  In a London-based study, the odds ratio of preterm 
delivery was increased in Black and Asian women compared with White women 
(Patel et al., 2004).  However, in another study, half of the cases of preterm labour in 
the Black ethnic group were associated with social deprivation in contrast with Asian 
women (Aveyard et al., 2002).  This implies that Black women are at increased risk 
of preterm labour due to circumstances, whilst with Asian women other factors, such 
as genetics, may increase the odds of preterm labour occurring. 
It is tempting to speculate, that in women of certain ethnicities, premature production 
of inflammatory proteins such as EMAP-II, MIPs and MCP-1 in CVF could 
accelerate the cervical ripening process leading to preterm labour, however further 
study is warranted.  Indeed, MIP-1α was predictive of preterm delivery within 1 
week, as levels were higher in women presenting with preterm labour who delivered 
within 1 week compared with those who did not (Dudley et al., 1996).  In accord, 
data show that MCP-1 and MIP-1β (EMAP-II is yet to be studied) in both amniotic 
fluid and CVF make good markers for predicting labour before 37 weeks gestation 
(Holst et al., 2009). 
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The higher concentration of RANTES in CVF from Asian compared with White 
women suggests increased T cell numbers are present in the CVF of Asian women, 
since RANTES is secreted by T cells.  This could be due to the presence of infection, 
however the swabs collected from Asian donors, after clinical testing, did not test 
positive for yeast or bacteria.  Another factor to consider is that highlighted by 
Witkin (Witkin, 2007), whereby there may be differences in the vaginal bacterial 
flora of women according to ethnicity.  Whether or not these differences could be 
related to hygiene practices is speculative but also a sensitive issue to discuss with 
women during the time of consent. 
In this study, concentrations of eotaxin were either very low or undetectable in CVF 
collected from preterm and term, pregnant donors. Eotaxin is a chemokine that 
selectively recruits eosinophils, of which are observed in greater densities at sites of 
allergic inflammation (Prussin and Metcalfe, 2003).  The lack of eotaxin in CVF 
sampled between 20 and 41 weeks gestation could reflect the specific regulation of 
inflammatory cells accompanying cervical remodeling.  Correspondingly, another 
allergy-associated immune cell: the mast cell, is present at very low densities 
compared with macrophages in lower segment, gravid uterus (Thomson et al., 1999). 
 
Results show also, that MCP-1, MIP-1α and IL-6 in CVF were significantly elevated 
1 week versus 2-7 weeks before labour onset.  This implies that immune cells are 
encouraged to infiltrate the cervix 1 week prior to parturition to accelerate ripening.  
Immunohistochemical staining for IL-6 was enhanced in the term, pregnant cervix 
and increased in ripe compared with unripe cervices (Sennstrom et al., 2000).  Also, 
women who developed a shorter cervix had higher concentrations of MCP-1 protein 
in their CVF (Chandiramani et al., 2010). 
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Therefore, it is possible that particular chemokines are up-regulated, most notably 
the week before term parturition to stimulate inflammatory cell flux into the cervix 
for ripening.  The mediators: MCP-1, MIP-1α/β and IL-6 are secreted by 
macrophages (Cavaillon, 1994) but also, MCP-1 chemoattracts the precursor of 
macrophages (monocytes) (Deshmane et al., 2009) and MIP-1α (more potently than 
MIP-1β) chemoattracts macrophages and T cells (Schall et al., 1993) but not 
neutrophils (Leonard and Yoshimura, 1990).  It is likely to be macrophages that flux 
to the cervix the week prior to labour and therefore macrophage-associated 
chemokines may be important predictors of labour onset.  There are previous reports 
of leukocyte accumulation in the cervical stroma before labour onset (Bokstrom et 
al., 1997) but not in relation to impending labour.  Bokstrom et al showed that the 
inflammatory infiltrate in the cervix at term consisted of mainly neutrophils and 
macrophages, which respond to or themselves secrete chemokines such as MCP-1 
and MIPs.  Indeed it was macrophages in humans (Bokstrom et al., 1997) and mice 
(Nedd-Roderique, 2011), which underwent a greater increase than other types of 
immune cells e.g. neutrophils in the cervix and lower myometrial segment, at term 
compared with an earlier stage of pregnancy. 
It is interesting that the metabolites which were enhanced in human CVF the week 
before term labour (this study), were increased in human, cord blood at preterm 
labour (with exception to an increase in IL-6 receptor and not IL-6) (Matoba et al., 
2009) and CVF sampled from women 7 days before preterm labour onset (Holst et 
al., 2009).  Furthermore, the pg/ml concentrations of MCP-1 (thesis work: prior to 
normalisation with protein (mg)) correlated well with those reported by other groups 
(Jacobsson et al., 2003), with MCP-1 more abundant than MIP-1α and IL-6 (Holst et 
al., 2009). 
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Corresponding with thesis data supporting IL-6 in CVF as a marker for impending 
term labour, IL-6 concentration was substantially higher in CVF from a donor 2 
weeks away from preterm labour, than that collected from a donor 2 weeks prior to 
term labour (thesis case study data).  Both women showed no differences in 
characteristics e.g. they were non-smokers, normotensive, a similar age, of white 
ethnicity and free of vaginal infection.  Therefore, IL-6 concentration could relate to 
preterm labour risk although analysis of more samples is necessary.  In accord, IL-6 
in CVF predicted preterm delivery within 2-7 days (Coleman et al., 2001, Holst et 
al., 2009) and has been measured by other groups in human CVF (Kurkinen-Räty et 
al., 2001) and amniotic fluid (Wenstrom et al., 1998) at intervals during the 
second/third trimester, whereby elevated IL-6 levels were associated with women at 
risk of preterm delivery. 
Results show that EMAP-II occurred more abundantly than sICAM-I, MCP-1, 
RANTES, MIP-1α, IL-6, MIP-1β with elastase and VEGF detected at <16 pg/mg.  
Vaginal swabs were taken from high in the vagina, and so metabolites in CVF, the 
latter of which is in contact with the cervix, should reflect quantities within and 
secreted by the cervical tissue.  Therefore the sheer abundance of EMAP-II may 
reflect a multifunctional and homeostatic role in the cervix.  Although the uterine 
vasculature adequately supplies the cervix (Walocha et al., 2012), VEGF may have 
been more important in promoting angiogenic effects in the earlier stages of 
pregnancy, consistent with a reduction of angiogenic factors in women suffering 
from recurrent miscarriage (Lash et al., 2012).  EMAP-II, being chemotactic and 
anti-angiogenic may fulfill a role during late gestation (Kao et al., 1994). 
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EMAP-II, which has not been detected in CVF from pregnant women previously, 
was 2-fold higher 1 week versus 2.5-7 weeks before term labour onset, although this 
difference was not statistically significant.  Thus EMAP-II loses value as a marker 
for impending labour, despite increased circulating concentrations in pregnancy 
(Wellings et al., 1999).  The many actions of EMAP-II may dilute its suitability as a 
predictive marker for preterm labour.  For example, EMAP-II stimulates apoptosis in 
mononuclear (Murray et al., 2004) and endothelial cells (Berger et al., 2000) and 
HUVECs (Tandle et al., 2005) and owing to abundant ng/mg concentrations in CVF, 
may fulfil a secondary role in the cervix before labour onset.  EMAP-II could 
compromise the integrity of the cervical tissue by helping to make space for water 
molecules so that the collagen content of the cervix decreases (Hertelendy and 
Zakar, 2004), thus allowing effacement to take place (Allaire et al., 2001).  Other 
roles for EMAP-II could include facilitating the recruitment of inflammatory cells to 
the cervix in the lead up to labour onset by being vasodilatatory by action on 
endothelium and by stimulating Nitric Oxide Synthase (NOS) expression (Tsai et al., 
2004).  Also, EMAP-II induces E- and P-selectin expression (Murray et al., 2004). 
E-selectins assist in chemotaxis since they bind to carbohydrates on leukocytes 
(Thomson et al., 1999) and allow their rolling along the endothelium of blood 
vessels to the chemotactic stimulus.  In addition, EMAP-II is able to stimulate 
production of TNF-α (Wakasugi and Schimmel, 1999), which as described 
previously can in turn enhance prostanoid production. 
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Furthermore, monocytes are cytokine producing (Hart et al., 1989), which might also 
affect prostanoid production leading to possible labour onset.  Interestingly, EMAP-
II is negatively regulated by PGE2 in human endometrium (Battersby et al., 2002).  
This may be plausible for the human uterus at term gestation, based on thesis data, 
whereby PGE2 in contrast with other prostanoids did not increase late gestation in 
lower segment myometrium when EMAP-II in CVF was most abundant. 
VEGF as the name suggests is an important regulator of angiogenesis, originally 
named vascular permeability factor (VPF) and as data show, does not change with 
progression to labour onset.  VEGF induced oedema in rodent cervices (Rhyne, 
2010) and may play a small role in cervical ripening in humans.  To the author’s 
knowledge VEGF has yet to be measured in human CVF late pregnancy in relation 
to interval to labour onset.  However, VEGF and NOS protein in the rodent cervix 
peaked late gestation (Mowa et al., 2004) in contrast with human CVF thesis data.  
This suggests that different mechanisms of cervical ripening with regard to changes 
to the cervical vasculature may occur in mammals.  In humans, VEGF-induced 
permeability of cervical blood vessels could accompany leukocyte extravasion and 
cervical remodeling through to labour.  However, this process may be progressive, 
occurring at low level many weeks before labour onset. 
Data show that neutrophil elastase concentration was uniform regardless of 
gestational state and therefore could compromise the mechanical properties of 
cervical connective tissue throughout the third trimester and during parturition.  
MMPs are thought to play a role in cervical ripening prior to late gestation in the 
cow (van Engelen et al., 2008) and imply a similar role for elastase. 
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Another study showed that endocervical mucus elastase (units/L) peaked in the last 4 
weeks of gestation but remained unchanged during the interval in between 
(Limvarapuss et al., 1992).  Also, elastase protein in cervical mucus correlated with 
elastase-like activity, which increased only with term labour onset (Kanayama and 
Terao, 1991), similar to expression of MMP-2 and MMP-9 (Stygar et al., 2002).  
Recruitment of neutrophils to the cervix is likely to be more important after than 
before labour onset (Osmers et al., 1992) to destabilise the integrity of the cervix, as 
indeed neutrophils increased with advancing cervical dilation, correlating with MMP 
production (Winkler et al., 1999a).  Whether or not elastase (and also other 
mediators secreted by neutrophils) could be a useful predictor of preterm labour 
remains speculative and requires more in depth study and comparisons with MMP 
activity. 
Although this study shows which factors could be useful predictors of term labour, 
translating this for preterm labour must be done with caution, since there are 
differences with regard to chemokine, COX and cytokine expression between what is 
a physiological and pathological process of parturition (refer to Figure 4.2.3, page 
155).  Thesis data show that sICAM-I did not mark impending term labour, however, 
sICAM-I concentration was 3-fold greater in CVF collected 2 weeks prior preterm 
labour commencement (case study: n=1) than 2 weeks before term labour onset 
(n=6-10).  Although a greater number of CVF samples collected from women who 
later go into preterm labour are required for analysis for more robust conclusions, 
other data show that elevated sICAM-I (low ng/ml values) in CVF predicted a short 
duration to preterm labour, in conjunction with fFN testing (Marvin et al., 2000b). 
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RANTES and MIP-1β in CVF, did not increase significantly the week before term 
labour (this study), but were predictive of preterm delivery within 1 week in CVF 
(Holst et al., 2009) and maternal serum (Tsiartas et al., 2012).  However, it must be 
borne in mind that both RANTES and MIP-1β concentrations were elevated the 
week prior to term labour but not significantly so due to inter-donor variation.  It is 
uncertain whether T cell involvement in cervical ripening may be secondary to 
macrophages, although RANTES has been implicated in the regulation of the 
inflammatory response and in the recruitment of macrophages (Athayde et al., 1999), 
consistent with the role of sICAM-I in the cervix (Ledingham et al., 2001).  
RANTES, in addition to sICAM-I, VEGF, elastase and EMAP-II may be required to 
fulfil a homeostatic role in the cervix during pregnancy and based on thesis data, 
may not help to determine when a donor is due to go into term labour.  However, a 
greater number of CVF specimens from women at varying intervals before preterm 
labour onset should be analysed to more adequately test the potential of these 
proteins as markers for preterm labour. 
In summary, although biopsy or blood testing may indicate uterine events (Laham et 
al., 1993), routine collection of CVF from women during the second and third 
trimester is less invasive and conveys valuable information regarding cervical 
processes during pregnancy and for identifying predictive indicators of preterm 
labour.  The measurement of cytokines and chemokines in CVF specimens implies 
that cervical ripening advances in the final week of gestation before term labour, 
although whether or not this is true for preterm labour requires further study.  In the 
future it could be beneficial to calculate positive predictive values for the mediators 
in CVF, which chemoattract macrophages (or macrophage secretory products) 
moreso than factors related to neutrophils and T cells. 
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    Chapter 6: Discussion 
The main aim of this study was to reveal simultaneous profiles of uterine prostanoids 
in the human uterus in response to changes in the hormonal milieu.  Results show 
that prostanoid synthesis changes according to hormonal status during the menstrual 
cycle and with pregnancy.  Furthermore, profiles of prostanoids were altered and 
corresponded with structural changes, such as stretch of the myometrium with 
gestation progression, in addition to genesis and degradation of the endometrium 
during non-pregnancy.  The hormonal milieu may in part govern reproductive events 
by influencing prostanoid production, which varies during the menstrual cycle, 
namely increasing during the oestrogenic follicular phase with attenuation in the 
progestogenic milieu of the luteal phase.  Indeed, oestradiol-ER interaction appears 
to promote prostanoid synthesis (Schatz et al., 1986). 
In vitro production of myometrial prostanoids increased with labour onset and is 
possibly the result of a functional progesterone withdrawal at parturition (Pieber et 
al., 2001).  For example, progesterone mediates inhibitory effects upon both 
oestrogen-ER interaction and the prostanoid biosynthetic machinery, as was 
demonstrated in endometrium in vitro (Abel and Baird, 1980, Abel and Kelly, 1983).  
However, in myometrium from pregnant women, only PGE2 and TXB2 increased 
significantly with labour onset at term gestation (PGF2α increased substantially but 
showed large variation).  Interestingly, lipidomic analysis of prostanoid production 
in six additional lower segment myometrial specimens, obtained from women with 
defective labour (failure to contract or requiring IOL with oxytocin), showed 
attenuated synthesis of TXB2, PGF2α and PGE2 compared with PGI2 and PGD2. 
Chapter six: Discussion 
179 
 
Therefore, oestrogen could preferentially interact with prostanoids, which have the 
ability to generate calcium via action at EP1/3, FP and TP receptors but not those 
which inhibit myogenicity and appear to be homeostatic, for example PGD2 and 
PGI2.  Progesterone may also specifically inhibit the same synthases (PGES, TXAS 
and PGFS), whose expression appears to be strongly stimulated by oestrogen and 
this may be one mechanism by which spontaneous labour contraction is initiated.  
Interestingly, an increase in TXB2 and PGE2 but not PGF2α production was 
demonstrated post-progesterone withdrawal in ovariectomized rats (Wilson and 
Lindsey, 1987) and might explain why only TXB2 and PGE2 were elevated 
significantly with labour onset, despite the preferential stimulation of PGF2α 
synthesis over TXB2 and PGE2 by oestrogen in the uteri of pregnant ovariectomized 
rats (Wilson and Lindsey, 1987) (refer to schematic in Figure 6.1 on the next page).   
It must not be ruled out however that neutrophil flux, in response to cytokine and 
chemokine production, to the myometrium at labour could contribute to the PG 
profiles seen at parturition, as described earlier in section 4.2.2.  Moreover, TXA2 as 
well as PGE2 may be involved in a feed forward mechanism with cytokines and 
COX-2 during labour requiring further study.  Further studies which analyse the 
effects of sex steroids (in the absence and presence of specific steroid receptor 
antagonists) on expression of each myometrial terminal prostanoid synthase and PG 
production in vitro may show interesting results. 
Chapter six: Discussion 
180 
 
LABOUR PROGRESSION
ER
PGE2
TXA2
PGF2α
Myometrial 
contraction 
initiated
PRA: PRB 
ERα
PGE2
TXA2
PGF2α
Myometrial 
contraction: 
frequency
intensity
Delivery of the 
foetus
Inhibitory action
Stimulatory influence
ONSET 4-5 cm cervical dilation
PRA: PRB 
Myometrial 
contraction: 
frequency
intensity
PLA2/COX
PGD2
PGI2
?
?
?
Homeostasis
?
10 cm
PRA: PRB ER
Myometrial 
contraction low level
PRA: PRB 
PGE2
TXA2
PGF2α
PLA2/COX
PGD2
PGI2
?
?
?
Homeostasis
?
PREGNANCY MAINTENANCE
Uterine 
stretch/oestrogen
PGE2
TXA2
PGF2α
PGD2
PGI2
Myometrial relaxation
*
*
* Product of neutrophils
 
 
 
 
 
 
Figure 6.1: Schematic representing the possible regulation of prostanoid formation by the hormonal milieu of pregnancy and parturition based 
on thesis data (in red) and the literature.  With the onset of labour, an increase in PRA may prevent transcription of PRB and hence PRB-
mediated inhibition of oestrogenic effects, so that COX is able to catalyse the synthesis of spasmogenic prostanoids from arachidonic acid.  
Whether or not progesterone has specific inhibitory effects on the terminal PG synthases, namely PGES, TXAS and PGFS is questionable.  
Either way, the spasmogenic prostanoids appear to play an important part in the labour process, namely TXA2 and PGE2. 
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Referring back to non-pregnancy, luteal phase myometrium saw a decline in 
prostanoid production, most notably PGF2α.  However, the data set was limited and 
an extended sample size is required to determine if sex steroid signalling (to wit 
progesterone) during the luteal phase may serve to silence myometrial activity, with 
the purpose to establish pregnancy in a similar manner to prolongation of pregnancy 
to term.  Preliminary data show predominant PGF2α synthesis by endometrium 
during menstruation may follow on from late luteal phase although luteal phase 
samples are required for analysis.  The vasoconstrictory effects elicited by PGF2α in 
uterine arteries could promote ischaemia and the initiation of endometrial evacuation 
(Critchley et al., 2006). 
Synthesis of PGD2 was higher in lower than upper segment, menorrhagic 
myometrium regardless of menstrual phase.  It is not clear whether this is a 
pathophysiological or physiological effect due to lack of suitable controls, although 
data is in support of a physiological effect since other studies have revealed that 
PGD2 production from menorrhagic versus non-menorrhagic endometrium was not 
significantly different (Smith et al., 1982) and rate of release of PGD2 from the 
uterus of menorrhagia sufferers was constant with non-sufferers (Rees and Kelly, 
1986).  The link between PGD2 and menorrhagia remains questionable but the 
literature and data support the theory that PGD2 may be physiologically important in 
the lower segment myometrium.  It is not yet clear what purpose this serves, yet one 
might postulate that PGD2 production in the cervical region could help to activate 
specific immune response via a CRTH2 (also known as GPR44 (Catalano et al., 
2011)) dependent mechanism.  Consequently, this could serve to prevent possible 
microbial invasion from the vagina when the cervix opens at ovulation and 
menstruation in non-pregnancy and also during pregnancy at parturition. 
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In contrast to PGD2, PGI2 predominates regardless of myometrial region throughout 
the menstrual cycle and appears to be an important homeostatic regulator.  PGI2 
acting via vascular IP receptors could possibly counteract the abundant synthesis of 
endometrial TXB2 and PGF2α, both of which act at TP receptors to mediate 
vasoconstriction of uterine arteries (Baxter et al., 1995).  The importance of IP-Gαs 
and also DP1-Gαs coupling in pregnancy maintenance and prevention of preterm 
labour is supported by data showing 1) the substantial production of PGI2 and to a 
lesser extent PGD2 compared with any other prostanoid in human, term, pregnant 
myometrium 2) increased myometrial PGI2 production at term versus preterm 
pregnancy 3) the excessive production of myometrial PGI2 and PGD2 in some cases 
of failed labour progression 4) attenuated PGI2 production in multiparous versus 
primiparous biopsies and 5) attenuated synthesis of PGI2 and PGD2 in myometrium 
from a PTL donor (n=1 case study).  PGIS therefore appears to determine, to an 
extent, whether labour initiation is successful, with over-stimulation detrimental to 
labour progression and under-stimulation owing to preterm labour-like symptoms or 
possibly more painful contractions. 
A relative degree of uterine quiescence during pregnancy could be consequential of 
PGI2 acting via IP receptors to stimulate cAMP generation downstream.  Subsequent 
activation of PKA, leading to phosphorylation of MLCK, will decrease the affinity 
of MCLK for the calcium-calmodulin complex, so that contraction is prevented 
(Word, 1995).  In an unexpected twist, however, PGI2, which is known classically as 
“inhibitory”, is dually capable of up-regulating myometrial contractile-associated 
proteins (CAPs), such as CX-43 (Fetalvero et al., 2008). 
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In the same study, the prostacyclin analogue iloprost significantly enhanced the 
contractile response of term non-labouring uterine tissue to oxytocin, which could 
occur either when prostacyclin concentrations are high enough (>200 pg/mg) such as 
late gestation or through purported interactions with ER.  For example, maternal 
oestrogen concentration is enhanced late gestation (Turnbull et al., 1974, McGarrigle 
and Lachelin, 1984, Darne et al., 1987) and is speculated to have a tethering effect at 
AP-1 sites on CAPs, which may counteract the effect of oestrogen acting via ER-β, 
of which dominates over ER-α during late pregnancy (Wu et al., 2000). 
In speculation, the mechanisms controlling prostanoid production could be defective 
in women who go into preterm labour, whereby hypercontraction is favoured 
(possibly reduced uterine PGI2 or PGD2 and excessive TXB2>PGE2>PGF2α 
production, based on thesis case study data).  For all data in Chapter four however, it 
must be considered a limitation that it was not clear in clinical information sheets, 
the exact reason why consenting pregnant women were undergoing Caesarean 
section, which could have had a bearing on results. 
Regarding the cervical changes which occur in the lead up to and during labour, data 
support a role for chemokines in accelerated cervical ripening in the week prior to 
labour.  This may eventually facilitate the breaking of the foetal membranes.  
Accordingly, it was leukocytes (which respond to chemotactic signal) deriving 
elsewhere and accessing the cervix via the vasculature, as opposed to resident 
cervical fibroblasts that induced cervical changes at labour (Osmers et al., 1992).  
Data showed a substantial increase in chemokine concentration, notably MCP-1, 
MIP-1α and IL-6 in CVF samples obtained from women who were sampled the 
week versus 2.5+ weeks before labour, implying an important function for these 
chemokines in cervical ripening. 
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Preliminary case study data show increased IL-6 in CVF from one donor 2 weeks 
before preterm labour (non-infected) compared with women who went into term 
labour 2 weeks after the swabs were taken.  MIPs and MCP-1 were not assayed in 
the PTL sample, however, it might be speculated that in addition to IL-6, production 
of MIPs and MCP-1 may be excessive in the cervices of some women leading to 
premature cervical effacement and preterm labour, although this implication requires 
further testing.  Women at risk of preterm labour could have an over-active immune 
response, since a role for IL-6 has been implicated in autoimmune disease (Ishihara 
and Hirano, 2002), the concentration of which was elevated in maternal plasma at 
preterm and not term labour (Laham et al., 1993).  With regard to tocolytic therapy, 
antagonists at the IL-6 receptor, for example, Tocilizumab may be useful with regard 
to halting cervical changes associated with labour.  However, this drug is expensive, 
only licensed for use in arthritic conditions and carries harmful side effects such as 
risk of respiratory infection and cannot be used during pregnancy.  Data support that 
chemokines would make suitable predictors of preterm labour, which would prove 
useful in targeting women a short interval away from preterm labour, so that agents 
which hinder cervical ripening can be administered propholactically.  Indeed, labour 
once started is difficult to delay with tocolytic agent, whereby labouring tissues 
appear to resist tocolytic effect more than non-labouring tissues (Saade et al., 1994). 
Lipidomic data from this study show that all myometrial prostanoids increase with 
the onset of labour, making the prostanoids suitable tocolytic targets.  However, it 
must not be overlooked that prostanoids produced in lower segment myometrium 
may have other unknown, paracrine functions in the cervix, unrelated to generation 
of myometrial force, such as cervical ripening. 
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For example, e.g. PGE2 and PGF2α can increase glycosaminoglycan synthesis 
(chondroitin and hyaluronate), water content (von Maillot et al., 1979) and 
chemotaxis of neutrophils (Winkler et al., 1999a).  Thereby, prostanoid-effector 
coupling could be manipulated for development of alternative agents of cervical 
ripening, a process which is hindered in women who experience longer labours 
(Uldbjerg et al., 1983).  Other groups have shown the possibility of EP4-mediated 
mechanisms in cervical ripening (Schmitz et al., 2001), which might be worth 
targeting for therapeutic use.  A more promising target is the EP3 receptor, since 
sulprostone (an EP1/3 agonist) was demonstrated to induce cervical ripening in 
pregnant women with minimal side effects after intracervical injection (Fruzzetti et 
al., 1988).  Meta-analyses show that therapies which target PG signalling such as 
misoprostol (a PGE1 analogue) are considered safe and well tolerated (Sanchez-
Ramos et al., 1997) possibly owing to local in utero effects. 
The abundant synthesis of PGF2α in vitro (thesis data) and the loss of responsiveness 
to PGF2α in lower segment myometrium at late labour (Fischer et al., 2008) implies 
an additional role for PGF2α, which does not involve FP-mediated effects.  
Interestingly, PGF2α was most the abundantly produced prostanoid in cervical tissue 
at labour onset (Ellwood et al., 1980) and so could play a role in the remodeling of 
cervical tissue, independent of uterine contraction via a non-classical FP pathway.  
Intra-vaginal application of a selective FP receptor antagonist or a specific inhibitor 
of the PGF2α synthase enzyme to the cervix could hinder both uterine contraction and 
cervical ripening in women experiencing preterm labour, although this remains 
elusive, with probable side effects to take into consideration (Reichler et al., 1995). 
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Thesis data support a role for the spasmogenic prostanoids (to wit, TXB2) in the 
labour process, particularly as myometrial biopsies obtained from women whose 
spontaneous or induced labours failed to progress, were unable to synthesise 
adequate quantities of uterotonins (PGE2, TXB2 and namely PGF2α) in vitro.  The 
reverse effect was observed in multiparous versus primiparous myometrium but was 
not statistically significant owing to small sample size.  TP receptor antagonists 
might be suitable agents to promote cessation of uterine contraction in women 
showing signs of preterm labour.  The agent GR32191 is an efficacious inhibitor of 
U46619-induced contractility in isolated human myometrium (Senchyna and 
Crankshaw, 1999), although licensing for in vivo use would require lengthy testing 
to gain phase III approval, in which success is not guaranteed.  Combination therapy 
of nifedipine or atosiban with celecoxib (a specific COX-2 inhibitor) was 
antagonistic on uterine contractility in vitro, unlike the additive effect of nifedipine 
and atosiban used together (Kuc et al., 2011) and places specific inhibitors of 
spasmogenic PG synthesis at the fore-front of tocolytic development. 
It is optimistic that inhibitors of TXAS for example, could delay preterm labour and 
may be less harmful to the mother and foetus than indometacin and selective COX-2 
inhibitors (refer to Appendix 2 for more detail regarding side effect profiles of 
currently used tocolytics and Table 6.1 on page 188, for theoretical alternative 
treatments).  A selective TXAS inhibitor (ozagrel hydrochloride) was shown to 
reduce TXB2 in maternal plasma and the occurrence of preeclampsia with minimal 
side effects to both the mother and foetus (Seki et al., 1999).  However, the effect of 
ozagrel hydrochloride on uterine contractility is unknown and requires further study. 
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Finally, thesis data support a role for PGE2 during term labour, which highlights the 
EP receptors as worthy tocolytic targets.  However, future profiling of prostanoids in 
preterm non-labouring and labouring myometrium must be considered also.  Data 
showing that the predominant response evoked by PGE2 was inhibitory in 
myometrium from pregnant donors at labour limits the EP1/3 receptors as targets for 
tocolysis (EP1/3 antagonist).  However, there may be potential for the selective EP2 
receptor agonist (butaprost) to delay preterm labour. 
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Disorder Compound Action 
Preterm labour 
Screening for positive predictor e.g. IL-6 in CVF  Administer EP3 antagonist to prevent premature cervical ripening 
FP antagonist>> Reduce myogenicity/ possible inhibition of cervical ripening 
EP2 agonist
>> Attenuation of uterine contraction 
TXAS inhibitor>> Attenuation of uterine contraction 
>>Intravaginal application 
Table 6.1: Summary of theoretical alternative treatments for preterm labour. 
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6.1     Future work 
Future work should focus on the following areas: 
Only one myometrial biopsy from a non-labouring and labouring donor at preterm 
gestation was donated for this study, which is inadequate for scientific analysis.  It is 
important now to focus on recruiting consenting preterm moreso than term pregnant 
women for uterine tissue donation, though this may prove to be challenging given 
the nature of emergency Caesarean sections.  The greater frequency of sample 
donations may help to set better criteria to exclude women receiving tocolytic 
treatment.  Data from this study show that prostanoids may be important for the term 
labour process, however comparisons between myometrium from PTL and TL donor 
are necessary.  This will determine if and which PGs are excessive or lacking in PTL 
myometrium to render novel targets for tocolysis, which would be an important step 
forward.  Also, it would be interesting to continue lipidomic and functional studies 
on myometrium according to progressive cervical dilation at both preterm and term, 
concomitant with PRA: PRB expression measurement, to further understand a 
pathological versus physiological process of parturition.  Future studies could 
include analysis of other bioactive PGD2 metabolites, for example, 9α, 11β-PGF2 
and 13, 14-dihydro-15-keto PGD2. 
In light of thesis data supporting a role for chemokines and cytokines in cervical 
ripening a short interval away from term labour, the comparison of MIPs, MCP-1, 
ICAM-I and IL-6 (measured by Luminex® with funds allowing), plus other 
mediators (using ELISA), which are secreted by macrophages and neutrophils in 
CVF from women swabbed at different intervals to preterm labour, would be the 
next logical step.  This may help to better determine which factors are worth 
exploring as predictors of preterm labour onset. 
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Also, data should be analysed according to ethnicity of the donor from which CVF 
swabs are collected, since data from this study show that ethnicity may have a 
bearing on chemokine profiles in CVF.  Findings of a larger group study may 
establish whether Asian or Black women should be tested earlier than White women, 
for preterm labour risk. 
 
Owing to the limitations of confirming menstrual state of non-pregnant donors in 
this study, future work should span to measure the full range of series-2 prostanoids 
in myometrium and endometrium from women who are aged 40 or less and have had 
their menstrual phase confirmed either by measurement of day-21 progesterone or 
histological technique.  This is achievable but would depend on approval from the 
HTA and liaisons with the medical staff involved in obtaining consent and 
subsequent tissue collection from women.  Only then can we properly understand 
how each prostanoid relates to a specific menstrual phase in distinct uterine tissues. 
 
Future work should aim to correlate eicosanoid profiles (analysed using lipidomic 
application) in endometrium and myometrium with volume of MBL, to establish 
more clearly whether specific PG signalling pathways could be targeted 
pharmacologically to reduce heavy MBL.  This is preferential to the standard 
pharmacological approach of hormonal therapy or NSAIDs, which are not without 
side effects.  MBL could be measured reliably in women similar to methods used by 
other authors (Smith et al., 1981b, Rees et al., 1984). 
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This will rely on obtaining tissues from women who complain only of menorrhagia, 
are not taking any form of therapy, are of a particular age (preferably below the age 
of 40) and show no signs of uterine/pelvic pathology upon clinical examination.  
Analysis of normal uterine samples from women undergoing oophorectomy could be 
included for comparison.  Past studies showed that MBL had no bearing on PG 
production in uterine superfusate (Rees et al., 1984, Rees et al., 1986), however, 
production of uterine TXB2 or tissue homogenate in vitro was not analysed.  Also, 
since thesis data support a role for TXA2 in endometrium, it would be useful to 
analyse the effects of U46619 on angiogenic and mitogenic gene expression and 
ERK1/2 phosphorylation in the absence and presence of EGFR tyrosine kinase 
inhibitor in human endometrial explants, in a similar manner to another group who 
tested the PGI2 analogue iloprost (Milling Smith et al., 2006).  This could reveal 
novel aspects of TXA2 signalling pathways in the endometrium, which could be 
manipulated for therapeutic benefit. 
It would be useful to quantify prostanoids using LC/ESI-MS/MS in eutopic versus 
ectopic endometrial tissue donated by women with or without endometriosis, given 
that PGE2 may be implicated in disease progression (Wu et al., 2010) and 
prostanoids may be mitotic in the human uterus (Sales et al., 2004).  It would be 
interesting to focus on TXB2 measurement in endometriotic tissues given the 
predominance of TXB2 production in JZ tissue (this study) and the hypercontractility 
of the JZ in endometriosis sufferers (Bulletti et al., 2002).  The use of 
immunohistochemistry may help us to better understand the aetiology of 
endometriosis by pin-pointing differences in the location of prostanoid synthases e.g. 
COX-2, TXAS, PGES-1, PGES-2 and PGES-3 in eutopic and ectopic endometrium 
from women with and without endometriosis (with ethical approval permitting). 
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6.2     Conclusion 
Lipidomic analysis allows a snap shot of the PG profile to be taken in any one 
specimen, which one may argue, could be more reliable than analysing one 
metabolite at a time in different tissue samples (using RIA).  Therefore, LC/ESI-
MS/MS may offer a gold standard in determining which PGs contribute to 
physiological and pathological reproductive processes.  To readdress the aims of this 
study: 
Lipidomic data show that TXB2 was more abundantly produced in endometrial than 
myometrial tissue and thereby TXA2 may share an important role alongside PGE2 
and PGF2α in the endometrium of menorrhagia sufferers (as hypothesised).  Whether 
or not TXA2 could fulfil a mitogenic role in the uterus or is related to menorrhagia 
requires further work. 
Data show that uterine prostanoid profiles change according to menstrual status, 
pregnancy and parturition and hence are influenced, in part, by the ovarian sex 
steroid milieu, namely oestrogen stimulation and progesterone attenuation of PG 
synthesis (as was expected).  Novel data show that production of PGE2 in the fundus 
and TXB2 in lower segment myometrium in vitro is higher during the follicular than 
menstruation phase, which may facilitate a change in the direction of uterine 
peristaltic waves as the menstrual cycle progresses. 
It was an unexpected finding that PGD2 during non-pregnancy is produced more 
abundantly in lower segment myometrium compared with the fundus.  There may be 
an important immunoprotective role for PGD2 in the lower reproductive tract 
involving the CRTH2 receptor.  Whether or not effects were related to donors 
suffering from menorrhagia requires further study. 
Data revealed which myometrial PGs may be important during pregnancy and 
labour, confirming that prostacyclin may be important for pregnancy maintenance to 
term.  PGE1 is used as an agent for cervical ripening and so it is unsurprising that 
data showed a significant increase in this myometrial metabolite late gestation.  
However unexpectedly, PGF1α synthesis increased in myometrium at late gestation.  
PGF1α could act via FP receptors in a similar manner to PGF2α to increase 
myometrial activity (Braxton Hick’s contractions) in the weeks leading up to labour. 
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Unexpectedly, PGJ2 production was attenuated with pregnancy and since PGJ2 was 
detected at low level in non-pregnant biopsies, a role for J2 metabolites in the uterus 
is not supported.  Speculatively however, at late gestation in the myometrium, PGD2 
is converted to 9α, 11β-PGF2 via AKR1C3 more so than spontaneously forming 
PGJ2. 
Thesis data now show that it is specific myometrial prostanoids which are important 
for the parturition process, namely PGE2 and TXB2.  The normal labour process may 
therefore rely on 1) synthesis of the spasmogenic prostanoid TXA2 to occur and act 
on a primed myometrium with resultant myometrial contraction and 2) the PGE2-
induced relaxation of the lower segment myometrium, to facilitate cervical dilation.  
Whether such prostanoids might drive the preterm labour process and could thereby 
make appropriate targets for treatment of this disorder requires further study. 
Findings from this study show that chemokines are tightly regulated prior to labour 
onset, whereby MCP-1, MIP-1α and IL-6 were most abundant in CVF the week 
compared with 2-20 weeks before term labour.  These metabolites show promise as 
indicators of labour onset before 37 weeks, and possibly moreso if paired with 
measurements of cervical length. 
The elevated concentrations of EMAP-II, MCP-1, MIPs and RANTES in CVF 
samples taken from preterm, pregnant Asian women compared with those of White 
women show that immune cell homing to the cervix (and hence ripening) may occur 
earlier in Asian than White women.  With caution it is speculated that Asian women 
could be at increased risk of preterm labour, similar to Black women (Patel et al., 
2004) and may benefit from predictive testing earlier than White women. 
Conclusion 
194 
 
To summarise, it may be some time before the aetiology behind idiopathic preterm 
labour (or syndrome) is fully understood in terms of the mediators and signalling 
pathways involved.  However, therapies directed at altering synthesis of specific 
prostanoids or pharmacological intervention at the prostanoid receptor level may 
make useful tocolytic treatments in the future.  Thesis data show that CVF may be a 
useful tool by which to identify women at risk of preterm labour, particularly if 
mediators associated with macrophage function are used as markers.  By selecting 
women at risk of going into labour prior to 37 weeks gestation, therapies to prevent 
cervical ripening and uterine contraction can be given a short interval before preterm 
labour has started.  This could have a major impact by reducing NHS costs but 
ultimately increasing the chance of neonate survival. 
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Treatment Menorrhagia 
Surgical option 
Endometrial ablation (DP) 
Hysterectomy (UP) 
 
Outcome: Ablation is a transient solution (Rees, 1987), permanent solution after hysterectomy (UP) 
Pharmacological treatment NSAIDs, COCs, LNG-IUS, Tranexamic acid, Mefenamic acid 
Mechanism of action: 
Non-specific inhibition of COX-1 and COX-2 by NSAIDs, Combined Oral Contraceptives (COCs) prevent ovulation, 
LNG-IUS progestogenic, tranexamic acid anti-fibrinolytic.  Fenamates inhibit COX and antagonise EP receptors  and 
attenuate PGE2 vasodilatatory signalling (Rees et al., 1988) 
Outcome: 
Reduction of menstrual blood loss by NSAIDs (Anderson et al., 1976), COCs (Gerd et al., 1992), LNG-IUS, Tranexamic 
acid (Bonnar and Sheppard, 1996) and Mefenamic acid (Cameron et al., 1987) 
Common side effects : 
NSAIDS can cause indigestion whilst mood changes, fluid retention and headaches are associated with COCs, LNG can 
take up to six months to elicit full efficacy and causes irregular bleeding and headache, Tranexamic acid results in 
gastrointestinal disturbance 
 
Appendix 1:  Types of treatment for menorrhagia and the associated side effects (NICE, 2007).  Despite the availability of treatment options, there still 
remains the requirement for development of pharmacological therapies for uterine disorders in non-pregnancy, which have greater efficacy and also specificity 
to prevent unwanted side effects, e.g. direct modulation of the prostanoid pathways in the uterus.  Abbreviations: Non-Specific Anti-Inflammatory Drugs 
(NSAIDs), desiring of pregnancy (DP), undesiring of pregnancy (UP), Levonorgestrel-intrauterine system (LNG-IUS). 
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Tocolytic Mechanism of action Side effects 
Indometacin 
COX-1 and COX-2 inhibition resulting in reduced 
prostanoid biosynthesis. 
Oligohydramnios and adverse side effects on the foetal ductus arteriosus 
(Macones et al., 2001, Kirshon et al., 1991). 
Cox-2 inhibitors 
COX-2 inhibition resulting in reduced prostanoid 
biosynthesis. 
Fewer side effects than indometacin (Sawdy et al., 1997). 
Cardiovascular concerns (Bresalier et al., 2005). 
β-mimetics β2 agonist to elicit smooth muscle relaxation. 
Helps to delay delivery for women transferred to tertiary care or who 
have completed a course of antenatal corticosteroids.  However, multiple 
adverse effects must be considered (Anotayanonth et al., 2004). 
 
FP receptor antagonists 
 
Antagonist of the PGF2α receptor (FP). 
THG113.31 delays preterm birth in sheep (Olson et al., 2003) and LPS 
induced preterm birth in mice (Quiniou et al., 2001) with no observable 
maternal or foetal side effects.  However none are specific for FP in 
humans. 
Atosiban 
 
Antagonist at OTR to elicit smooth muscle relaxation. 
Fewer side effects than conventional β agonist therapy (Lopez Bernal, 
2003), nausea (Abou-Setta et al., 2012), minimal side effects on foetus 
(de Heus et al., 2009). 
 
Nifedipine (Adalat), a 
dihydropyridine 
L type calcium channel blocker causing vascular and 
other smooth muscle relaxation. 
 
Reduction in respiratory stress of the foetus when compared with 
atosiban (Coomarasamy et al., 2003),  minimal side effects on foetus (de 
Heus et al., 2009), contraindicated in women with cardiovascular 
complications (van Geijn et al., 2005), may cause hypotension (Chan et 
al., 2008). 
Appendix 2: The various pharmacological agents which could be used to treat preterm labour by attenuating uterine contractions. Some agents are 
used routinely in the clinical setting for example, atosiban and nifedipine.  Tocolytic agents have different mechanisms of action and cause 
unwanted side effects.  Abbreviations: Cyclo-oxygenase (COX), Oxytocin receptor (OTR), Lipopolysaccharide (LPS). 
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ISAC Reference (project registration code): Application/08/004 
ERTB study name: Isolated human intrauterine tissues to develop therapies for 
uterine disorders 
Leeds LREC Reference: 07/H1306/98 (prior to 2007: 02/11/282) 
_______________________________________ 
ISAC Reference (project registration code): Application/08/005 
ERTB study name: Development of a diagnostic device for preterm labour 
 
 
Appendix 3: LREC and ERTB study numbers and additional information.  
Abbreviations are as follows: Independent Scientific Advisory Consultants (ISAC), 
Local Regional Ethics Committee (LREC) and Ethical Research Tissue Bank 
(ERTB). 
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Appendix 4: Copy of consent form used to obtain smooth muscle samples 
from non-pregnant donors. 
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Appendix 5: Copy of consent form used to obtain smooth muscle samples 
from pregnant donors. 
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Uterine Smooth Muscle Research Projects 
 
 Postgraduate Studies 
 School of Pharmacy 
 Richmond Road 
 University of Bradford 
 BRADFORD 
 Telephone: (01274)234693 or 232323 ext. 4732/ 4675 
 
 Debbie Fischer, Anna Griffiths, Joanne Durn & Dr. K.M. Marshall 
 
Patient Number: 
 
 
Age:  
Blood pressure (mmHg): 
 
/ 
Last Menstrual Period: 
 
 
Reason for Hysterectomy: 
 
 
Ethnicity:  
Consultant:  
Any current medication: 
 
 
 
Appendix 6:  Patient information form for uterine specimen donors at hysterectomy. 
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Uterine Smooth Muscle 
Research Projects 
 
Miss Debbie Fischer, Miss Anna Griffiths, Miss Joanne Durn & Prof Kay Marshall 
 
Reproduction Research Group, School of Pharmacy, University of Bradford 
     
 Tel: 234693, 232323 ext. 4732 or 4675 Mob: 07737 183 232 
  
 Date: 
 Time of delivery: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 7: Patient information form for myometrial donors at Caesarean section. 
Patient Number 
 
 
Duration of Pregnancy  
Blood Pressure (mmHg)  
Number of previous 
pregnancies 
 
Number of previous 
labours 
 
 
Number of previous 
caesareans 
 
Age  
Ethnicity  
Consultant  
Does the mother smoke? 
If so, how many per day? 
 
Does the mother suffer 
from any of the following: 
- hypertension 
- pre-eclampsia/ PH 
- diabetes-IDDM 
NIDDM 
Gestational 
- Rh factor 
- Other (please state) 
 
Any current medication  
Anaesthetic: 
General/ Spinal 
 
If labouring: duration (hrs) 
stage of labour + dilation 
(cm) 
 
Drugs used in labour 
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Patient ET No. (top left box of 
consent form) 
 Age (yrs)  
Date  Time of surgery  
Consultant  
Ethnicity (White European, Indian 
subcontinent, black African, black 
American/ Caribbean, Chinese) 
      - Other (please specify) 
 
Stage of Menstrual cycle Menstruation Follicular Ovulation Luteal 
Type of surgical procedure laparoscopy hysterectomy 
Other (please 
state): 
Site of endometrial tissue 
excision (please specify): 
Eutopic: Ectopic: 
Comments on location, size & 
number of endometrial lesions 
 
Site of hysterectomy (please 
ligature fundus end) 
Fundus Lower Total 
Blood Pressure (mmHg)  
Body Mass Index  
Number of previous  
gravida: miscarriages: abortions: 
vaginal births: Caesarean sections: 
Does the patient smoke? Y N 
If Yes, how many per day?  
Does the patient have any of the 
following medical conditions: 
 
(please tick where appropriate) 
 
- endometriosis mild moderate severe 
- fibroids  
- menorrhagia  
- dysmenorrhoea  
- pelvic pain  
- Fertility problems infertility subfertility 
- Diabetes IDDM NIDDM 
- Other (please state)  
Rh factor  
Medication history and dates 
 
 
Any current medication  
Reason for procedure: 
 
- recurrent pathology  
- severe disease state  
- Other (please specify)  
Date medical condition was 
diagnosed 
 
Any other comments 
? Planned treatments 
? Planned follow up 
 
 
 
Appendix 8: Patient information form for non-pregnant donors (Ethical Tissue form). 
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Patient ET No. (top left box of consent 
form) 
 Age (yrs)  
Date  Time of delivery  
Consultant  
Ethnicity (White European, Indian 
subcontinent, black African, black 
American/ Caribbean, Chinese) 
      - Other (please specify) 
 
Gestation length (weeks)  
Blood Pressure (mmHg)  
Number of previous gravida:  
Number of  miscarriages: abortions: 
Number of previous labours Preterm: Term: 
Number of previous Caesareans Preterm: Term: 
Number of previous vaginal births Preterm: Term: 
Does the mother smoke? Y N 
If Yes, how many per day?  
Does the mother have any of the 
following medical conditions: 
 
(please tick where appropriate) 
 
- essential hypertension  
- gestational hypertension  
- pre-eclampsia  
- diabetes  - IDDM  
 - NIDDM  
 - Gestational  
- Other (please state)  
Rh factor  
Body Mass Index before pregnancy  
Any current medication 
 
 
 
Anaesthetic General Spinal 
If labouring: 
Duration  
(hrs):  
Stage: 
Dilation   
(cm): 
Drugs used in labour: 
 
 
Reason for Caesarean section: 
 
(please tick where appropriate) 
 
- Maternal/ foetal distress  
- Multiple births  
- Abnormal presentation  
- Failed induction of labour  
- Dystocia  
- Other (please state)  
Any other comments 
? Planned treatments 
? Planned follow up 
 
 
 
 
 
 
 
Appendix 9: Patient information form for pregnant donors (Ethical Tissue form). 
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Patient ET No. (top left hand box of 
consent form) 
 Age (yrs)  
Date  Time of swab collection  
Consultant  
Ethnicity (White European, Indian 
subcontinent, black African, black 
American/ Caribbean, Chinese) 
      - Other (please specify) 
 
Gestation length (weeks)  
Blood Pressure at time of swab 
collection (mmHg) 
 
Number of previous gravida:  
Number of miscarriages: abortions: 
Number of previous labours (please 
put 0 if not laboured) 
Preterm: Term: 
Number of previous Caesareans Preterm: Term: 
Number of previous vaginal births Preterm: Term: 
Does the mother smoke? Y N 
If Yes, how many per day?  
Does the mother have any of the 
following medical conditions: 
 
(please tick where appropriate) 
 
- essential hypertension  
- gestational hypertension  
- pre-eclampsia  
- diabetes  - IDDM  
 - NIDDM  
 - Gestational  
- Other (please state)  
Rh factor  
Body Mass Index before pregnancy  
Any current medication 
 
 
Swab taken from: High vagina Low vagina 
Reason for swab: 
? SROM, infection, high risk preterm 
labour, other (please state) 
 
Time & date of suspected start of 
SROM/ infection 
 
Comments on fluid quantity/ viscosity/ 
odour/ colour 
 
Any other comments 
? Planned treatments 
? Planned follow up 
 
 
 
 
Appendix 10: Patient information form for pregnant donors of cervico-vaginal 
fluid (Ethical Tissue form). 
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Appendix 11: Schematic demonstrating the antibody interactions in IL-6 and sICAM-I ELISA.  The concept of elastase and EMAP-II 
ELISA is similar to IL-6 
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Metabolite 
Prostanoid production in paired, isolated, 
human, non-pregnant uterine tissues (pg/mg) 
Upper Myometrium 
(n=15) 
Lower Myometrium 
(n=15) 
PGE2  14.4 ± 5.7 13.7 ± 4.4 
PGD2 33.4 ± 9.6
 a 63.5 ± 12.9  
TXB2 20.6 ± 7.7  20.8 ± 3.4 
6-keto-PGF1α 30.9 ± 8.4 41.0 ± 9.6 
PGF2α 14.6 ± 6.5 18.9 ± 4.4 
Appendix 12: Prostanoids produced by paired upper and lower segment 
myometrium taken from menorrhagic, pre-menopausal donors not taking 
any form of hormonal therapy.  Data are expressed as arithmetic means of 
metabolite (pg/mg protein) ± S.E.M.  Statistical analysis was carried out 
using the Wilcoxon signed rank test as appropriate: a PGD2: upper compared 
with lower segment myometrium (p<0.05). 
Refer to Appendix 13 on the following page for spectra of LC/ESI-MS/M analysis. 
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Appendix 13: Representative spectra of LC/ESI-MS/MS analysis of PGE2, PGD2 and PGB2-d4 (Internal standard) in 
isolated from upper and lower segment myometrium taken from a consenting, non-pregnant woman in the follicular 
phase. 
PGD2 
PGE2 
PGD2 
Internal Standard Internal Standard 
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Labouring donors  
Metabolite (pg/mg) 
PGE2 6-keto-PGF1α TXB2 PGF2α PGD2 
Blood pressure       
Normal blood pressure (n=5) 62.5 ± 36.5 383.2 ± 126.9 47.6 ± 14.9 195.2 ± 139.9 181.1 ± 70.4 
Pre/Hypertensive (n=4) 243.9 ± 221.8 214.9 ± 53.9 52.0 ± 26.3 343.1 ± 334.4 43.4 ± 8.6 
      
Gravidity       
Primagravida (n=5) 25.3 ± 6.7 459.3 ± 87.5 29.0 ± 7.2 42.4 ± 13.2 99.0 ± 62.4 
Multigravida (n=2) α, + 26.7  ± 0.9 675.4  ± 492.0 48.6  ± 9.8 38.7  ± 38.7 β 96.1  ± 65.1 
Appendix 14: The effect of donor characteristics on prostanoid production in isolated, lower segment myometrium obtained 
from pregnant spontaneously labouring women at term gestation (41 ± 0.2 weeks).  Data are expressed as arithmetic means of 
metabolite ± S.E.M (pg/mg) where cases are n ≥ 3 and ± S.D where n=2.  Statistical comparisons were carried out using the 
Student’s t-test with no significant differences between groups. 
α No previous labour; β PGF2α undetected in one specimen; 
+ sample excluded from statistical analysis based on the small n number. 
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Appendix 15: Spectra of series-2 prostanoid standards (100pg/ml) analysed using LC/ESI-MS/MS and run alongside biological samples (in this 
case specimens from non-pregnant and term, pregnant women were analysed, refer to Figures 4.2-4.4 to view spectra).  Non-pregnant and 
pregnant samples in this case were analysed during separate experiments, owing to less frequent donation of non-pregnant samples. 
Non-pregnancy Term non-labour 
PGE2 PGD2 
TXB2 
6-keto-PGF1α 
PGF2α 
PGE2 
PGD2 
TXB2 
6-keto-PGF1α 
PGF2α 
8-iso-PGF2α 8-iso-PGF2α 
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Appendix 16: Spectra of prostanoid standards (100pg/ml and labelled accordingly) analysed using LC/ESI-MS/MS and run alongside biological 
samples (in this case specimens from non-pregnant and term, pregnant women were analysed, refer to Figures 4.2-4.4 to view spectra). 
15-keto PGE2 
Δ
12-PGJ2 
PGJ2 
15-deoxy-∆12, 14 PGJ2 
Non-pregnancy Term non-labour 
PGB2-d4 
PGJ2 
Δ
12-PGJ2 
15-deoxy-∆12, 14 PGJ2 
15-keto PGE2 
PGB2-d4 
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PGE1 
PGF1α 
Appendix 17:  Spectra of series-1 and series-3 prostanoid standards (100pg/ml) analysed using LC/ESI-MS/MS and run alongside biological 
samples (in this case specimens from non-pregnant and term, pregnant women were analysed, refer to Figures 4.2-4.4 to view spectra). 
Non-pregnancy Term non-labour 
PGD3 
PGE3 
TXB3 
PGD3 
PGE3 
PGF1α 13, 14 dihydro-PGF2α 
PGE1 PGD1 
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Appendix 18: Spectra of prostanoid standards labelled appropriately (50pg/ml) analysed using LC-ESI/MS/MS and run alongside biological 
samples (in this case, a myometrial specimen from a consenting, term, pregnant woman in spontaneous labour was analysed, refer to Figures 4.5 
and 4.6 to view spectra). 
PGD1 
PGF1α 
PGE1 
13, 14 dihydro-PGF2α 
PGE2 
PGD2 
TXB2 
PGJ2 
15-deoxy- ∆12, 14 PGJ2 
∆12-PGJ2 
6-keto-PGF1α 
PGF2α 
8-isoPGF2α 
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Appendix 19: Representative spectra of the metabolites derived from PGD2 (labelled as appropriate) analysed using LC/ESI-MS/MS in isolated, 
lower segment myometrium from a consenting, term a) labouring donor after induction of labour with oxytocin and b) non-labouring donors. 
a) 
b) 
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Early Labour (3 cm) 
Appendix 20: Representative chromatograms of LC/ESI-MS/MS analysis of 
prostanoids in myometrium obtained from a consenting term, pregnant donor 
who was in labour and whose cervix had dilated 1.5cm. 
PGF2α 
TXB2 
6-keto-PGF1α 
PGD2 
PGE2 
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Metabolite 
PG production in isolated, human myometrium (pg/mg) 
Non-
pregnant 
Preterm Term 
Non-labour L† Non-labour L: 0.5 cm 
+
 L: 4.5 cm L: 8 cm
++
 
PGE2 13.3 23.7 25.9 5.9 23.9 16.9 909.1 
PGD2 89.4 65.5 41.1 29.8 29.6 348.1 66.5 
TXB2 40.1 82.7 31.9 88.3 13.6 26.0 129.3 
6-keto-PGF1α 85.0 136.2 56.0 225.4 204.4 433.0 107.6 
PGF2α 54.3 17.2 0.0 22.9 12.1 54.4 1346.2 
Appendix 21: Concentrations of prostanoids in isolated, myometrium taken from donors who were not pregnant (n=1), not in labour (n=1) or 
labouring (L; n=1) at either preterm (27-34 weeks) or term (39-41 weeks) gestation.  Labour was defined as painful contractions of the uterus 
with cervical dilation at 0.5cm (n=1), 4.5cm (n=1) or 8cm (n=1). Data are expressed as metabolite (pg/mg, all cases n=1). 
† Extent of cervical dilatation undisclosed on patient information sheet; + donor did not experience labour contractions after IOL with 3 x 1mg 
prostaglandin over 48 hours prior to Caesarean section; ++ donor was administered phenergan (dose undisclosed).  The preterm labouring donor 
and non-labouring donors were hypertensive (blood pressure over 140/90 mmHg).  A summary Table of this data is shown in Appendix 22.  
Selected representative spectra are located in Appendices: 23-24. 
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Physiological 
marker 
Preterm 
pregnancy 
Term 
pregnancy 
Preterm 
labour 
Failed IOL 
(early labour) 
Term mid 
labour 
Sex steroid 
hormones and 
receptors 
O ++ O+++ O +++? O +++? O +++ 
ER-α/β ER-β+  ER-α +? ER-β +? ER-α + 
P +++ P +++ P +++? P +++? P +++ 
PRA:PRB - PRA:PRB - PRA:PRB +? PRA:PRB -? PRA:PRB + 
Prostanoids 
PGI2 + PGI2 ++ PGI2 --? PGI2 ++ PGI2 +++ 
TXB2 + TXB2 + TXB2 ++? TXB2 --- TXB2 + 
PGD2 - PGD2 -- PGD2 -? PGD2 -- PGD2 ++ 
PGE2 ++ PGE2 -- PGE2 +? PGE2 + PGE2 + 
PGF2α -- PGF2α -- PGF2α? PGF2α --- PGF2α + 
Abbreviations are as follows: O oestrogen, P progesterone; ? unknown; + indicative of increase and - indicative of reduction based on the 
following comparisons 1) preterm pregnancy versus non-pregnancy 2) term versus preterm pregnancy 3) preterm labour versus preterm non-
labour and term labour 4) failed IOL versus term non-labour and 5) mid labour versus term non-labour.  The predominantly synthesised PG is 
in bold. 
Appendix 22: Comparison of the sex steroid hormones, sex steroid hormone receptors and prostanoids in different physiological states of 
pregnancy and physiological/pathological states of parturition based on thesis data of lipidomic prostanoid profiles in isolated, lower segment 
human myometrium obtained by elective Caesarean section.  Sex steroid hormone information was obtained from the literature (detailed in 
Chapter one).  
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Appendix 23: Representative spectra of LC/ESI-MS/MS analysis of prostanoids (labelled appropriately) in isolated, lower segment 
myometrium obtained from a consenting a) non-labouring donor at 34 weeks gestation b) labouring donor at 27 weeks gestation and c) non-
labouring donor at 39 weeks gestation. 
Preterm non-labour Preterm labour Term non-labour a) 
 
b) 
 
c) 
 
PGE2 
PGD2 
PGD2 PGE2 
PGE2 
PGD2 
TXB2 
TXB2 TXB2 
6-keto-PGF1α 6-keto-PGF1α 6-keto-PGF1α 
PGF2α 
PGF2α undetected 
PGF2α 
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Term labour (8cm) Term labour (failure to progress) 
Appendix 24: Representative spectra of LC/ESI-MS/MS analysis of prostanoids (labelled appropriately) in isolated, lower segment 
myometrium obtained from a consenting a) pregnant donor at 41 weeks gestation whose labour induction failed and b) labouring donor at 41 
weeks gestation (8cm cervical dilation).  For representative spectra for the labouring donor at 4.5cm cervical dilation refer to Chapter four: 
Figure 4.1. 
a) 
 
b) 
 
PGF2α 
PGF2α barely detectable 
6-keto-PGF1α 6-keto-PGF1α 
TXB2 TXB2 
PGE2 
PGE2 
PGD2 
PGD2 
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Parameter 
Metabolite (pg/mg) 
Elastase IL-6 MIP-1α MIP-1β MCP-1 RANTES VEGF 
Blood pressure        
Normal blood pressure (n=21-29) 9.3 ± 2.1 47.6 ± 9.6 16.4 ± 4.3 16.6 ± 3.7 32.5 ± 6.9 17.8 ± 3.6 6.9 ± 1.4 
Pre/Hypertensive (n=1-3) 4.7 ± 0.5 19.5 ± 2.0+ 20.6+ 19.6+ 26.6
+ 8.1+ 12.5+ 
Smoking        
Non-smoker (n=19-25) 8.1 ± 1.5 37.7 ± 7.8 17.1 ± 4.7 14.1 ± 2.9 35.1 ± 7.7 18.7 ± 4.5 7.3 ± 1.4 
Smoker (n=3-6) 14.0 ± 8.0 54.6 ± 29.3 14.1 ± 6.3 12.1 ± 2.1 19.8 ± 8.1 22.1 ± 14.3 5.8 ± 2.7 
Gravidity & Parity        
Primagravida,  parity 0  (n=7-8) 11.7 ± 5.8 28.4 ± 12.5 11.4 ± 3.0 9.9 ± 1.3 42.7 ± 17.4 21.0 ± 5.9 7.5 ± 1.8 
Multigravida, parity 0 (n=5-7) 12.6 ± 4.1 67.8 ± 26.4 16.0 ± 7.7 17.1 ± 6.2 26.5 ± 10.3 25.5 ± 12.7 7.8 ± 3.8 
Multigravida, parity 1 (n=5-8) 6.3 ± 2.6 27.6 ± 10.5 29.4 ± 15.7 17.4 ± 9.1 35.9 ± 14.6 19.4 ± 11.1 5.4 ± 2.5 
Multigravida, parity 2 (n=5-8) 6.9 ± 0.8 43.5 ± 14.5 12.1 ± 3.8 12.4 ± 2.8 23.2 ± 5.8 10.2 ± 3.7 7.7 ± 2.4 
Body mass index        
15-25 (n=15-23) 7.1 ± 1.3 39.4 ± 9.0 20.3 ± 5.8 15.5 ± 3.6 39.3 ± 9.4 23.4 ± 5.7 8.7 ± 1.6 
26-34 (n=9-11) 14.6 ± 4.8 63.8 ± 20.7 11.3 ± 4.1 18.8 ± 6.2 31.3 ± 8.6 14.9 ± 3.8 6.5 ± 2.5 
Appendix 25: The effects of donor characteristics on profiles of molecular markers of inflammation in cervico-vaginal secretions donated by 
pregnant women who were swabbed between 20 and 36 wks gestation.  Data are expressed as arithmetic means of metabolite ± S.E.M (pg/mg) 
where cases are n ≥ 3 and means of metabolite ± Standard Deviation (S.D) (pg/mg) where cases are <2.  Statistical comparisons were carried out 
using One-Way ANOVA or the Student’s t-test as appropriate for parity and BMI comparisons.  Blood pressure and smoking parameters were 
statistically analysed using the Kruskal-Wallis and Mann-Whitney test as appropriate. 
+Sample size too small for statistical analysis. Normal blood pressure defined as: systolic <130, diastolic <80 and high blood pressure 
(pre or hypertensive): systolic >130 and diastolic >80; Vaginal infection: confirmation of yeast or haemolytic streptococci on swab. 
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Duration to 
labour (wks) 
IL-6 
(pg/mg) 
2 a 66.5 
2 b 1.7 
Appendix 26: In vitro concentration of IL-6 in cervico-vaginal 
secretions donated by women who were swabbed a 2 wks prior to 
preterm labour (n=1, age 23 years) or b 2.5 wks prior to term labour 
(n=1, age 22 years).  Data are expressed as metabolite pg/mg.  
Sample size was too small to carry out statistical testing. 
Donors were white, non-smokers with normal blood 
pressure (<120/75 mmHg) and BMIs between 20 and 
21.  Both women tested negative for bacterial 
vaginosis, yeast and Streptococci B. 
